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Abstract 
Obesity is strongly associated with type-2 diabetes mellitus (T2DM). Gut hormones 
are peptides secreted from the gut in response to nutrient intake that act to regulate 
appetite, food intake, energy and glucose homeostasis. Thus, alterations in gut 
hormone abundance and/or signalling can contribute to the development of the obese 
and T2DM phenotype. The incretin hormones glucagon-like peptide-1 (GLP-1) and 
glucose-dependent insulinotropic hormone (GIP) augment glucose-mediated insulin 
secretion. Peptide YY (PYY) is released from the gut post-prandially and acts 
primarily as a satiety signal. Recently studies have highlighted a potent role for PYY 
in regulating glucose homeostasis, which however to date remains partially 
understood. Dipeptidyl peptidase-4 (DPP-4) is involved in the biological inactivation 
of the incretins hence; DPP-4 inhibition is used for the treatment of T2DM. DPP-4 
also mediates the enzymatic processing of the full length PYY 1-36 to the truncated 
isoform PYY 3-36. Thus, DPP-4 inhibition may potentially impact on pancreatic 
PYY function and signalling and may alter the effects of the PYY system on glucose 
homeostasis by shifting the balance between the PYY isoforms. In addition, gut 
peptides have been identified as possible contributors to cases of hyperinsulinaemic-
hypoglycaemia (HH) resulting from bariatric surgery. Therefore, this thesis aimed to 
(1) determine the contribution of pancreatic PYY deletion to the intra-islet PYY 
system; glucose homeostasis and body weight phenotype and (2) establish the impact 
of hyperinsulinism (HI) on DPP-4 and its gut hormone substrates. To address the 
first point, pancreatic-specific Pyy null (PdxPyy KO) mice were phenotyped for 
changes in the pancreatic endocrine system, followed by body weight and glucose 
metabolism, in vivo. Further investigations measuring gut hormone mRNA 
suggested the intra-islet system was contributing to the observed reduction in weight 
gain and HI. Finally, patients with congenital forms of HI (in particular KATPHI) 
were evaluated for PYY, GLP-1 and GIP and their enzyme. This study highlighted a 
role for DPP-4, PYY and GIP in mediating HI. In conclusion, this thesis 
demonstrates a role for gut hormones in energy and glucose homeostasis. Further 
work is required to understand the interaction of gut peptides on islet function. This 
will provide the essential understanding to develop tissue-specific targeted treatment 
for obesity and T2DM. 
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1. Introduction 
1.1. Energy and glucose homeostasis 
Energy balance is required for an array of homeostatic functions essential for survival. 
The fine tuning of this control is achieved through interactions of complex feedback 
systems from neuronal inputs to the gut-brain axis regulating what and when we eat 
(Murphy and Bloom, 2006). However, it is not the dysfunction of one of these specific 
steps that has caused obesity and diabetes pandemics, but a regulatory system that is 
finding the demand too great. 
Obesity is characterised as a condition where stores of fat exceed normal and healthy 
limits. This is crudely but clinically defined as a body mass index (BMI) of 30 kg/m
2
 or 
more in adults. In school-aged children and adolescents, this is measured by growth 
references matched for age and sex. Two standard deviations from the normal 
distribution is characterised as obese.  
The modern age supply of cheap and highly calorific dense food and sedentary lifestyles 
are forcing malfunctions in this otherwise stable and constant metabolic homeostatic 
setting (Hill et al., 2003). Obesity is a multifaceted condition with pathogenic 
contributions occurring via physical, psychological and social involvements (Moore et 
al., 1962). It appears to have no boundaries, virtually affecting all individuals regardless 
of age or socioeconomic group in the developing and developed world. According to 
2008 statistics from the World Health Organisation (WHO), it was estimated that 500 
million adults across the globe were obese, which is over 10% of the world’s adult 
population. 40 million under-5s were also classified as overweight by 2011 with 30 
million of this number being from developing countries (WHO, 2013). In general, the 
incidence of obesity is higher in females, but poses a very high and serious risk of other 
conditions such as cardiovascular diseases, several forms of cancers (Calle and Thun, 
2004) and most notably type-2 diabetes mellitus (T2DM) to both sexes (Haslam, 2010). 
Maintenance of energy balance; energy intake (food intake) and expenditure 
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(metabolism) must be homeostatically matched (Morton et al., 2006). Traditional 
exercising and dieting methods are failing to control obesity, making it essential to 
improve our understanding of the mechanisms implicated in body weight changes in the 
bid to solve the soaring obesity crisis seen worldwide. 
Glycaemic control is important in maintaining the storage of fuels, in particular glucose. 
Glucose is stored in tissues from ingested carbohydrates. The stomach and remaining 
gastrointestinal tract (GI) break down the carbohydrates eaten and absorb the glucose 
molecules, which circulate in the periphery. The increase in plasma glucose levels 
promotes glucose-stimulated insulin secretion (GSIS). Insulin; a pancreatic -cell 
hormone aids in the transport of glucose to tissues. Like the dysregulation of energy 
homeostasis, imbalances in glucose control can also be detrimental, leading to a severe 
condition known as diabetes mellitus (DM). Normally fasted blood glucose 
concentrations in adult humans are maintained within a very tight and narrow range of 
3.9 to 5.5 mM. DM arises in individuals where there is a resistance for insulin to 
function normally (also known as ‘insulin resistance’), which is termed as T2DM. 
T2DM is hyperinsulinaemia (HI)-induced insulin resistance and thus, promotion of 
hyperglycaemia.  
‘Diabesity’ (Astrup and Finer, 2000), a term used to link obesity to diabetes is thought 
to be caused by the build-up of fat surrounding tissues (visceral fat) and thus, prevents 
insulin from functioning. This inhibits an intake of glucose into the tissue causing blood 
glucose concentration to remain high. As the tissue appears to be deficient in fuel 
required for cellular activity, it continues to send signals to the pancreas to produce 
more insulin; this results in exertion of the insulin-producing pancreatic -cells. This 
eventually leads to -cell failure with a subsequent reduction and sometimes loss of 
insulin production. This can eventually result in the individual going from insulin 
resistance to an insulin deficient state. 
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Currently, predictions are that more than half of obese persons will eventually be 
diagnosed with T2DM. Shaw et al. (Shaw et al., 2010) predicted that the prevalence of 
adult diabetes was 6.4% in 2010, worldwide.  A further 20 years will apparently see this 
figure go to 7.7%. Disturbingly, it is estimated a rise in the number of adults with DM 
will occur; an increase by 20% in developed countries and 73% in the developing world. 
Thus, it is fundamental that we progress to understanding and treating the root cause of 
this metabolic imbalance. 
 
1.2. The central regulatory circuits of appetite and body weight 
control 
During the 1950s, Stellar identified the hypothalamus and the brainstem as the central 
homeostatic sites of energy balance (Grill and Kaplan, 2002). These feeding sites 
receive both endocrine and neural inputs from the periphery to adjust to both the short-
term nutritional status and the long-term tissue stores. The non-homeostatic regions of 
the central nervous system (CNS) such as the orbital frontal cortex (OFC) have also 
been implicated in feeding behaviour (Batterham et al., 2007). This is thought to be an 
adaptation to our current environment and lifestyles.  A prominent role of the brain and 
in particular the hypothalamus in regulating the feeding behaviour was established about 
50 years ago, however the last 20 years have provided the milestones in our major 
developmental understandings of how the brain exerts control over energy balance 
(Murphy and Bloom, 2006). Taken from the Greek (hypo- below; below thalamus), the 
hypothalamus (Figure 1.1) is a major centre for the regulation of food intake and energy 
balance (Harrold, 2004). The hypothalamus is present in all mammals; it occupies the 
midbrain below the thalamus and lies on either side of the third ventricle (3V). It also 
plays an important role in hormonal regulation and links the nervous system to the 
endocrine system via the pituitary gland. Whilst the hypothalamus is a simple looking 
structure, it is integrated into numerous complex neuronal systems. These neuronal 
circuits interchange regulatory factors, which causes subsequent changes in food intake 
and fat deposition. Identified through classical lesioning experiments, the hypothalamic 
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regions involved in the regulation of energy balance and food intake have led to 
observations of certain phenotypes in rodents (Morton et al., 2006). Lesions to the 
medial basal portions of the hypothalamus (MBH) results in increased adiposity; 
whereas damage to the lateral hypothalamic areas (LHA) produces a reduction in food 
intake and body weight (Hetherington and Ranson, 1940). Further work demonstrated 
the primary region of the MBH area that was disrupted and caused hyperphagia and 
obesity was in fact the ventromedial hypothalamus (VMH), and hence, was 
appropriately named the ‘satiety’ centre. In contrast, the LHA was termed the ‘feeding’ 
centre and taken together led to the ‘dual centre’ hypothesis (King, 2006).  
The hypothalamic control of feeding is now well-known to be far more sophisticated 
and complex than previously thought. For example, lesions to other MBH subnuclear 
areas, such as the paraventricular nuclei (PVN) and arcuate nucleus (ARC) led to 
hyperphagia and weight gain (Elfers et al., 2011). However, lesions restricted to the 
dorsomedial hypothalamus (DMH) resulted in hypophagia, without producing changes 
to body weight (Bellinger and Bernardis, 2002). This identified the role of many 
hypothalamic nuclei in controlling body weight and energy stores.  
Post-prandially, the hypothalamus senses the changes in metabolic status from both 
central and peripheral factors (Table 1.1). Circulating factors appear to be released in 
response to adiposity, in addition to secretion of satiety factors from the GI tract in 
response to nutrient-intake (Cuomo et al., 2011). This hypothalamic-gut crosstalk 
governs the regulation and expression of central mediators involved in energy balance. 
The orexigenic mediators act to stimulate food intake and reduce energy expenditure, 
causing an increase in adiposity (Tiesjema et al., 2007). However, after a meal and/or 
when adiposity is above physiological requirements, the satiety factors (anorectic 
factors) act to reduce feeding and increase the body’s natural thermogenic pathways to 
remove excess stores. These anorectic factors provide negative feedback to the 
hypothalamic regions that control food intake (Xu et al., 2011). 
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Figure 1.1: Diagrammatic representation of the hypothalamic nuclei involved in 
energy homeostasis (grey box) (Schwartz et al., 2000). ARC: arcuate nucleus; PVN: 
paraventricular nucleus; VMH: ventromedial hypothalamus; DMH: dorsomedial 
hypothalamus; LH: lateral hypothalamic area; OC: optic chiasm.  
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Orexigenic peptides 
 
 
Anorectic/Anorexigenic peptides 
 
Peripheral Ghrelin 
Peptide YY (PYY) 
Insulin 
Leptin 
Glucagon-like Peptide- 1/2 (GLP-1/2) 
Oxyntomodulin (OXM) 
Cholecystokinin (CCK) 
Central 
Neuropeptide Y (NPY) 
Agouti- Related Peptide (AgRP) 
 
Melanocortins 
Cocaine- and Amphetamine- Related Transcript (CART) 
 
 
Table 1.1: Regulatory factors involved in the control of food intake and energy balance. The orexigenic mediators act to 
stimulate food intake and reduce energy release, thus, increasing adiposity. However, after a meal and/or when adiposity is above 
physiological requirements, the satiety factors (anorectic) act to reduce feeding and increase the body’s natural thermogenic pathways 
to remove excess stores. These anorectic factors provide negative feedback to the hypothalamic regions that control food intake. This 
energy homeostatic mechanism is fine-tuned to a ‘set’ balance, ensuring the stores are sufficient for physiological requirements.  
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1.3. Leptin 
Leptin is an adipocyte-derived hormone that acts to reduce food intake by inducing a 
feeling of ‘satiety’ (Wang et al., 1997). Leptin is a 167 amino acid hormone, which was 
discovered by Friedman, Leibel and Coleman whist working with leptin mutant mice 
(Coleman, 1978, Green et al., 1995). These mice were spontaneously found in the 
Jackson Laboratories as obese and hyperphagic. Further work led to finding of the gene 
that encoded leptin (Ob gene) and the leptin receptor (Lepr) gene; Lepr. The anorectic 
action of leptin is partially mediated via the down-regulation of hypothalamic orexigen 
neuropeptide Y (NPY). Central leptin receptors (Lepr) are expressed on neurones in the 
ARC, PVN and DMH, including the NPY/AgRP (agouti-related peptide: orexigen 
peptide) neurones. After a fatty meal, adiposity increases and with this the adipocytes 
release leptin to provide a negative feedback to areas expressing the Lepr, including the 
hypothalamic feeding and satiety centres (Zhang et al., 1997). Leptin crosses the blood-
brain barrier (BBB) and enters the CNS via a saturable transport system (Banks et al., 
2000).  
The NPY/AgRP neurones are negatively regulated by leptin, consequently causing a 
reduction in Npy mRNA and inhibiting the stimulation to eat. Peripherally, leptin 
increases energy expenditure by stimulating uncoupling protein (UCP) -1 in brown 
adipose tissue (BAT) (Wang et al., 1997). However, obese individuals appear to become 
leptin-resistant, a phenomenon that remains unknown (Myers et al., 2010).  
Apart from the hypothalamus, satiety factors signal from the periphery to other central 
regions of the brain, including the brainstem. These central sites are linked via neuronal 
projections that have yet to be identified and characterised (Thorens, 2012). It was 
recently demonstrated that the brainstem exhibits superior homeostatic control than the 
hypothalamic circuits (Williams and Schwartz, 2011). Transgenic mice deficient in Lepr 
within the nucleus of the solitary tract (NTS) of the hindbrain (Phox2b Cre 
Lepr(flox/flox) display hyperphagia, increased weight gain as seen in the 
hypothamlamic-specific LeprKO
VMH
 mice (Bingham et al., 2008); however, unlike the 
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LeprKO
VMH
 mice, the increases in metabolic rate seen in the Phox2b Cre Lepr(flox/flox) 
mice produced a compensatory increase in food intake but prevented the development of 
obesity (Scott et al., 2011). 
 
1.4. The enteroinsular axis: A bidirectional interaction of the gut & 
pancreas 
In 1902, the first description of a connection between the gut and the pancreas was 
established by Bayliss and Starling who demonstrated that a factor in intestinal mucosa 
extracts, which they named as ‘secretin’ (Bayliss and Starling, 1902, Hirst, 2004). 
Secretin acted via blood to stimulate the pancreatic exocrine secretions (Chey and 
Chang, 2003). This was followed by Perley and Kipnis showing that ingested nutrients 
increased the stimulation of insulin release more potently than intravenous 
administration of glucose (Perley and Kipnis, 1967). Creutzfeldt then labelled this effect 
as an ‘incretin’ effect, i.e. a GI hormone that is released due to enteral stimulation which 
in turn augments insulin release (Figure 1.2) (Creutzfeldt, 1979). The link between the 
gut and pancreas was referred to as the ‘enteroinsular axis’ (Unger and Eisentraut, 
1969).   
 
 
 
 
 
 
 
Figure 1.2: Graphical illustration of 
the incretin effect. This figure 
illustrates the difference in insulin 
response to oral versus intravenous 
glucose load. This difference between 
the insulinotropic effect is the incretin 
effect. Adapted from (Nauck et al., 
1986).
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1.4.1. Insulin 
Apart from glucose, insulin secretion is also stimulated by other factors including the 
autonomic nervous system (ANS) and gut peptides. However the ANS mechanisms are 
not fully understood (Rodriguez-Diaz and Caicedo, 2013). Proinsulin is synthesised 
from the human INS or rodent Ins gene and via proconvertase- (PC-) 1, 2 and 
carboxypeptidase activity yields the mature insulin and C-peptide. Post-prandial glucose 
enters the β-cells via the glucose transporter type-2 (GLUT2) transporter. Glucose then 
enters glycolysis and respiratory cycles and yields the high-energy molecule, ATP. The 
ATP molecules travel to and inhibit the potassium-dependent ATP channels (KATP) 
resulting in depolarisation of the cell membrane via its two subunits: sulphonylurea 
receptor-1 (SUR-1) and inward rectifying potassium channels (Kir6.2). This triggers 
voltage-gated calcium channels (VGCC) to open and an influx of calcium (Ca2+) occurs. 
The Ca2+ promotes exocytosis of the pre-packaged mature insulin and active C-peptide, 
which are released into the circulation (Figure 1.3). Hence, C-peptide is used as a 
surrogate marker for insulin resistance. Pancreatic β-cells release insulin in two phases. 
The first phase release is rapid and mediated by increases in blood glucose 
concentrations. Whereas, the second phase of insulin secretion is glucose-independent. 
This is much slower and more sustained as newly synthesised insulin-containing 
vesicles are released (Seino et al., 2011).  
Insulin has an oscillation phase; it increases and then steadily decreases levels every 3-6 
minutes. This rhythmic delivery keeps the body in fine balance and is thought to prevent 
insulin resistance occurring. Insulin travels to responsive tissues, typically the liver, 
muscle and adipocytes and binds to its receptor; the insulin receptor (IR); a tyrosine 
kinase receptor. IR activates kinases to phosphorylate insulin receptor substrate-1 (IRS-
1) to induce the translocation of GLUT4 to the outer plasma membrane. This allows for 
an increase in cellular glucose entry (Figure 1.4). The cascading phosphorylation by 
IRS-1 simultaneously promotes hepatic glycogen synthesis or lipid synthesis in 
adipocytes. Ir KO mice develop HI, thought to be a result of insulin signalling from the 
insulin-like growth factor-1 receptor (IGF-1R) (Accili et al., 1996, Joshi et al., 1996). 
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Joshi et al., 1996). On the other hand, Ins null mice develop DM (Duvillié et al., 1997). 
An eventual loss of β-cell volume and function are seen in T2DM. Thus, restoration or 
maintenance of β-cell health and function with new treatments and knowledge are 
actively pursued. 
Unlike the peripheral tissues, the brain uses glucose in an insulin-independent manner 
(Seaquist et al., 2001). However, IRs have been identified in the hypothalamus and 
studies have recognised the importance of brain insulin signalling and function in 
maintaining glucose balance (Szabo and Szabo, 1975). Central administration of 
exogenous insulin reduces glucose synthesis from the liver, however, inhibition of IR 
signalling leads to increased hepatic glucose production in the presence of insulin 
resistance (Obici et al., 2002).  Furthermore, specific ablation of IRs in mice from 
discrete hypothalamic neurons causes glucose intolerance and insulin resistance. 
However, these findings are confounded by the development of obesity in these mice 
(Bruning et al., 2000). 
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Figure 1.3: Diagrammatic representation of -cell function. 1) Post-prandial glucose 
is taken into the -cells via the GLUT2 glucose transporters. 2) Glucose is oxidised and 
the high-energy molecule, ATP is produced. 3) ATP travels to the KATP – dependent 
channels and 4) prevents the efflux of potassium which in turn causes the membrane to 
depolarise. 5) This trigger the opening of voltage-gated calcium (Ca
2+
) channels 
(VGCC) and 6) calcium inflow 7) stimulates insulin exocytosis. KATP – dependent 
channels: SUR-1 (sulphonylurea receptor-1) and Kir6.2 (the inward rectifying 
potassium ion channel).   
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Figure 1.4: Diagrammatic representation of the proposed insulin action on 
responsive tissues. 1) Insulin binds to its receptor (IR) on responsive tissues and 2) 
activates IRS-1. 3) IRS-1 binds to and phosphorylates GLUT4 vesicles and leads to 
translocation. 4) Eventually there is an increase in the GLUT4 affinity for glucose. 5) 
Additionally, the IRS-1 supports glycogen or lipid synthesis.  
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1.4.2. Glucagon 
During low energy states, the liver extracts insulin from the blood and down-
regulates IR expression. At the same time, there is activation for the synthesis of 
glucagon, a pancreatic hormone produced from the proglucagon precursor via PC-2 
activity into a 29 amino acid protein. Glucagon was initially discovered in the 1920s 
and found primarily in islet -cells (Gaede et al., 1950). The hormone acts on the 
glucagon receptor (GCGR) and activates the secondary messengers; cyclic adenosine 
monophosphate (cAMP) and protein kinase A (PKA) (Hue, 1982). It also functions 
to tonically promote insulin release. However, the counter-regulation of glucagon 
secretion is lost in T2DM, promoting fasting and post-prandial hyperglucagonaemia 
which additively affects hyperglycaemia (Larsson and Ahren, 2000). In turn, 
glucagon activates hepatic glucose production through the glycogenolysis and 
gluconeogenesis pathways, whilst simultaneously inhibiting the glycogenesis and 
glycolysis pathways (Jiang and Zhang, 2003).  
GCGR disruption by antagonism and antisera reduces hyperglycaemia in rodent 
models of diabetes (Johnson et al., 1982, Unson et al., 1996). Gcgr KO mice have an 
increase in glucose tolerance, and are resistant to streptozotocin- (STZ-) induced 
diabetes, in vivo. This suggests a decrease in glucagon action may act as potential 
therapy for T2DM (Gelling et al., 2003).  Subsequently, Ali et al. showed Gcgr
-/-
 
have an decrease in fasting glucose and islet cell hyperplasia but glucose tolerance 
was blunted (Ali et al., 2011).  
 
1.4.3. Somatostatin 
A third islet cell subtype; the -cell expresses somatostatin. Six somatostatin genes 
exist in the vertebrates, whereas only one has been identified in the human. 
Somatostatin has also been found expressed in the stomach, here it functions to 
reduce gastric acid secretion via parietal cells (Gao and Hu, 2006). It is also known 
as growth hormone-inhibiting hormone (GHIH) or somatotropin release-inhibiting 
factor (SRIF) and has a role in other non-metabolic endocrine functions (Park et al., 
2000). Somatostatin exists as two equipotent isoforms: as a 14 amino acid protein 
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(SS-14) or as a 28 amino acid product (SS-28) from a 92 amino acid precursor 
(Schally et al., 1980). Somatostatin inhibits glucagon and insulin release. It has been 
shown that Sst KO isolated islets have an increase in their first phase insulin 
response thought to be via lack of inhibitory action at KATP channels. A Sst
-/-
 mouse 
was generated and phenotyped in vivo (Cordoba-Chacon et al., 2013). This mouse 
lost its first phase of insulin secretion but the second phase was exaggerated in the 
KO group. Moreover, Sst deletion also resulted in an increase in both insulin and 
glucagon secretion, in vitro and in vivo but failed to suppress glucose-mediated 
suppression of glucagon release (Hauge-Evans et al., 2009).  
Somatostatin mediates its glucoregulatory effects via its G protein-coupled receptors 
(GPCR); somatostatin receptors (SSTR1-5). Transgenic mice for the different 
somatostatin receptor-subtypes have provided a deeper understanding of their 
function in glucose homeostasis. All SSTRs with the exception of SSTR3 couple to 
voltage-gated potassium channels (Youos, 2011). Somatostatin activates the 
potassium channels and promotes hyperpolarisation and inhibition of Ca
2+ 
-mediated 
exocytosis (Sharp, 1996). Both SSTR2 and 4 are more potent at increasing the 
potassium currents (Yang et al., 2005).  
SSTR 1-5 are located on α- and β-cells. Exogenous somatostatin and its analogues 
inhibit nutrient-stimulated insulin and glucagon secretion, both in vitro and in vivo. 
SSTR2 is found expressed on α-cells (Cejvan et al., 2003), whilst SSTR1 and 5 are 
both found on β-cells (Youos, 2011). Sstr2 null mice have an increase in nutrient-
stimulated glucagon secretion without altering insulin release. Sstr5 KO mice have 
an increased level of islet insulin content, a reduction in blood glucose and plasma 
insulin levels yet have more glucagon compared to control mice (Strowski et al., 
2003). These mice also developed hyperleptinaemia but are resistant to high-fat diet 
(HFD)- induced insulin resistance. Subsequently, Ramirez et al. developed another 
Sstr5 KO mouse, and the male transgenic group showed increases in SSTR1-3 
immunoreactivity (ir), pancreatic somatostatin like-ir and gene expression and a 
reduction in islet insulin content (Ramirez et al., 2004).   
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1.5. The role of gastrointestinal hormones in energy control and 
glucose homeostasis 
Our understanding of gut hormones and their role in regulating energy and glucose 
homeostasis has dramatically increased over the past few years. Consequently, 
strategies aimed at modulating circulating gut hormone concentrations or targeting 
their receptors is being developed as pharmacotherapies to treat obesity and/or DM.   
 
1.5.1. Ghrelin 
Ghrelin is a 28 amino acid peptide secreted from the gastric fundus’ P/D1 cells and 
can also be found in the -cells of the islets (Arnes et al., 2012). This orexigenic 
hormone is released in response to hunger. Levels peak prior to a meal and are at its 
lowest post-prandially. It was discovered in 1999 by Kojima and co-workers. 
Ghrelin is transcribed from a 177 amino acid precursor to act on its GPCR; growth 
hormone secretagogue receptor (GHSR) (Kojima et al., 1999). Primarily, the peptide 
is synthesised as a unacylated protein and becomes bioactive once acylated by 
ghrelin O-acyltransferase (GOAT) (Zhao et al., 2010). To date, this is the only 
identifiable peripheral orexigen. Ghrelin has also been found to have a role in 
proliferation and anti-apoptotic effects on pancreatic β-cells (Granata et al., 2007). 
Studies have also suggested that body weight and ghrelin are negatively associated. 
Hence, obese adults have a blunted ghrelin response in comparison to lean controls 
(Stock et al., 2005).  
Development of mutant mice have allowed for an understanding of an in vivo role 
for ghrelin in energy and glucose homeostasis. Ghr
-/-
 mice showed no difference in 
appetite or body weight when compared to Ghr
+/+ 
mice, suggesting that ghrelin may 
not be involved in energy homeostasis (De Smet et al., 2006). Sun and co-workers 
developed mutant mice with disruption in ghrelin and GHSR signalling. Using these 
mice they showed that the primary role of ghrelin in the adult mouse might not be 
involved in energy control but instead be to balance glucose sensing (Sun et al., 
2004). This was further supported by the Goat null mouse phenotype (Zhao et al., 
2010). However, theories have been proposed to suggest ghrelin may have other 
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receptor targets other than GHSR and/or GHSR may have another endogenous 
ligand (Uchida et al., 2013). Thus, the variability of the different phenotypes from 
the different transgenic models makes it difficult to confirm ghrelin’s regulatory 
pathway. Though these studies may be inconsistent, all this data suggests 
collectively a role for ghrelin’s regulatory pathway in energy and glucose 
homeostasis does exist. 
 
1.5.2. Glucose-dependent insulinotropic peptide (GIP) 
After the stomach, post-prandial nutrients come into contact with and stimulate 
duodenal K-cells to release the first incretin hormone; glucose-dependent 
insulinotropic peptide (GIP). The incretin effect is the augmented response produced 
by enteral glucose stimulation versus the comparable glucose load placed by an 
intravenous administration to promote insulin release (Creutzfeldt, 1979). GIP is a 
42 amino acid peptide encoded by the GIP gene from a 153 amino acid precursor. 
Once released into circulation, it is rapidly deactivated by an aminopeptidase; 
dipeptidyl peptidase-4 (DPP-4) (Drucker and Nauck, 2006). DPP-4 is an enzyme that 
removes the dipeptide from the terminal of any peptide containing either an alanine 
or proline at position 2. Hence, GIPs half-life is short; 7 minutes in healthy 
individuals and becomes reduced to less than 5 minutes in diabetic patients (Deacon 
et al., 2000). By comparison rats have 2 minutes of GIP bioactivity.  
Bioactive GIP has a vital role in potentiating GSIS (Drucker, 2007b). GIP regulates 
this effect by acting on its receptor (GIPR) to increase islet -cell cAMP levels 
whilst inhibiting the KATP channels. Collectively, these effects mediate the release of 
insulin. GIP triggers an increase in anti-apoptotic protein levels, in vitro (Trumper et 
al., 2001). Many studies have examined the role of GIP action in energy and glucose 
homeostasis (Irwin and Flatt, 2009). These studies have highlighted the importance 
of GIP action and have shown when endogenous GIP is redundant; the incretin effect 
is lost (Tseng et al., 1999, Miyawaki et al., 1999, Baggio et al., 2000). GIP promotes 
an increase in glucagon levels and dose-dependently stimulates a rise in somatostatin 
(Szecowka et al., 1982). Additionally, GIP appears to function as a promoter of 
lipoprotein lipase activity in adipocytes and is potently stimulated by fat. This has 
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been demonstrated in Gipr KO mice, which have a decrease in fat stores and are 
resistant to diet-induced obesity (DIO), but have increased insulin sensitivity in 
comparison to their controls (Miyawaki et al., 1999).  
GIPR antagonists administered in ob/ob mice have been shown to (1) cause a 
reduction in weight gain with an improvement in glycaemia as well as (2) an 
increase in insulin release and sensitivity independent of food intake and weight 
changes in WT mice (Green et al., 2004). Taken together, the collated data suggests 
endogenous GIP acts in the adipocytes to increase energy storage as well as inhibit 
insulin action. On the other hand, GIPR activation on the -cells promotes an 
improvement in insulin release. Consequently, it remains difficult to suggest whether 
stimulation or blockade of GIP signalling could be a method to combat diabesity.  
 
1.5.3. Glucagon-like peptide-1 (GLP-1) 
The second incretin hormone to be released post-prandially is glucagon-like peptide-
1 (GLP-1), a peptide produced by the lower gut (Lamont et al., 2012). Its precursor; 
the proglucagon gene is expressed in the GI tract, pancreas and CNS (Ellingsgaard et 
al., 2011). In the pancreas, processing yields glucagon, and gut post-translational 
cleavage leads to GLP-1, GLP-2, with the remaining region being cleaved to other 
inactive fragments and oxyntomodulin (OXM) (Drucker, 2002) (Figure 1.5). GLP-1 
circulates as either GLP-1 7-36 amide or GLP-1 7-37, with the predominant form in 
humans being GLP-1 7-36 amide. GLP-1 is released and most abundantly found in 
circulation post meal. However, its biological activity is less than 2 minutes due to 
degradation by DPP-4 (Hansen et al., 1999). GLP-1s function includes -cell 
proliferation, increasing insulin synthesis and secretion both via and independently 
of cAMP and PKA activation. GLP-1 also increases -cell function by stimulating 
an increase in Kir6.2 and SUR-1 expression via its GLP-1R (McClenaghan et al., 
2006). Moreover, it also prevents the down-regulation of KATP channels in the 
presence of high levels of glucose (Drucker, 2007a). GLP-1 antisera, GLP-1R 
antagonism and Glp-1r KO mice have all shown the importance of GLP-1s 
glucoregulatory function (Baggio and Drucker, 2007). All these studies have 
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collectively suggested impaired endogenous GLP-1 signalling causes defective 
endogenous glucose tolerance.  
Flamez and co-workers have also shown glycaemia disruptions occur in Glp-1r
-/-
 
mice, as well as an enhanced rise in cAMP and Ca
2+
 suggested to be due to an 
increase in GIP sensitivity (Flamez et al., 1999). Another Glp-1r KO mouse 
displayed fasting hyperglycaemia and abnormal glucose tolerance after an oral and 
i.p. glucose challenge (Scrocchi et al., 1996). This work confirms that GLP-1 action 
on GSIS can be mediated independently of the route glucose enters the system.  
In addition, GLP-1 appears to have a tonic inhibitory effect on islet -cells at basal 
levels (Schirra et al., 1998). Gcgr
-/-
 have an increase in plasma GLP-1 levels (Gelling 
et al., 2003). A previous study found glucagon to potentially have affinity for the 
GLP-1R on β-cells (Moens et al., 1998). Furthermore, glucagon has also been shown 
to have capacity as a substrate for DPP-4, since like GLP-1, it is a post-translational 
product of proglucagon (Hinke et al., 2000, Pospisilik et al., 2001). Whether DPP-4 
regulates endogenous glucagon remains unknown. Furthermore, Ali and co-workers 
constructed a double Gcgr/Glp-1r KO mouse which displayed an increase in GIP 
sensitivity (Ali et al., 2011). Further work by another group using GIPR antagonism 
in mice with deletion in the Glp-1r gene showed an increase in blood glucose and 
reduction in GSIS after an glucose challenge, in vivo  It was postulated that exendin 
(9-39) may have the potential to antagonise the GIPR and thus disrupt GIP action 
(Wheeler et al., 1995). However, this was disproved by Baggio and group, who 
demonstrated that exendin (9-39) lost its effect on glucose excursions in the Glp-1r 
KO mice (Baggio et al., 2000). This also confirmed the antagonist’s specificity for 
the GLP-1R. 
Interestingly, GLP-1/R insulinotropic signalling is preserved in T2DM. Given these, 
current treatment of T2DM includes the use of GLP-1 analogues. These exogenous 
synthetics effectively lower glucose in T2DM patients, although these effects are 
dependent on glucose. Hence, there are limited hypoglycaemic events (Reid, 2012). 
Exogenous GLP-1 administration at physiological levels fails to produce a change in 
feeding behaviour, only when given at supra-physiological levels does it evoke an 
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anorectic response in humans. The GLP-1 analogues provide the incremental 
increase in GLP-1 levels and promote weight-loss in patients with T2DM. GLP-1 
has a crucial role in neogenesis and this has been extensively studied. STZ-induced 
pancreatic destruction causes an up-regulation of the Glp-1 gene (Nie et al., 2000). 
Furthermore, the neogenic properties of GLP-1 can be seen in the improvement of 
islet morphology in rodents treated with GLP-1R agonists. Conversely, DPP-4 
inhibition appears to have no effect on islet morphology in DM models. This 
suggests that GLP-1R signalling may be therapeutically better at controlling 
glycaemia and improving islet health. 
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Figure 1.5: Figure illustrating the processing of the proglucagon precursor 
to its tissue-specific post-translational processing products. (Drucker, 2002). 
 
 43 
1.5.4. Peptide YY (PYY) 
Peptide YY (PYY) is a linear 36 amino acid peptide, which contains a tyrosine 
residue on either side of the terminals. The tyrosine is abbreviated to the letter Y, 
hence the name peptide YY. Initial isolation of this peptide occurred from porcine 
small intestinal extracts (Tatemoto and Mutt, 1980) which later led to the discovery 
of NPY and pancreatic polypeptide (PP) from the brains and pancreas, respectively 
(Tatemoto et al., 1982). Tatemoto et al. also found that the sequences and structure 
between these three peptides were homologous and therefore termed them as the 
Polypeptide family (Figure 1.6).  
The PreproPYY gene is co-expressed in the pancreatic -cells and in particular the 
ileal L-cells with proglucagon products glucagon and GLP-1 respectively 
(Kreymann et al., 1991). Once processed, the mature PYY 1-36 is formed. Post-
prandially, this form of PYY is converted to the predominant circulating PYY form 
(3-36) that has known appetite-inhibiting effects (Batterham et al., 2002, Batterham 
and Bloom, 2003, Batterham et al., 2003). The removal of the first two amino acids 
from the N-terminus of PYY 1-36 (proline-tyrosine) is catalysed by the same DPP-4 
enzyme that degrades the incretin hormones (Figure 1.7). Unlike the incretins, the 
degradation of PYY changes the conformational structure of the peptide interfering 
with receptor affinity and thus, changing the biological function of the peptide. 
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Figure 1.6: Comparison of sequence homology between PYY, NPY and PP. Different colours represent individual amino acids with 
homology between peptides linked by bars. 
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Figure 1.7: Figure illustrating the processing of the proPYY precursor to 
different bioactive isoforms of PYY. (Keire et al., 2002, Michael Conlon, 2002). 
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The target receptors for the polypeptide family belong to the GPCR superfamily and are 
known as the Y-receptors. The Y-receptors to date, have been identified as Y1R, Y2R, 
Y3R, Y4R, Y5R and Y6R, however, only Y1R, Y2R, Y4R, and Y5R are thought to 
regulate body weight and are expressed on various cells and organs (Michel et al., 
1998). Y-receptors display varying affinities to PYY, NPY and PP (Ballantyne, 2006b). 
The Y1R and Y4R receptor bind to the C- and N-terminals on the peptides, whereas, 
Y2R and to a lesser degree Y5R only bind to the C-terminus, hence the PYY 3-36 is an 
Y2R > Y5R receptor specific ligand. Whereas, PYY 1-36 which has both terminals 
intact, is a ligand for Y1R & Y5R > Y4R. PP on the other hand is a Y4R-specific and 
preferred ligand and NPY acts at Y1R and Y5R (Ballantyne, 2006b).  
Transgenic models targeting the YRs have provided useful information and the tools to 
study the individual pathways that regulate energy and glucose homeostasis. Many 
transgenic models have been developed to assess the implications of YR subtypes on 
energy balance. Global Y1r KO mice appear to develop late-onset obesity and HI in the 
absence of hyperphagia (Burcelin et al., 2001). Germ-line Y2r KO and global Y4r null 
mice both display a decrease in body weight and overall adiposity (Sainsbury et al., 
2002a, Sainsbury et al., 2002b). However, Y5r KO mice appear to develop mild obesity 
with increases in food intake and body fat (Marsh et al., 1998). 
PYY is mainly expressed in endocrine L-cells of the lower GI tract (terminal ileum and 
colon) as well as the stomach, intestine, and pancreas (Boey et al., 2008). The peptide 
can also be found in the brain including the brainstem (Glavas et al., 2008), and is 
known to mediates its effects on feeding behaviour in the hedonic centres (OFC) 
(Batterham et al., 2007), and various hypothalamic nuclei. PYY 3-36 levels post-
prandially rise (to 67% of total PYY) and fall (to 37% of total) during fasting. Grandt 
and co-workers identified 60% of total murine circulating PYY as the full-length 
peptide, with the remaining accounting for the truncated form (Grandt et al., 1992). On 
the other hand, the ratio of human PYY 1-36: 3-36 was found to be relatively equal. The 
distribution of PYY varies greatly throughout the GI tract (Ballantyne, 2006a). The 
stomach has levels <3.4 pmol/g, with the duodenum and proximal jejunum expressing 
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<17.1 pmol/g and 65.4 pmol/g in the distal jejunum. The most abundant area appeared 
to be the terminal ileum (100 pmol/g). PYY has only been detected in the mucosal layer 
of the GI tract.  
PYY has been well-documented for its role in the regulation of feeding (Karra et al., 
2009). PYY 1-36 is known to cause an increase in food intake, primarily occurring at 
the Y1R and PYY 3-36 is known to produce satiety and increases in energy expenditure 
at the Y2R. PYY inhibits a number of functions, including insulin secretion, gastric 
secretion and emptying, GI motility, pancreatic and gut secretion, stimulates water and 
salt absorption into the colon and promotes vasoconstriction to the vessels of the GI tract 
and pancreas (Karra et al., 2009, Liu et al., 1997, Karcz-Socha et al., 2011). 
In humans, protein consumption is the most potent macronutrient simulating PYY 
release & satiety in both obese and normal-weight individuals. In mice, increased 
dietary protein caused a reduction in adiposity, and food intake with an increase in 
plasma PYY (Batterham et al., 2006). Circulating PYY has a key satiety role in feeding 
behaviour as discussed above and has been well characterised for its involvement in 
energy balance (Batterham and Bloom, 2003, Batterham et al., 2002). On the other 
hand, pancreatic islet PYY appears to demonstrate a fundamental role in glucose 
homeostasis; however to what extent, still remains unknown (Boey et al., 2007, Boey et 
al., 2006b).  
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1.6. Hyperinsulinaemic hypoglycaemia (HH)  
Primary importance of gut hormone action in maintaining glucose balance and 
alterations in their physiology in the T2DM state has been of great interest to many 
biochemists. Indeed, there are different approaches to treatment including GLP-1R 
agonists and DPP-4 inhibitors which exert their effects through the incretins and PYY. 
However, more recently, the implication of these peptides in hyperinsulinaemic 
hypoglycaemia (HH) is harbouring interest. HH is a condition caused by the 
dysregulation of -cell secretion of insulin producing a hypoglycaemic state (Arya et al., 
2013).  
 
1.6.1. Weight loss surgery-induced HH 
Islet adaptation to insulin resistance is critical to prevent the onset of T2DM. At present 
there is a vast array of drugs available to treat diabetes including insulin sensitizers 
(bigunaides) that promote an increase in tissue glucose uptake from the circulation as 
well as insulin secretagogues (sulphonylureas) which regulate insulin release from the 
islet -cells. However these drugs are known to induce hypoglycaemic events, hence the 
use of DPP-4 inhibitors (gliptins) are becoming the drug of choice when treating T2DM 
as it works in line with normal physiology. Since gut GLP-1 release is only promoted by 
enteral stimulation and an autocrine negative feedback exists by GLP-1 on L-cells (le 
Roux and Bloom, 2005, Näslund et al., 1999), hence, serious hypoglycaemic events are 
not anticipated or noted.  
Apart from the glycaemia control, the drug effects on body weight and lipid profiling 
have shown promise. However, limited drugs are available for the treatment of obesity 
and are ineffective in bringing individuals to a near-normal weight. So, more obese 
patients are opting for bariatric surgery for quick and effective results (Chandarana and 
Batterham, 2012). One such procedure is the gastric bypass surgery (GBP) which is 
regarded as the ‘gold standard’ weight-loss procedure in particular for those with 
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T2DM. It is effective in decreasing 80% of excess weight and resolves insulin resistance 
immediately post-surgery and prior to significant weight reduction. However, the reason 
for such drastic changes is still questioned. GBP reduces the stomach volume and is 
anastomosed to the mid-gut (jejenum) bypassing the in situ proximal GI tract. This 
results in decreased gastric content and limits food intake as well as absorption of 
nutrients to facilitate weight loss. A few clinical studies have shown that the GBP leads 
to an increase in post-prandial GLP-1 and PYY levels post-surgery and prior to noted 
weight loss (Peterli et al., 2009, Olivan et al., 2009). To explain for such changes in gut 
hormones post GBP, two theories have been proposed (Rubino et al., 2006). The first 
hypothesises that the bypass of the upper gut eliminates an ‘anti-incretin’ component 
which promotes an improvement in glycaemic control. Alternatively the second theory 
suggests that an increase in undigested nutrients stimulates the distal enteroendocrine L-
cells and promotes a surge in GLP-1 and PYY levels. Further preclinical work using 
rodent models of GBP have allowed for the understanding of gut hormones in energy 
and glucose metabolism (Chambers et al., 2011). GBP performed in DIO rats improved 
glucose tolerance and insulin sensitivity. However, exendin (9-39) administration in 
these rats dampened the GBP-mediated improvement in glucose tolerance. Moreover, 
obese Pyy KO mice that underwent the GBP surgery did not display a significant 
reduction in body weight (Chandarana et al., 2011). These studies together support a key 
role of gut hormones in mediating weight and glycaemic balance.        
Despite these encouraging effects of GBP on obesity-induced co-morbidities and 
mortality, the frequency of HH cases as a complication of such a procedure is mounting 
(Service et al., 2005, Patti et al., 2005). At the same time, it was suggested that if these 
incidents were investigated in more detail, a novel understanding could be sought for the 
treatment of T2DM (Cummings, 2005).   
Post-prandial HH in GBP-induced nesidioblastosis suggests an enteral stimulus for the  
glucose impairment (Service et al., 2005). Two theories for this phenomenon exist, the 
first suggests GBP-induced HH was because of diabesity (i.e. obesity-induced HI) and 
the second line of thought is that the GBP foregut and/or hindgut peptides cause changes 
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in the function of the enteroinsular axis (Marsk et al., 2010). However, to date no studies 
have researched this further. A GBP-HH case report supports the notion that HH is not a 
result of islet dysfunction or an obesity-induced effect since most of the pancreas had 
been removed and the GBP was not reported to be reversed (Qintar et al., 2012). 
Furthermore, in the absence of stimulation in normal WT mice, a pancreatectomy model 
(Ppx) which has 90% removal of the pancreas has shown regeneration of pancreatic 
tissue (De León et al., 2003). This effect was thought to be mediated by GLP-1. 
Moreover, studies using GLP-1 and its analogue (exendin-4) induced a differentiation of 
pancreatic exocrine tumours to endocrine glucagon- and insulin-producing cells, in vitro 
(Zhou et al., 1999). Whereas, GLP-1R antagonism of Sur-1 null islets promoted 
hyperglycaemia in the absence of glucose in vitro and independent of body weight 
changes in vivo (De Leon et al., 2008) which is what is required in patients who have 
undergone weight-loss surgery. GIPR antagonism has also shown potential in mediating 
suppression in HH, in vitro and in vivo (Ravn et al., 2013). It was historically reported 
that GIP dose-dependently increases somatostatin secretion, in vitro (Szecowka et al., 
1982). On the other hand, a case was reported in which it was described that SST 
mimetics suppress incretins and HH. However, the SSTR subtype that promotes these 
effects remains unknown (Sato et al., 2013). Overall, these reports indicate towards a 
potential of incretin receptor antagonism as candidates for therapy in GBP-HH persons. 
Therefore, investigations into the physiological involvement of gut hormones in HH will 
provide novel insights in the regulation of the enteroinsular axis.  
Other forms of HH exist, which have been researched for many years and can provide 
the unique model to study this disease in the absence of confounding factors such as 
obesity. One such condition is the congenital form of HH. 
 
 51 
1.6.2. Congenital forms of HH 
Congenital hyperinsulinism (CHI) is the most common cause of transient and permanent 
hypoglycaemia in neonates and because of this, the disorder could potentially be life 
threatening causing neurological damage and requires quick and effective treatment and 
management (Hussain, 2011) (Table 1.2). This disorder is rare and has an incidence of 
around 1:50,000 births in the general population (Senniappan et al., 2013). 
Hypoglycaemia in infants is characterised as a blood glucose concentration < 3.5 mM. 
Infants require constant feeding to stabilise the hypoglycaemia. Congenital genetic 
dysregulation of insulin function represents the most frequent type of permanent 
hypoglycaemia. Currently eight gene mutations have been identified to be associated 
with CHI. These genes encode for glucokinase (GCK), glutamate dehydrogenase 
(GLUD1), 3-hydroxylacyl-CoA dehydrogenase (HADH), hepatocyte nuclear factor-4 α 
(HNF4α), monocarboxylate transproter-1 (MCT-1), UCP-2 and the two subunits: SUR-1 
and Kir6.2; that make up the KATP channels (Table 1.3). These have all been described at 
length for their implications in HH (De Leon and Stanley, 2007).  
Defects in the KATP channels are one of the most common causes of CHI (KATPHI)  
(Hussain, 2011). Therefore, this thesis will focus on KATPHI. KATP channels are 
comprised of two subunits; the Kir6.2 ion channels and SUR-1 (Inagaki et al., 1995). 
Both these subunits are sensitive to the ADP/ATP nucleotide ratio and work together to 
promote cell depolarisation and eventually insulin secretion. Mutations in the 
KCNJ11/ABCC8 genes are known to cause defects in trafficking of these subunits to the 
plasma membrane, thus causing KATPHI (De Leon and Stanley, 2007).  
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Table 1.2: Aetiology of hypoglycaemia in neonates. (De Leon and Stanley, 2007). 
Transient hypoglycaemia:  
 Impaired gluconeogenesis and ketogenesis in neonate 
 Maternal factors: maternal DM, glucose administration during labour or birth or 
prescription to hypoglycaemic drugs 
 
Prolonged hypoglycaemia: 
 Perinatal stress-induced HI 
 Beckwith-Weidemann syndrome 
 Hypopituitarism 
 
Permanent hypoglycaemia: 
 CHI: genetic mutations in GCK, GLUD1, HADH, HNF4α, SLC16A1, UCP2, 
ABCC8 and KCNJ11 
 Impaired counter-regulatory hormones: hypopituitarism, adrenal insufficiency 
 Gluconeogenesis or glycogenolysis enzyme defects 
 Fatty oxidation disorders 
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Table 1.3: Key genes involved CHI. (Senniappan et al., 2013). 
Gene (mutation type) Protein Reference 
1. GCK (Dominant) Glucokinase (Christesen et al., 
2008) 
2. GLUD1 (Dominant) Glutamate dehydrogenase (Xu et al., 2013) 
3. HADH (Dominant) 3-hydroxylacyl-Co A 
dehydrogenase 
(Kapoor et al., 2010) 
4. HNF4α (Dominant) Hepatocyte nuclear factor-4 α (Kapoor et al., 2010) 
5. UCP2 (Dominant) Uncoupling protein-2 (González-Barroso et 
al., 2008) 
6. SLC16A1 
(Dominant) 
Monocarboxylate transproter-1 (Pullen et al., 2012) 
7. ABCC8 and 
8. KCNJ11 (Dominant) 
KATP channels two subunits: 
SUR-1 and Kir6.2 
(James et al., 2009) 
 
 
Histologically, there are two types of KATPHI; focal (F-CHI) and diffuse disease (D-
CHI). F-CHI is sporadically inherited but D-CHI can be autosomally recessive or 
dominantly inherited (Senniappan et al., 2013). Due to these factors, management of 
the two types of KATPHI are very different. F-CHI only requires a lesionectomy 
(potentially curing the patient), whereas, D-CHI require medical therapy often with 
diazoxide; a KATP channel activator. However, some D-CHI patients are diazoxide-
unresponsive; they are treated with alternative drugs including glucagon as well as 
somatostatin analogues (octreotide and lanreotide) to counteract the unregulated HH. 
If all these avenues fail, a near-total pancreatectomy is performed. This usually risks 
DM and possible pancreatic exocrine insufficiency (Senniappan et al., 2013). Hence, 
it is very important to understand the mechanisms that cause the dysregulation of 
insulin function so that patient care and management is most effective. Such invasive 
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treatments are limited to the failure of drug therapy so more research is actively 
required.   
Though no reports have been published in determining the circulating levels of 
somatostatin and little is known of glucagon in HH individuals, these appear to play 
a clear role in reducing the surge in insulin and its action since they are commonly 
used in the management of HH. More research is required to ensure the action and 
signalling of these drugs is not limited.  
The mouse model for KATP mutation is the Sur-1 null mouse which presents with 
mild CHI. Sur-1 deletion causes a defective glucagon secretory response, in vivo 
(Shiota et al., 2002). Clinical presentations of CHI are also known to be induced by 
protein ingestion and amino acid-stimulated insulin release (Fourtner et al., 2006). 
More recently, the role of gut hormones in HH has become of interest to KATPHI 
researchers due to the implications seen in bariatric surgery. It was demonstrated in 
both WT and Sur-1 KO mice that the GLP-1R antagonist; exendin (9-39) induces a 
decrease in plasma insulin levels coupled with a rise in blood glucose (De Leon et 
al., 2008). This finding was subsequently confirmed in the Glp-1r KO mice. 
Furthermore, this group reported an improvement in glucose tolerance in KATPHI 
persons after exendin (9-39) administration in the absence of changing plasma GLP-
1 concentrations (Calabria et al., 2012). Hence, suppression of the incretins 
signalling/function appears to be important in reducing HH. At present it remains 
unknown as to the mechanism of such observations. Moreover, there are currently no 
reports on the effects of PYY which is known to mediate GLP-1 action in the liver 
(Chandarana et al., 2013).  
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1.7. Rationale of study 
A biochemical correlation between obesity and T2DM exists. Gut hormone-targeted 
therapy appears to be the way forward when trying to develop effective treatments 
for diabesity. However, many studies have been contradictory. GIP is known to 
promote fat storage  and glucagon secretion as well improve glucose tolerance. On 
the other hand, GLP-1 produces an increase in circulating insulin and improves 
glycaemic control in DM patients (Drucker, 2007b). However due to its rapid 
inactivation by the ubiquitously expressed enzyme DPP-4 current therapy for T2DM 
includes the use of DPP-4 inhibitors to block the enzymes inhibitory action on both 
incretins. It remains unknown if DPP-4 inhibition leads to an increase in adiposity by 
GIP action. Additionally, this enzyme also interacts with PYY. The DPP-4 inhibition 
would stimulate changes to the PYY isoform, hence a change in physiological 
function on energy and glucose balance.  
The current available data illustrates the importance of PYY in glucose and energy 
homeostasis and implicates intra-islet PYY as a physiological regulator in this 
balance. This is supported by findings including the inhibition of insulin secretion in 
mouse islets by exogenous PYY 1-36 (Chandarana et al., 2013, Chandarana, 2009). 
In addition, blocking of PYY with antisera (Karlsson and Ahren, 1996), global Pyy 
KO (Boey et al., 2006b) or global Y1r KO (Burcelin et al., 2001) in mice have all 
shown a potentiation of insulin release . However, the obese phenotype of the Pyy 
KO mouse doesn’t agree with HI (Batterham et al., 2006). Together, all this data 
suggests intra-islet PYY 1-36 action at the Y1R may cause the inhibition of GSIS. 
DPP-4 changes the biological activity of PYY by converting it to a Y2R-specific 
ligand and thus, promotes a reduction in inhibition on insulin release, post-prandially 
(Figure 1.8).  
Naslund and group have shown that GLP-1 has a negative feedback on PYY 
(Näslund et al., 1999). Recently a published article has reported that PYY 3-36 via 
Y2Rs mediate the GLP-1 glucoregulatory action in the hepatoportal system 
(Chandarana et al., 2013). Hence the use of DPP-4 inhibitors could be potentially 
counter-regulatory with regard to glucose control. On one hand, DPP-4 inhibition 
 56 
would promote a prolonging of active GLP-1 action on the enteroinsular axis and on 
the other, PYY 3-36 would be inactivated and thus inhibit the enteroheptic action of 
GLP-1. Therefore it would appear DPP-4 inhibition switches GLP-1s site of action 
but the consequences of such a change remains elusive. Additionally, there would be 
an increase in intra-islet PYY 1-36 which could induce a suppression of GSIS 
(Burcelin et al., 2001, Boey et al., 2006b) and also have the potential to promote 
hunger (Burcelin et al., 2001). The duality of DPP-4 activity in the inhibition and 
activation of the different gut hormones and its consequential effects on energy and 
glucose homeostasis are important towards an understanding of tackling obesity and 
glucose dysregulation. 
 
 
 
Figure 1.8: Possible regulatory pathways of intra-islet PYY. Intra-islet PYY 1-36 
inhibits glucose-stimulated insulin secretion via an unknown YR. DPP-4 changes the 
biological activity of PYY by converting it to a Y2R-specific ligand and therefore 
promotes an unknown effect on glucose homeostasis. 
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As described at length, obese and T2DM individuals are known to have a blunted 
level of PYY (Batterham et al., 2003, le Roux et al., 2006). Moreover, low levels of 
circulating PYY has been implicated in the predisposition of obesity and T2DM 
(Boey et al., 2006a). Incretin hormones are also known to have a role glucose 
homeostasis (Drucker, 2007b). GIP and GLP-1 are implicated in the pathogenesis of 
obesity and diabetes. GIP responses are attenuated in T2DM. On the other hand, 
GLP-1 activity is preserved in T2DM and thus is has been thoroughly researched for 
its potential as a therapeutic target.  
The GBP surgery is primarily the weight loss surgical option for T2DM obese 
individuals. This invasive procedure re-routes the GI tract, so that the area from 
where GIP is synthesised and secreted is bypassed and food is passed further into the 
lower gut where GLP-1 and PYY are co-released. Results from the procedure 
include the resolution of T2DM and improved glycaemia to a healthy range even 
prior to body weight changes (Chandarana and Batterham, 2012). Whilst the 
mechanism of action still remains ambiguous it has been hypothesised to be due to 
GLP-1 and PYY hyperfunction (hindgut theory). However, there has been a surge in 
the number of nesidioblastoma diagnoses as a result of GBP which induce HH 
(Service et al., 2005) assumed to be due to the hyperfunction of GLP-1. Support for 
this theory is the Sur-1
-/- 
mice which when given exendin (9-39) displays 
hyperglycaemia (De Leon et al., 2008). This phenotype is similar to the Glp-1r KO 
mice (Baggio et al., 2000). Jointly, all this data suggests that suppression of GLP-1R 
signalling may be a therapeutic target for the treatment of HH (Figure 1.9). Finally, 
the knowledge of how GBP-induces HH will allow for the pre-surgical identification 
of bariatric patients that are at risk of this complication, thus improving the doctors 
ability to make an educated decision about the patients surgical options. As well as 
understand how the implicated pathways can be manipulated in insulin resistance 
and hyperglycaemia.  
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Figure 1.9: Schematic representation of reported pathways that potentially promote islet β-cell regeneration and secretion. DPP-4 
stimulates the production of GLP-1 action via PYY and its Y2R. GLP-1 acts on its receptor to promote β-cell neogenesis, proliferation, increases 
in insulin synthesis and secretion and prevents β-cell apoptosis and glucagon release. The GLP-1R compound; exendin (9-39) antagonises this 
regulatory pathway. Post-prandially, GIP acts on the GIPR to promote insulin and glucagon secretion (Baggio et al., 2000, Chandarana et al., 
2013). 
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The work of this thesis discusses the data generated and reviews the interpretation of 
these findings in relation to published studies. Overall it aims to improve our 
understanding of gut hormones in the role and regulation of energy and glucose 
homeostasis. 
 
1.8. Objectives of thesis 
 To characterise the intra-islet PYY system, 
 To investigate the in vivo role of intra-islet PYY on energy and glucose 
homeostasis, 
 To characterise the role of gut hormones in HH. 
 
 
 
 
 
 60 
Chapter 2 
 
Methodology 
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2. Methodology 
2.1. Materials 
Supplies such as pipette tips, various solvents and reagents were obtained from Sigma 
Aldrich (Sigma Aldrich, Dorset, UK), Invitrogen (Invitrogen, Paisley, UK) or VWR 
(VWR, Lutterworth, UK) unless stated otherwise.  
2.2. Patients 
2.2.1. Ethics 
Ethical approval was obtained from National Research Ethics (NRES) Committee 
(Reference: 05/Q0508/84). Institutional approval was obtained from Great Ormond 
Street Hospital for Children NHS Foundation Trust, the Research and Development 
Office. Study information and patient leaflets were provided to the family and a detailed 
discussion was held prior to obtaining informed consent.  
2.2.2. Patient recruitment  
Great Ormond Street Hospital (GOSH) is a referral centre for the diagnosis and 
management of children who present with all complexities of HI. Once the patient 
arrives, they are diagnosed by blood sample collection during hypoglycaemia and 
simultaneous measurement of glucose and insulin. Patients are managed on medication 
and sometimes, surgery. Distinguishing between the histological-type of KATPHI disease 
makes the management of the patient easier. KATPHI patients, who do not respond to 
medications, undergo a PET scan to determine whether they have a focal lesion, in the 
absence of this diagnosis, it is assumed the patient has diffuse disease. Thereafter, 
surgery for focal (removal of lesion) or diffuse (near total pancreatectomy) takes place. 
All patients that undergo pancreatectomy have their biopsies checked by GOSH 
pathologists to confirm the type of KATPHI and to confirm that all pathological tissue has 
been removed. KATPHI patients are recruited into the study in a prospective manner. All 
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subjects are recruited prior to histological diagnosis. Thereafter, they were removed 
from the study if they were not in line of the criteria. Exclusion criteria for this are use 
of anti-reflux medications and oral feed-dependency with the inability to achieve a 
minimum 3-hour fast to baseline reading for the hypoglycaemia screening. 
2.2.3. Patient blood collection 
Blood is collected from the KATPHI patient prior to- and the end of a hypoglycaemia 
screen through a cannula by a specialist CHI nurse/doctor. Patients are fasted for a 
minimum of 3 hours and medication weaned off 48 hours prior to study. During the 
hypoglycaemia screen, the patient’s i.v. dextrose (20-40%) is slowly decreased and 
blood sample taken by a qualified HI specialist nurse. Blood was collected into chilled 
syringes and immediately transferred to ethylenediaminetetraacetic acid (EDTA) 
vaccutainers (BD, Oxford, UK) containing DPP-4 inhibitor (10 μl/ml blood: Millipore, 
Watford, UK) and aprotinin (Trasylol 5000 KIU/ml blood: Bayer, Newbury, UK). 
Blood samples were collected and processed according to the manufacturers’ 
instructions for the measurement of hormones using commercially available assays.  
2.2.4. Patient tissue collection 
After consent from KATPHI patient’s guardians, pancreatectomised tissue was either 
taken for quantitative expression analysis or for histological examination by the GOSH 
Histopathology Lab. For gene expression studies, tissue was placed in 5 ml RNAse 
inhibitor (RNAlater, Invitrogen, UK) until extraction of RNA. For histological analysis, 
pancreatic tissue were placed in 70% formalin and fixed according to section 2.7. 
2.3. Animals 
All animals were housed in the registered biological services unit (BSU) facility 
University College London with breeding, handling and experimental procedures being 
in accordance with Home Office Animals Scientific Procedures Act (1986) and the UCL 
Animal Users Ethics Committee (Project Licence No.70/7151 and 70/6648). The 
 63 
animals were kept in a specific-pathogen free (SPF) barrier facility and maintained 
under a controlled environment (temperature 21 +/-1°C, 12 hour light/dark cycle, lights 
on at 07.00) with free access to water and food (RM1 diet SDS UK Ltd) unless stated 
otherwise.  
2.3.1. C57BL/6 mice   
C57BL/6 mice were obtained from Charles River (Charles River, USA) and 
acclimatised for one week prior to any experimentation. Mice were housed appropriately 
for each specific study carried out at the ages stated for each experiment.  
2.3.2 Pyy mice 
Previously published Pyy KO (Pyy 
-/-
), Pyy lox 
+/+
 (Pyy floxed) and Pyy WT (Pyy 
+/+
) 
mice were used for appropriate studies (Batterham et al., 2006). Breeding and 
genotyping of the animals were carried out in-house. Pyy null mice have no expression 
of PYY mRNA and protein. These mice have also been reported to be hyperphagic and 
obese. The floxed Pyy mice showed no difference in PYY levels and expression, body 
weight or feeding behaviour when compared to the Pyy WT mice (Batterham et al., 
2006). 
2.3.3 PdxPyy mice 
PdxCre (pancreatic duodenal homeobox-1 promoter driven cre recombinase) transgenic 
mice were generated and generously donated as a gift by Professor Pedro Herrera 
(Herrera, 2000). PdxCre mice and the Pyy heterozygous floxed mice were crossed to 
produce the PdxPyy KO (Pdxcre
+
 Pyy lox 
-/-
) and their control littermate mice; PdxPyy 
WT (Pdxcre
+
 Pyy 
+/+
). 
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2.3.4 YfpPyyCre mice 
ROSA26YFP-reporter mice were crossed with PyyCre (promoter driven cre 
recombinase) mice generating PyyYfp transgenic mice. These mice express yellow 
fluorescent protein (YFP) within PYY-expressing cells within the gut, pancreatic-islets 
as well as other Pyy-expressing cells (Gelegen et al., 2012). 
2.4. Genotyping 
2.4.1 Ear clipping 
At weaning (postnatal day 21-28), 2 mm ear or tail biopsies were taken from mice using 
ear clips or scissors (Kent Scientific, Connecticut, USA) in order to confirm the 
genotype of mice. DNA was subsequently extracted as described in section 2.4.2 to 
determine the genotype of each mouse using polymerase chain reaction (PCR) as 
described in section 2.4.3. 
2.4.2 DNA extraction 
150 μl of tail lysis buffer was added to  each tissue sample. The sample was incubated at 
100 °C for 10 minutes in a heat block and cooled before 5 μl of proteinase K (20 mg/ml) 
was added, pulse spun and incubated at 55 °C for approximately 2 hours. The samples 
were then heated for 10 minutes at 100 °C and finally spun at 13,000 rpm for 5 minutes 
to settle debris. 1 μl supernatant was then used as template DNA for PCR amplification 
as described in section 2.4.3. 
2.4.3 Polymerase chain reaction (PCR) 
Genotyping PCR was performed using 1 μl of DNA template. PCR primers 
(Eurogentec, Southampton, UK) and conditions are shown in Table 2.1. Pdx genotyping 
was done with LoxP and Pdx PCR to detect the floxed and/or the WT gene in the 
presence or absence of the PdxCre gene. The Pyy mice were genotyped with the LoxP 
and Pyy GN PCR to detect the WT or KO amplicons, respectively. PCR products were 
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visualized using a UV transilluminator (Bio-Rad Laboratories Ltd) following 
electrophoresis at 95 mV for 100 minutes. The gel was prepared as a 2 % w/v agarose 
gel using 1x Tris-acetate- EDTA (TAE) and stained with 0.02 % v/v ethidium bromide. 
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Table 2.1: Genotyping primers and PCR conditions. F: Forward primer, R: Reverse Primer, LoxP: Floxed gene, GN or KO: gene 
deletion, Pdx: PdxCre gene, WT: wild-type gene. 
PCR Allele Primer sequence 
Product size 
(bp) 
Tm 
(
o
C) 
Cycles 
Extension 
(seconds) 
LoxP 
WT 
F: 5’ GACCTCGGTGTTTAATGGG 3’ 
R: 5’ GAGTTTAAGGTCCAGGAG 3’ 
326 
60 30 30 
Floxed 350 
Pdx 
Pdx 
 
F: 5’ CGGTGAACGTGCAAAACAGG 3’ 
R: 5’ AGGACACATTGTGCCAAAGG 3’ 
 
750 
60 30 30 
IL2 
(control) 
 
F: 5’ TAGGCCACAGAATTGAAAGATCT 3’ 
R: 5’ GTAGGTGGAAATTCTAGCATCATCC 3’ 
 
324 
Pyy GN KO 
 
F: 5’ GACCTCGGTGTTTAATGGG 3’ 
R: 5’ ATCTCCTGTCCCTTGTAGCC 3’ 
 
300 60 30 30 
YFP 
YFP  
F: 5’ AAAGTCGCTCTGAGTTGTTAT 3’ 
F: 5’ GCGAAGAGTTTGTCCTCAACC 3’ 
R: 5’ GGAGCGGGAGAAATGGATATG 3’ 
 
250 
60 40 30 
WT 550 
Cre Cre F: 5’ GCGGTCTGGCAGTAAAAACTATC 3’ 
R: 5’ GTAAAACAGCATTGCTGTCACTT 3’ 
100 60 30 30 
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2.5 Gene expression measurements 
To minimize destruction of RNA by environmental RNases, all equipment was cleaned 
with an RNase inhibitor (RNaseZap; Ambion, Huntingdon, UK) and only nuclease-free 
filter pipette tips were used during RNA isolation. Instruments were autoclaved before 
use. 
2.5.1. Islet isolation 
Mice were killed by cervical dislocation and a laparotomy was performed. The pancreas 
was perfused with 2 ml of ice-cold pancreatic digestion solution and immediately 
dissected out and placed in a 15 ml falcon tube containing 2.5 ml of ice-cold pancreatic 
digestion solution. After 16 minutes of incubation at 37 C in a water bath, the sample 
was placed on ice and 20 ml of ice-cold quenching buffer was added and the tube was 
shaken vigorously to dissociate exocrine tissue from the islets. The digest was poured 
through a 500 µm mesh well in and then centrifuged at 200 rcf for 1 minute at 4 C. The 
supernatant was discarded and the pellet was resuspended in 20 ml of quenching buffer. 
The centrifugation step was repeated two more times, and after the last spin the pellet 
was resuspended in 30 ml of Ficoll-Paque and the sample vortexed. 10 ml of ice-cold 
quenching buffer was added followed by centrifugation at 1100 rcf for 22 minutes at 10 
C. The islets in the Ficoll layer were collected and passed through a 40 m cell strainer 
and were washed with ice-cold 1x PBS (phosphate buffered saline) and RNA 
immediately extracted from freshly isolated islets (as described in section 2.5.2.). 
2.5.2. Islet RNA extraction 
Due to the low yield of RNA that can be extracted from islets isolated from mice 
(Chapter 4, Table 4.1), a different method was utilized. Islets were collected following 
isolation described previously and centrifuged for 1 minute at 13,000 rpm at 4 C. The 
supernatant was removed from the islet pellet and RNA was extracted using the RNeasy 
mini kit (Qiagen, Crawley, UK). 350 µls of the homogenising buffer supplied with the 
kit was added to the islet pellet and passed through a 20-gauge syringe and then a 33-
 68 
gauge needle, 10 times each. 350 µl of 70 % ethanol was added to the lysate and mixed 
by pipetting. This mixture was transferred to a spin column attached to a 2 ml collection 
tube and centrifuged at 10,000 rpm for 15 seconds at 4 C. The flow through was 
discarded and the spin column washed with buffers provided in the kit. The spin column 
was placed in a clean eppendorff and 30 μl of nuclease-free water (NFW)  (Ambion, 
Huntingdon, UK) was added to the column to elute RNA. The final RNA sample was 
either placed on ice for further analysis or stored at –80 °C for long-term storage. 
2.5.3. Whole tissue RNA extraction 
According to manufacturer’s instructions, whole tissue RNA extraction was performed 
using TRIzol reagent. Tissues were homogenized in 1 ml TRIzol followed by the 
addition of 200 μl of chloroform. The mixture was vortexed and incubated at room 
temperature for 5 minutes before being centrifuged at 13,000 rpm for 15 minutes at 4 C. 
The RNA-containing aqueous phase was transferred to a new eppendorff tube and 500 µl 
of chilled isopropanol was added and the sample vortexed. The tubes were incubated at 
room temperature for 20 minutes, and then centrifuged at 13,000 rpm for a further 30 
minutes at 4 C. The supernatant was aspirated and discarded without disturbing the 
RNA pellet and 500 µl of 70 % ice-cold ethanol was added to the tubes, vortexed and 
centrifuged at 8000 rpm for 5 minutes at 4 C. The supernatant was discarded and pellet 
air-dried for 5-10 minutes. The RNA pellet was resuspended in NFW and incubated for 
10-15 minutes at 55-60 C. The final RNA sample was either placed on ice for further 
analysis or stored at –80 °C for long-term storage. 
2.5.4. RNA purification  
Additional precautions were taken to purify RNA, by removing DNA contaminants 
using a DNA-free kit (Ambion, UK). 10 µl of DNase chelating reagent was added and 
vortexed over 2 minutes. This was followed by centrifugation of the samples at 13,000 
rpm at 4 C. The supernatant was removed without disturbing the DNA pellet. These 
DNA-free samples were then used to measure the RNA integrity number (RIN) using 
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the Agilent 2100 bioanalyzer (Figure 2.1). 1 μl of RNA was loaded into a RNA Nano 
LabChip where the degradation products and the RNA quality were determined. An 
algorithm assigns a number from 1 to 10, with 10 extrapolating intact RNA. A RIN 
value of >8 was deemed statistically significant (validated in-house), hence only 
samples with a RIN of more than 8 were used (See Chapter 4: Table 4.1). 
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Figure 2.1: RNA integrity number measurement by the Agilent bioanalyser. Intact RNA is indicated by two bands on (A) and two 
peaks on the electropherogram (B). The blue and red arrows show the 18s and 28s (ribosomal) RNAs, respectively. FU- fluorescence 
units, s-size. 
 
 
 
 
 
 
 
 
 
rRNA Ratio [28s/18s]: 2.040185   
RNA Integrity Number (RIN): 9.8 AU   
Concentration of RNA: 89 ng/l 
 
A B 
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2.5.5 Quantification of RNA 
1 μl from total RNA was quantified using the NanoDrop Bioanalyzer ND1000 
(NanoDrop; Labtech, Ringmer, UK). DNA contaminants are measured by the ratio of 
A260/A280. A ratio value of 2 equates to pure RNA, hence, a value of 1.80-2.20 was 
found to be suitable for synthesis of cDNA. 
2.5.6. cDNA synthesis 
Following isolation, reverse transcription of RNA template to make cDNA was done 
using a TaqMan Retrotranscription kit (Applied Biosystems, Warrington, UK). Each 
reaction was set up as follows: 3.0 μl 10x reverse transcription buffer, 1.2 μl 25X dNTP 
(deoxyribonucleotide phosphate) mix, 3.0 μl random hexamers, 1.5 μl reverse 
transcriptase, 6.3 μl NFW, 15.0 μl (0.5 µg) RNA template. Samples were heated to 25 
°C for 10 minutes, 37 °C for 120 minutes and then 85 °C for 5 minutes. The cDNA 
template was kept at 4 °C until further analysis. 
2.5.7 Quantitative Real-Time PCR (qRTPCR) 
Gene expression measurements were performed in duplicates unless otherwise stated. 
Each reaction replicate contained 1 μl of cDNA template (0.5 µg), 5 μl TaqMan PCR 
master mix, 2 μl of 20X primer of each respective proprietary FAM/TAMRA probe 
(Table 2.2) and 2 μl NFW. Tubes are vortexed and pulse spun at 13,000 rpm before 
loading 10 μl into respective wells of a 384-well clear optical reaction plate and sealed 
with an optical adhesive cover (Applied Biosystems, Warrington, UK) and centrifuged 
at 1,000 rpm for 1 minute before loading into the ABI Prism 7900 HT Thermocycler. 
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qRTPCR cycle: 
Temperature Time 
50 °C, 2 minutes 
95 °C 10 minutes 
95 °C 
60 °C 
15 seconds 
1 minute               
72 °C 5 minutes 
 
 
In order to normalise mRNA levels, genes of interest were evaluated in proportion to a 
stable, unchanging housekeeping gene. The Ct value for each sample was automatically 
computed using SDS software (Applied Biosystems, Warrington, UK). The Ct value 
of each target was compared to the Ct value of the housekeeper to normalise the gene 
expression and show direct difference between groups in arbitrary units (AU). 
 
 
cycle 40 
times 
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Gene     Symbol Product number  Amplicon 
          Size (bp) 
Peptide YY    Pyy  Mm00520715-m1 61 
  PYY  Hs00373890_g1** 150 
Glucose-dependent insulinotropic  GIP  Hs00175030_m1 78 
Peptide             
Cholecystokinin   Cck  Mm00446170_m1 79 
Ghrelin    Ghr  Mm00439093_m1 61 
Glucagon Like Peptide-1*  Glp-1  Mm00553234_m1 63 
Glucagon Like Peptide-1 receptor  GLP-1R Hs00157705_m1 78 
Dipeptidyl Peptidase -4  DPP4  Hs00175210_m1 90 
Neuropeptide Y receptor Y1   Npy1r  Mm01348999_m1 121 
     NPY1R Hs007020150_s1** 120 
Neuropeptide Y receptor Y2  Npy2r  Mm01218209_m1 86 
     NPY2R Hs01921296_s1** 143 
Neuropeptide Y receptor Y4  Npy4r  Mm01220859_m1 109 
     PPY1R  Hs00275980_s1** 95 
Neuropeptide Y receptor Y5   Npy5r  Mm00443855_m1 148 
     NPY5R Hs01883189_s1** 149 
Neuropeptide Y receptor Y6   NPY6R Hs00246222_s1** 98 
Insulin     Ins2  Mm00731595_gH** 99 
Glucagon    Gcg  Mm01269055_m1 62 
     GCG  Hs01026189_g1** 64 
Somatostation    Sst  Mm00436671_m1 86 
     SST  Hs00356144_m1 86 
Ubiquitin C    Ubc  Mm02525934_g1** 176 
Glyceraldehyde-3- phosphate  Gapdh  Mm 99999915_g1** 109 
dehydrogenase 
Hypoxanthine guanine  Hprt  Mm446968_m1 65 
phosphoribosyl transferase 
18s ribosomal RNA    Rn18s  Mm03928990_g1** 86 
β Actin    ACTB  Hs99999903_m1 171 
 
Table 2.2: Probes used for TaqMan gene expression analysis. Probes used for 
qRTPCR, gene symbol, product number and amplicon size. *Glp-1 referred to as 
enteroglucagon gene, **primer does not span intron/exon boundaries and detects 
gDNA. Hs-human gene and Mm-mouse gene. 
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2.6. In vivo metabolic studies 
2.6.1. Acute feeding studies 
16-hour fasted mice were given a pre-weighed amount of chow. At 1, 2, 4, 8, and 24 
hours post fast, food remaining in the cage dispenser and mouse body weight were 
weighed using a GW 600 balance (ATP Instrumentations, Ltd., Ashby-De-la-Zouche, 
UK) recording to the nearest 0.1g. 
2.6.2. Chronic feeding studies 
Body weight and food intake were measured once a week between 09.30-11.00 hours 
from weaning until age stated.  
2.6.3. Fasting blood glucose measurement 
Mice were fasted for 16 hours and blood glucose levels were measured from the tail 
vein, after application of local anaesthesia (Cryogesic, UK) with a glucometer (Bayer, 
UK). 
2.6.4. Intraperitoneal glucose tolerance test (IPGTT) 
Mice were fasted for 16 hours and injected intraperitoneally (i.p.) with a bolus of 1 g/kg 
of glucose (relative to body weight (BW) w/v). Blood glucose was measured before and 
at t = 15, 30, 60, 90 and 120 minutes after injection.       
2.6.5. Oral glucose tolerance test (OGTT) 
Mice were treated as stated in 2.6.4 and glucose was administered by oral gavage. 
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2.6.6. Oral glucose-stimulated insulin secretion (OGSIS) measurement 
During the OGTT, blood was collected in starstedt tubes at time points indicated. The 
blood was kept on ice until processing. To process, blood was spun at 10,000 rpm for 15 
minutes at 4 ⁰C and 10 µl of serum was collected in tubes before assessment of plasma 
insulin was determined by ELISA, described in section 2.8.2.  
 
2.7. Pancreatic immunohistochemistry (IHC) and morphological 
analysis 
2.7.1. Preparation of pancreata 
I. Murine 
Mice were killed by cervical dislocation and laparotomy performed. The pancreata were 
quickly dissected out, immediately spread and pinned to cork boards, which were 
rapidly placed into jars containing 10% neutral buffered formalin (NBF). Tissues were 
fixed in formalin for up to 24 hours, rinsed well with tap water and stored in 70% 
alcohol (all at room temperature). 
II. Human 
Patients diagnosed with KATPHI who are non-responsive to drug therapy are 
pancreatectomised. All tissues were checked by Histopathologists (GOSH, NHS Trust). 
The normal areas from focal KATPHI pancreatic tissue were used as controls. All tissues 
fixed in formalin for up to 24 hours, rinsed well with tap water and stored in 70 % 
alcohol (all at room temperature). 
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2.7.2. Tissue processing for paraffin embedding 
Tissues were processed as described below. Steps 1 to 9 were performed at room 
temperature and 9-11 at 60 ⁰C. Each step was 30 minutes. After processing, the tissues 
were embedded in paraffin and cooled on ice. 
1) 70 % ethanol 
2) 80 % ethanol 
3) 95 % ethanol I 
4) 95 % ethanol II 
5) 100% ethanol I 
6) 100% ethanol II 
7) Xylene I 
8) Xylene II 
9) Paraffin wax I 
10) Paraffin wax II 
11) Paraffin wax III 
 
2.7.3. Sectioning and de-paraffinisation 
Paraffin embedded tissues were sliced with a microtome using a Finesse 325 retraction 
microtome (Thermo Shandon, Loughborough, UK) and low-profile disposable Tissue-
Tek AccuEdge blades (VWR, Lutterworth, UK) to obtain 5 μm sections. The sections 
were float mounted on to positively charged Swiss glass slides and dried at room temp 
overnight. Dried slides were baked at 60 ⁰C for 2 hours. Deparaffinisation of the 
sections was performed as described below: 
1) Xylene I, 5 minutes 
2) Xylene II, 5 minute 
3) Xylene III 5 minutes 
4) 100 % ethanol I, 1 minute  
5) 100 % ethanol II, 1 minute 
6) 95 % ethanol, 1 minute 
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7) 70 % ethanol, 1 minute 
8) ddH2O, 5 minutes 
 
2.7.4. Immunostaining for fluorescent detection 
Following deparaffinisation, sections were placed in a heat-induced antigen retrieval 
solution (Dako, UK) for 3 minutes. Followed by cooling of the slides in 1 X PBS at 
room temperature. Thereafter, the slides were incubated at room temperature for 30 min 
with appropriate blocking solution. Blocking solution was removed and the sections 
were placed in a hydration chamber and incubated overnight at 4 ⁰C with a primary 
antibody (or antibody cocktail in co-localisation experiments, Table 2.3). 
Next day the sections were washed with PBS for 5 minutes at room temperature. The 
sections were incubated at room temperature in darkness for 30 minutes with secondary 
antibody conjugated to an Alexa Fluor dye (1:200), and washed with PBS for 15 
minutes. Lastly, the sections were mounted with 4', 6-diamidino-2-phenylindole (DAPI) 
mounting media (Vector Laboratories, UK) and visualised using either a fluorescent or a 
confocal microscope (Zeiss, UK). 
2.7.5. Pancreatic immunofluorescent images and morphometric analysis 
Immunostained pancreatic images were taken with a Zeiss LSM 710 inverted confocal 
microscope with x10, x20 (dry) or x40, x63 and x100 (oil) objective lens. For 
morphometric measurements, pancreatic sections were taken 50 µm apart and captured 
on an Olympus fluorescent microscope (Olympus, Southend-on-sea, UK). Fluorescent 
filters were used at 405 nm for DAPI, 488 nm for FITC and between 555-594 nm for 
TRITC at the magnification stated. Immunofluorescence was measured using ImageJ 
software and results were expressed as a percentage of total pancreatic area. 
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Primary: 
Antibody Supplier 
Catalogue 
Number 
Raised in 
Cross-
reactivity 
Working Dilution 
Anti-PYY Acris EUD5201 Guinea Pig H, R 1:750- R, 1:50-H 
Anti- insulin Dako A0564 Guinea Pig R 1:6000-R 
Anti- insulin Cell Signalling 4590S Rabbit H, R 1:100-R, 1:25-H 
Anti- proinsulin Novus bio NBP1-50246 Rabbit H, R 1:4000-R 
Anti-glucagon Abcam A0565 Rabbit H, R 1:50-H & R 
Anti-somatostatin Millipore AB5494 Rabbit H, R 1:500-R, 1:50-H 
Biotinylated-DPP-4 R&D Systems BAF954 Goat R 1:10-R 
Biotinylated-DPP-4 R&D Systems AF1180 Goat H 1:10-H 
Anti-Y1R Abcam AB73897 Rabbit R 1:2 
Anti-Ki67 BOND PA0118 Mouse H, R Ready-to-use 
Secondary: 
Antibody Supplier Catalogue Number 
 
Raised in 
Working 
Dilution 
Goat anti-guinea pig Alexa Fluor 
Molecular Probes 488/555 
Invitrogen, 
USA 
A-11073 
A-21435 
Goat 
1:200 
1:200 
Goat anti-rabbit Alexa Fluor 
Molecular Probes 488/594 
Invitrogen, 
USA 
A-11034 
A-11012 
Goat 
1:200 
1:200 
Streptavidin Alexa Fluor Molecular 
Probe 488 
Invitrogen, 
USA 
S-11223 N/A 1:200 
Table 2.3: IHC antibodies. Table summarising the supplier, host species and working 
dilution of antibodies used for IHC. H-Human, R-Rodent. 
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2.7.6. Haematoxylin and eosin staining 
Sectioning of pancreata tissue was carried out as previously described. A Leica 
autostainer was used to deparaffinise and stain the sections as described below, 
followed by mounting with vectashield mounting media (Vectashield, USA): 
1) Xylene I, 3 minutes 
2) Xylene II, 3 minutes 
3) Xylene III, 3 minutes 
4) 100 % ethanol I, 3 minutes 
5) 100 % ethanol II, 3 minutes 
6) 95 % ethanol, 2 minutes 
7) 70 % ethanol, 2 minutes 
8) ddH2O I, 2 minutes 
9) ddH2O II, 2 minutes 
10) Haematoxylin, 1 minute 
11) ddH2O, 2 minutes 
12) Clarifier, 30 seconds 
13) ddH2O, 2 minutes 
14) Blueing, 1 minute 
15) ddH2O, 2 minutes 
16) 95 % ethanol, 1 minute 
17) Eosin, 10 seconds 
18) 100 % ethanol I, 1 minute 
19) 100 % ethanol II, 1 minute 
20) 100 % ethanol III, 2 minutes 
21) Xylene I, 1 minute 
22) Xylene II, 1 minute 
23) Xylene III, 1 minute 
24) Xylene IV, 1 minute 
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2.8. Assays 
Assays were used to quantify the circulating concentration of peptides or hormones 
of interest from studies. Each assay was carried out in accordance with the 
manufacturer’s guidelines in duplicates (Millipore, Watford, UK). 
Kit 
Immunoassay 
type 
Catalogue Number 
Human PYY (3-36) Specific RIA RIA PYY-67HK 
Human Total GIP ELISA EZHGIP-54K 
Multispecies Active GLP-1 ELISA EGLP-35K 
Rodent Insulin ELISA EZRMI-13K 
Table 2.4: Immunoassays used for quantification of circulating hormones. Table 
summarising the assay kit, type and catalogue number for the quantification of 
circulating hormones of interest.  
 
 
2.8.1.    Radioimmunoassay (RIA) 
The kit was used as per the manufacturer’s guidelines with reactions being carried 
out in duplicates. 300 μls of assay buffer was added to tubes for non-specific binding 
(NSB), 200 μls added to the reference tubes (Bo), and the remaining tubes had 100 
μls assay buffer added to them. 100 μl of either a standard or quality control samples 
supplied with the kit of known concentration and was also added to separately 
labelled tubes in duplicates. 100 µl of the unknown samples were added to the 
remaining tubes. 100 μl of the antibody was added, each tube was vortexed, covered 
and incubated 20 – 24 hours at 4 °C. Thereafter, 100 μl of the radioactively labelled 
(
125
I) tracer was added to all tubes and two tubes labelled ‘total count’ (TC). Tubes 
were again vortexed, covered and incubated for a further 20 – 24 hours at 4 °C. 
Finally, 1ml of precipitating reagent was added to all tubes except TC tubes. The 
tubes were vortexed and incubated for 40 minutes at 4 °C. Later on, all tubes with 
the exception of TC tubes were centrifuged at 10,000 rpm for 40 minutes at 4 °C. 
The supernatant was decanted from these tubes immediately after centrifugation. The 
radioactivity remaining in each test tube was then quantified with a gamma emission 
counter (Packard Cobra, MN, USA).  
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2.8.2. Enzyme-linked immunoassay (ELISA) 
The ELISA assays feature the capturing of a specific protein in samples by 
antibodies. Firstly, the sample is added to a microtitre plate which contain the 
antibodies and any unbound material is washed off. The detection conjugate is then 
added to the bound material, producing a chemical reaction which is either 
fluorescently or spectrophotometrically quantified. Results are interpolated from a 
reference curve which is generated in the same assay by known standard 
concentrations. All samples were performed in duplicates as per the manufacturer’s 
instructions. 
2.9. Statistical analysis of data 
All data is presented as mean ± standard error of mean (SEM) unless otherwise 
stated. Statistical interpretation for body length, gonadal fat mass, gene expression 
and immunostaining analysis were assessed by unpaired Student’s t-test. For 3 or 
more variables, one-way analysis of variance (ANOVA) was used. For studies 
assessed over time such as body weight, feeding studies, GTTs and GSIS, analysis 
was carried out by repeated- measures ANOVA (RM-ANOVA) followed by Fishers 
post-hoc multiple comparison test. Area under curve (AUC) was determined by the 
trapezoidal method and compared by unpaired Student’s t-test. Differences in plasma 
hormones and metabolite concentrations of KATPHI subjects were assessed by paired 
Student’s t-test. Correlation analyses were examined by Pearsons correlation. Raw 
data was organised and collected in Microsoft Excel and GraphPad Prism 6. Further 
analysis and preparation for graphical presentation was carried out in GraphPad 
Prism 6. For all results significance was set at p < 0.05. 
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Chapter 3 
 
Characterisation of the intra-islet 
PYY system
83 
3. Characterisation of the intra-islet PYY system 
3.1. Introduction  
The islets of Langerhans are composed as complex multicellular structures forming the 
endocrine portion of the pancreas. Insulin-producing -cells make up the largest islet-
cell subtype at around 70-80% of the islet (Elayat et al., 1995). Glucagon-producing -
cells account for 15-20% of the islet with somatostatin-producing -cells, PP-producing 
PP-cells and ghrelin-producing -cells accounting for the remaining minority. PYY is 
expressed in the pancreatic islets of Langerhans in rodents (Ekblad and Sundler, 2002) 
and humans (Ali-Rachedi et al., 1983). In particular PYY is expressed in the -, - and 
PP-cells post-natally (Ali-Rachedi et al., 1983, Nieuwenhuizen et al., 1994, Jackerott et 
al., 1996, Myrsén-Axcrona et al., 1997), with some data also suggesting that co-
localization occurs prenatally with -cells (Upchurch et al., 1994). Furthermore, PYY is 
found to be the earliest detectable peptide to appear during ontogeny in the 
enteroendocrine cells (Upchurch et al., 1996) and islets (Upchurch et al., 1994). It 
appears to share lineage with all five islet-cell subtypes (Upchurch et al., 1994, Arnes et 
al., 2012), with the highest expression occurring in the embryonic pancreas, falling 
dramatically post-birth and continuing to reduce through adulthood (Upchurch et al., 
1994). The physiological consequences of PYY as an early appearing bioactive peptide 
(during development in the intra-islet cells) are still not fully understood.    
Isolated islets placed in media containing PYY have been shown to inhibit stimulated 
insulin secretion (Bottcher et al., 1989, Bottcher et al., 1993). DPP-4, a ubiquitously 
expressed enzyme cleaves PYY 1-36, a bioactive form (that acts on all YRs), to the 
Y2R-selective isoform; PYY 3-36. Nieuwenhuizen et. al., (Nieuwenhuizen et al., 1994) 
have also shown PYY’s inhibitory effect on GSIS, in vitro, mediated by a reduction in 
cAMP. Chandarana et. al., (Chandarana, 2009) presented studies in which they showed 
that PYY 1-36 supplemented with DPP-4 inhibitor result in a significant increase in 
GSIS when compared to isolated islets placed in media containing PYY 1-36 alone. 
They additionally showed that PYY 3-36 in the presence or absence of DPP-4 inhibitor 
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did not cause a change to GSIS, in vitro. Thereafter, a study using transgenic mice 
ablated PYY in PYY-expressing tissues including the pancreatic islets (Sam et al., 
2012). In this report, the resultant Pyy null mouse (PYY-DTR) was given PYY 3-36 to 
assess if the loss of islet content could be rescued, and found no difference in the 
pharmacologically-treated versus the vehicle-treated mice. Moreover, STZ-treated mice 
and the PYY-DTR mice were both given a PYY 1-36 analogue. Both mice strains 
displayed a reduction in -cell death. In vivo, transgenic Y1r and Pyy null mice display 
an increase in insulin release (Burcelin et al., 2001, Boey et al., 2006b). Taken together, 
these reports suggest very distinct roles for these two molecular species of PYY on 
glucose homeostasis. This implies that islet PYY 1-36 inhibits GSIS possibly via the 
Y1R. However, studies so far have failed to confirm this and the physiological role and 
regulation of this population of islet PYY still remains largely unknown. 
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3.3. Hypothesis 
‘PYY 1-36 is the bioactive isoform within the intra-islet system’ 
 
3.4. Aims: 
 To establish and optimise a murine islet isolation protocol for extraction of RNA 
for gene expression. 
 To confirm the presence of islet Pyy and Dpp-4 from isolated islets of C57BL/6 
mice. 
 To determine the Yr subtype gene expression in isolated islets from C57BL/6 
mice. 
 To evaluate the localisation and distribution of PYY, DPP-4 and Y1R in islet 
cell subtypes of the WT mouse using IHC. 
 To evaluate the gene expression of Ins, Gcg and Sst in the Pyy mice. 
 To evaluate the expression changes of -, - and -cell area in the Pyy and 
PdxPyy mice using IHC. 
 
3.5. Study design: 
An islet isolation protocol was established and optimised (Liao, 2012). In addition, the 
presence or absence of Yr-subtypes from C57BL/6 (WT) islets was determined. 
Thereafter, distribution of DPP-4 and PYY expression in the different islet cell subtypes 
and the expression of Y1R with insulin and DPP-4 was evaluated using IHC in 
C57BL/6 mice. Finally, changes in gene and protein expression of insulin, glucagon and 
somatostatin were measured in the Pyy and PdxPyy mice.   
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3.5. Results 
3.5.1. Establishing and optimising an islet isolation protocol in mice 
The pancreas is made up of the exocrine cells and endocrine islets. The islets contain 
signalling factors and hormones that are involved in glucose homeostasis. Hence, to 
assess the response of various conditions and factors on the islet PYY system, islets 
were isolated successfully and repetitively to ensure accuracy and reproducibility. 
Initially, to acquire islets, separation from the remaining pancreatic tissue was done by 
perfusion of a collagenase buffer via the common bile duct. 
Figure 3.1 shows the anatomical positioning of various tissues with respect to the 
pancreas. The ampulla of Vater or hepatopancreatic ampulla (circle) is formed by the 
merging of the pancreatic duct and the common bile duct and is specifically located at 
the junction with the duodenum. Pancreatic secretions are carried from the pancreas and 
passed through these pathways into the gut (the enteroinsular axis). Using these 
networks, a collagenase buffer was administered along the common bile duct through 
the incision of the ampulla. 
Once successful perfusion of the pancreas had taken place, fractions of various cells 
were centrifuged off until a floating layer of islets in a Ficoll gradient remained. A pellet 
containing mostly exocrine and undissociated islets formed at the bottom of the tube 
(Figure 3.2A). A fraction containing islets are passed through a 40 m strainer and then 
plated before islets were isolated by handpicking (Figure 3.2B-D). The healthy islets are 
generally then either (1) incubated overnight and used for static incubation studies to 
assess the intra-islet physiology when incubated in a given test buffer and/or (2) taken to 
extract RNA immediately and perform qRTPCR to assess gene expression. 
 
87 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: Successful pancreatic perfusion with collagenase buffer to yield isolated 
islets. (A) Anatomical view of abdominal tissue with respect to the pancreas. (B) 
Difference seen when successful perfusion occurs in the pancreas. Red arrow indicates 
spleen. (C-E) Images showing various stages of perfusion. Circle shows site of needle 
insertion: ampulla. Black arrow indicates the common bile duct. Representative line = 1 
cm.  
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Figure 3.2: Islet isolation from collagenase perfused whole pancreata. (A) Isolated 
islets gather in the Ficoll gradient layer seen after centrifugation. (B) Cell fraction 
pipetted from layer after passing through 40m cell strainer. (C-D) Handpicked isolated 
islets prior to RNA isolation. Red arrows indicate exocrine pancreas, lysed islets etc. 
Blue arrows indicate islets that are isolated and RNA extracted. Representative line = 
200 µm.  
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3.5.2. Optimising the qRTPCR protocol to determine the Yr subtypes present in 
isolated pancreatic islets from C57BL/6 mice 
Gene expression of Pyy, Dpp-4 and Yr in the isolated islet was evaluated in C57BL/6 
mice to direct our studies into determining the islet PYY isoforms and target receptors. 
As previously described, PYY 1-36 is an endogenous ligand for all YRs; however PYY 
3-36 has specific Y2R affinity. Studies were performed with the assistance of Dr J. Way 
and Ms D. Danger. 
3.5.2.1. RNA extraction: 
To assess the protocol validity and enquire about the possible RNA yield from isolated 
islets, RNA was isolated from a pool of 2 mice. Extraction was successful using the 
RNeasy mini kit, and yield was both high (98 ng/µl) and almost completely intact (RIN- 
9.8 AU). Hence, it was considered that sufficient RNA could be extracted from 
individual mice. Thereafter, islets were individually isolated from another six mice and 
RNA extracted successfully (Table 3.1). 
Date of RNA 
isolation 
 
Tissue 
 
RNA conc. 
(ng/μl) 
Absorbance 
(A260/A280) 
 
RIN (AU) 
30/11/2011 Islets* 98.0 2.13 9.8 
01/12/2011 (i) Islets 20.1 2.12 >8 
(ii) Islets 83.6 2.09 >8 
(iii) Islets 60.1 2.09 >8 
(iv) Islets 33.0 2.18 >8 
(v) Islets 20.5 2.13 >8 
(vi) Islets 23.7 2.17 >8 
 
Table 3.1: RNA extraction of isolated islets from wild type mice using Qiagen 
RNeasy kit. Quantification and integrity of RNA was determined by Nanodrop 
photospectrometry and electropherogram. N = 8. *pool of 2 mice. RIN: RNA integrity 
number. 
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3.5.2.2. Reverse transcription: 
cDNA was synthesised from the islet RNA. RT reactions performed were successful; 
however, since the RNA concentrations of the samples were sometimes low, we used 
0.6 -1.0 mg of RNA template for RT to get a minimum of 10 ng/µl per sample of cDNA 
template required for the qRTPCR reactions.  
3.5.2.3. qRTPCR 
Expression levels for Yr subtypes were quantified by qRTPCR. Commercially available 
brain and intestine cDNA (Zyagen, USA) were used as positive control tissues for Y1, 
Y2, Y4 and Y5 receptors expression. All probes were confirmed to be expressed in 
control tissue, and this ensured the probes were active and qRTPCR protocol was 
successful (Chapter 2, Table 2.2).  
 
Gapdh was strongly expressed in all tissues, with stable patterns of within-tissue 
expression, hence it was deemed suitable as a housekeeping gene. Ct values were 
recorded for the different probe sets after 40 PCR cycles. ΔCt was calculated which was 
used to normalise abundance of the gene of interest relative to the housekeeping gene 
(average abundance of target/average abundance of Gapdh). Values that remained 
undetected after the 40 cycles were deemed as unexpressed. Isolated islets were 
retrieved and RNA extracted by methods previously described. The qRTPCR probes 
were initially assessed using brain tissue cDNA.  
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3.5.2.4. Determining islet Yr subtype expression  
Previous data have made suggestions of the YR subtype mediating intra-islet PYY’s 
inhibition on insulin. But have thus far failed to confirm this.  
Thereafter, we detected Y1r expression in cDNA from whole pancreas and isolated islets 
in the WT mice. On the other hand, Y4r mRNA was only found to be present in whole 
pancreas, but was absent in all islet samples after 40 PCR cycles. Y2r and Y5r 
expression were undetectable from both whole pancreas and isolated islets. Y4r 
expression (0.0071AU) was almost six-fold higher than Y1r expression (0.0012AU) in 
the whole pancreas of the WT mice (Figure 3.3A). In isolated islets, of all the YR-
subtypes, Y1r gene expression was the only receptor that was detectable (Figure 3.3B). 
 
          
Figure 3.3: Differences in Yr expression of the whole pancreas and isolated islets. 
Expression of Yr in A) whole pancreas and B) the endocrine islets. Y1r expression 
(purple) in islets and pancreas, Y4r expression (black) in pancreas N = 8 for islet 
samples & n = 1 for pancreas from C57BL/6 mice. Data shown as mean of triplicates + 
SEM.  
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3.5.3. Evaluating the intra-islet localisation of PYY and DPP-4 in normal WT 
mouse pancreata using IHC 
The pancreatic endocrine islets consist of five islet-cell subtypes. Insulin was used as a 
marker for -cells, which are located in the core of the islets. Glucagon was used as an 
-cell marker, and somatostatin as a -cell marker. Both of these cell subtypes are found 
on the mantle/periphery of the islets. Other cell types include the PP- cells, and the -
cells. Of the five cell-subtypes, we assessed distribution of PYY, DPP-4 and Y1R 
expression in the -, - and -cells.  
 
3.5.3.1. Confirmation of islet PYY expression using transgenic reporter mice 
PYY protein expression was confirmed and validated in the YfpPyy mouse. YFP was 
predominantly expressed in the lower gut and islets consistent with the localisation of 
PYY (Figure 3.4). 
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Figure 3.4: Validation of PYY protein expression using a transgenic reporter line. (i) The ROSA26 promoter drives the 
expression of the yellow fluorescent reporter gene (Yfp) located upstream of the floxed (orange triangles) stop cassette (green).  
Expression of the PyyCre within the same cell population produces a recombination that removes the stop cassette and thus, activates 
the expression of the ROSA26-driven Yfp gene. This allows for the identification of cells that express Pyy and in which Cre has 
functioned. (ii) Representative pancreas and gut sections showing YfpPyy in green (bars: 100 µm) within (A) Islets (B) stomach, (C) 
proximal duodenum, (D) jejenum, (E) distal ileum, (F) ascending colon and (G) descending colon. DAPI blue nuclear staining 
(Gelegen et al., 2012).   
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3.5.3.2. IHC antibody optimisation & controls 
Using immunostaining, normal islet-cell subtype distribution was confirmed. Primary 
and secondary antibody dilution factors were determined for all antibodies (Chapter 2, 
Table 2.3). Staining distribution was assessed to evaluate correct staining of the 
antibodies. Insulin was found to stain the core of the islet, whereas the glucagon and 
somatostatin staining localised on the mantle of the islet. Thus, localisation of islet cell 
subtypes appeared to stain as expected (Figures 3.5). IHC imaging was conducted with 
the assistance of Dr E. Kleymenova. 
 
 
 
Figure 3.5: Confirmation of normal islet cell staining in WT mice. Representative 
image showing islet immunostaining in WT mice (A) using glucagon as an -cell 
marker (green) and insulin as a marker for -cells (red). (B) -cell marker insulin (red) 
was co-stained with somatostatin as marker for islet -cells (green). Nuclei are labelled 
with DAPI (blue). Magnification x 20. N = 8 mice per group, 6 sections per mouse. 
Reference line: 20 µm. 
B A 
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3.5.3.3. Assessing PYY antibody cross-reactivity with homologous sequences 
It has previously been reported that PYY antibodies are non-specific and cross-react 
with NPY (Glavas et al., 2008). To validate the PYY antibody, we used our transgenic 
Pyy KO mice that have the global Pyy gene deleted with complete absence of the PYY 
protein (Batterham et al., 2006). The Pyy KO showed no staining for islet PYY; hence 
we conclude that the antibody did not cross-react with NPY (Whim, 2011) or any other 
homologous sequence within the pancreas (Figure 3.6).    
  
 
 
 
 
 
 
 
Figure 3.6: Absence of PYY staining in Pyy KO mice. Representative image showing 
islet immunostaining for (A) PYY (green) and (B) Proinsulin (red) in the Pyy KO mice. 
Nuclei are labelled with DAPI (blue). Magnification x 40. N = 8 mice per group, 6 
sections per mouse. Reference line: 20 µm. 
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3.5.3.4. The DPP-4 antibody 
DPP-4 can be found in circulation and is expressed on the endothelial lining of blood 
vessels. DPP-4 expression was primarily confirmed to the cell surface of islets with 
some cytoplasmic staining also (Figure 3.7).  
 
 
Figure 3.7: Validation of DPP-4 antibody in WT mice. Representative image 
showing immunostaining for (A) DPP-4 (green), blood vessels-immunoreactivity 
indicated by arrows (x 40). (B) Islet DPP-4 immunostaining in green at higher 
magnification (x 63). Nuclei are labelled with DAPI (blue). N = 8 mice per group, 6 
sections per mouse. Reference line: 10 µm. (For more detailed images, see 
supplementary data supplied; appendix II A1-A2). 
B A 
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3.5.3.5. Assessing the distribution and localisation of PYY and DPP-4 within 
different islet cell subtypes in WT mouse pancreata.  
3.5.3.5.1. PYY localisation in -, - and -cells. 
To determine if PYY was localised to the -cells, 5 µm pancreata sections from WT 
mice were immunostained for insulin in red and PYY in green. As expected, we found 
that PYY was not co-localised with insulin (Figure 3.8A-C). PYY was found to be 
present in glucagon positive cells (Figure 3.9A-D). However, PYY was found 
predominantly, but not exclusively co-localised with somatostatin positive cells, i.e. the 
-cells (Figure 3.9E-H).  
 
 
 
 
 
 
 
 
Figure 3.8: PYY is not localised in the -cells. Representative image showing islet 
immunostaining in WT mice for (A) PYY (green) and (B) insulin (red). (C) Merging of 
the immunostaining. Nuclei are labelled with DAPI (blue). Magnification x 40. N = 8 
mice per group, 6 sections per mouse. Reference line: 10 µm. 
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Figure 3.9: Islet PYY is present in the - and -cells in WT mice. Islet immunostaining in WT mice for (A) glucagon -cells 
(green), (B) PYY positive cells (red), (C-D) Merging of the immunostaining.  (E) PYY cells (green) and (F) somatostatin -cells (red). 
(G-H) Merging of the immunostaining. Nuclei stained in DAPI (blue). Magnification x 40, and inset magnification x 63. N = 8 mice 
per group, 6 sections per mouse. Reference line: 10 µm. 
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3.5.3.5.2. DPP-4 localisation in -, -, - and PYY positive cells 
DPP-4 expression was localised to islet cell surfaces. DPP-4 appeared to be distributed 
on insulin positive -cells (Figure 3.10A), and on a small population of glucagon 
positive cells (Figure 3.10B). However, the enzyme could not be found on somatostatin 
positive cells (Figure 3.10C). DPP-4 was also located on one population of PYY 
positive cells, but was absent on another PYY positive cell population in the WT mice 
(Figure 3.10D). 
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Figure 3.10: DPP-4 is localised on α-, β- and PYY positive cells but not with 
somatostatin in WT mice	  Islet immunostaining for DPP-4 (green) co-stained with (A) 
insulin (red), (B) glucagon (red), (C) somatostatin (red) and (D) PYY (red) in WT mice. 
Nuclei are labelled with DAPI (blue). Arrow indicates PYY positive cells absent of 
DPP-4 staining. Magnification x 20 and x 40. N = 8 mice per group, 6 sections per 
mouse. Reference line: 10 µm. (For more detailed images, see supplementary data; 
appendix II A3-A8). 
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3.5.3.6. Confirming the expression of the Y1R on β- and DPP-4 positive cells in 
WT mouse pancreata.  
To determine if the Y1R was localised to the β-cells, 5 µm pancreata sections from WT 
mice were immunostained for insulin in red and Y1R in green. As expected, we found 
that Y1R was localised to the cell surface of insulin-positive β-cells (Figure 3.11A). In 
addition, Y1R was co-localised to DPP-4 positive cells (Figure 3.11B).  
 
 
 
 
 
 
 
 
 
 
Figure 3.11: Y1R is localised on β-cells and DPP-4 positive cells in WT mice. Islet 
immunostaining in WT mice for (A) Y1R (green) co-stained with insulin (red) and (B) 
Y1R (green) co-stained with DPP-4 (green). Nuclei are labelled with DAPI (blue). 
Magnification x 40. N = 3 mice per group, 4 sections per mouse. Reference line: 10 µm. 
(For more detailed images, see supplementary data; appendix II A9-A10). 
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3.5.4. Evaluating the effect of pancreatic-specific & global Pyy deletion on islet 
morphology and expression 
To assess changes in islet morphology of the pancreatic-specific and global Pyy KO 
mice, we stained pancreatic sections with the widely popular haematoxylin and eosin 
stain (H&E). H&E staining is routinely used to in pathological assessments for detection 
in changes of morphological tissue structure. The protocol involved applying an 
aluminium ion and haematoxylin complex, haemalum. This produced a blue nuclear 
staining. Eosin was then used to counterstain other cellular structures in various shades 
of red. 
 
3.5.4.1. Morphological islet changes in the PdxPyy and Pyy mice 
The Pyy KO and the PdxPyy KO mouse displayed an increased number of islet nuclei 
when compared to their respective controls (Figure 3.12). 
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Figure 3.12: Changes in morphological structure the Pyy transgenic mice. 
Representative haematoxylin eosin (H&E) stained sections of islets in the PdxPyy 
KO and Pyy KO with their littermate control mice aged 12-14 weeks. Black arrows 
represent islet cell nuclear staining. White arrows represent acinar cells. 
Magnification x 20. N = 3-8 mice per group, 4 sections per mouse. Reference line: 
25 µm. 
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3.5.4.2. Assessment to detect changes in pancreatic cell area expression of the 
Pyy KO mouse using IHC and qRTPCR 
To determine the islet phenotype of the Pyy KO mice; we assessed the expression of 
islet genes and proteins in male 16-18 week old mice.  
 
3.5.4.2.1. Pyy KO: Pancreatic insulin mRNA and -cell area 
No differences in pancreatic islet Ins expression (WT: 12.88  0.34 vs. KO: 13.50  
0.36 AU) or -cell area (WT: 0.0041  0.00006 % vs. KO: 0.0041  0.00004 % total 
area) was found between the Pyy WT and KO mouse (Figure 3.13). 
 
3.5.4.2.2. Pyy KO: Pancreatic glucagon mRNA and -cell area 
There were no differences in pancreatic islet Gcg expression in the Pyy mice (WT: 
12.89  0.65 vs. KO: 11.67  0.71 AU). However, there was a reduction in -cell 
area of Pyy KO mice (WT: 0.0013  0.00002 % vs. KO: 0.0012  0.00001 % total 
area) (Figure 3.14). 
 
3.5.4.2.3. Pyy KO: Pancreatic somatostatin mRNA and -cell area 
When evaluating the Sst gene expression there was no change between the groups 
(WT: 17.94  0.59 vs. KO: 18.05  0.38 AU). Whereas, there was a difference in -
cell area of the Pyy mice (WT: 0.00014  0.000005 % vs. KO: 0.00030  0.00006 % 
total area) (Figure 3.15). 
 
 
105 
P y y  W T P y y  K O
0
5
1 0
1 5
In
s
 m
R
N
A
 l
e
v
e
ls
 (
A
U
)
P y y  W T P y y  K O
0 .0 0 0
0 .0 0 1
0 .0 0 2
0 .0 0 3
0 .0 0 4
0 .0 0 5

-c
e
ll
 a
r
e
a
 (
%
 o
f 
to
ta
l 
a
r
e
a
)
A C
B
P
y
y
W
T
P
y
y
K
O
Figure 3.13: Global Pyy deletion has no effect on Ins gene expression or -cell area. (A) Expression of Ins mRNA in whole pancreatic tissue 
samples of the Pyy WT and KO mice. B) Pancreatic β-cell area expression in the Pyy mice. C) Representative immunostained images of 
pancreatic islets of the Pyy WT and KO mice (DPP-4 green, insulin: red & nucleus: DAPI blue). Magnification x 40. Reference line: 20 µm. 
Gene expression: data shown as mean of duplicates + SEM, n= 9-11 mice per group. Pancreatic islet cell area: data shown as mean + SEM, n = 2 
mice per group, 2 sections per mouse. 
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Figure 3.14: Global Pyy deletion leads to a reduction in -cell area. (A) Expression of Gcg mRNA in whole pancreatic tissue samples of the 
Pyy WT and KO mice. B) Pancreatic α-cell area expression in the Pyy mice. C) Representative immunostained images of pancreatic islets of the 
Pyy WT and KO mice (GCG green, insulin: red & nucleus: DAPI blue). Magnification x 40. Reference line: 20 µm. Gene expression: data 
shown as mean of duplicates + SEM, n= 9-11 mice per group. Pancreatic islet cell area: data shown as mean + SEM, n = 2 mice per group, 2 
sections per mouse. 
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Figure 3.15: Global Pyy deletion leads to an increase in -cell area. (A) Expression of Sst mRNA in whole pancreatic tissue samples of the 
Pyy WT and KO mice. B) Pancreatic -cell area expression in the Pyy mice. C) Representative immunostained images of pancreatic islets of the 
Pyy WT and KO mice (SST green, insulin: red & nucleus: DAPI blue). Magnification x 40. Reference line: 20 µm. Gene expression: data shown 
as mean of duplicates + SEM, n= 9-11 mice per group. Pancreatic islet cell area: data shown as mean + SEM, n = 2 mice per group, 2 sections 
per mouse.  
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3.5.4.3. Morphometric assessment of islet-cell area in the PdxPyy KO mouse 
using IHC  
To determine and compare the islet phenotype of the PdxPyy KO mouse to the PdxPyy 
WT mice, we assessed the islet cell morphometry, since no differences in islet gene 
expression was found amongst the Pyy mice. PdxPyy male mice aged 12-16 weeks were 
investigated. 
3.5.4.3.1. PdxPyy KO: Changes in pancreatic -cell area 
No differences in pancreatic islet -cell area were found between the PdxPyy WT and 
KO mice (WT: 0.0067  0.00009 vs. KO: 0.0065  0.00001 % total area) (Figure 3.16). 
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Figure 3.16: PdxPyy deletion has no effect on -cell area. (A) Representative 
immunostained images of pancreatic islets of the PdxPyy WT and KO mice (DPP-4 
green, insulin: red & nucleus: DAPI blue). Magnification x 40. Reference line: 20 µm. 
B) Pancreatic β-cell area expression in the PdxPyy WT and KO mice. Data shown as 
mean + SEM, n = 2 mice per group, 2 sections per mouse. 
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3.5.4.3.2. PdxPyy KO: Changes in pancreatic -cell area 
Like the Pyy KO mice, the PdxPyy null mice also showed a reduction in -cell area 
when compared to the control mice (WT: 0.0016  0.00007 vs. KO: 0.0014  
0.00006 % total area) (Figure 3.17). 
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Figure 3.17: PdxPyy deletion results in a reduction in -cell area. (A) 
Representative immunostained images of pancreatic islets of the PdxPyy WT and 
KO mice (GCG green, insulin: red & nucleus: DAPI blue). Magnification x 40. 
Reference line: 20 µm. B) Pancreatic α-cell area expression in the PdxPyy mice. 
Data shown as mean + SEM, n = 2 mice per group, 2 sections per mouse.  
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3.5.4.3.3. PdxPyy KO: Changes in pancreatic -cell area 
Surprisingly, we found an increase in -cell area of the PdxPyy KO mice compared 
to the WT controls (WT: 0.00019  0.000002 vs. KO: 0.00022  0.000001 % total 
area) (Figure 3.18). 
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Figure 3.18: PdxPyy deletion results in an increase in -cell area. (A) 
Representative immunostained images of pancreatic islets of the PdxPyy WT and 
KO mice (SST green, insulin: red & nucleus: DAPI blue). Magnification x 40. 
Reference line: 20 µm. B) Pancreatic δ-cell area expression in the PdxPyy WT and 
KO mice. Data shown as mean + SEM, n = 2 mice per group, 2 sections per mouse.  
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3.6. Summary 
Previous research and literature has highlighted a role for intra-islet PYY in glucose 
homeostasis, in vivo and in vitro. However, to date no studies have researched the intra-
islet PYY system in-depth. Therefore, we pursued to characterise islet PYY and 
demonstrate the importance it has in mediating insulin control.   
3.6.1. Islet isolation for gene expression analysis 
Beginning with the optimisation of a murine islet isolation protocol, we subsequently 
evaluated the expression of islet Yrs. Y2r and Y5r were unexpressed in the pancreas. Y1r 
and Y4r were identified as the only two PYY receptors present in the pancreas, with Y4r 
expression almost six-fold higher than Y1r expression. RNA extracted from isolated 
islets was then checked for Y1- and Y4r expression. Islets only expressed Y1r mRNA in 
all 8 tissues samples (Ct <36). 
3.6.2. Pancreatic localisation of PYY, DPP-4 and Y1R in the WT mouse 
Confirmation of PYY protein expression was verified in the pancreatic islets using the 
YfpPyy reporter mouse. Antibodies were sourced from literature searches and 
corroborated to the correct immunostaining patterns of the islets. Using Pyy KO mice, 
we confirmed the specific staining of the PYY antibody. Next we assessed the 
distribution of PYY to specific cell-subtypes in the WT mouse. The -cell 
predominantly expressed PYY. The next most abundant PYY positive cells co-localised 
with DPP-4. The -cells stained the least for PYY. Unlike PYY, DPP-4 mainly co-
localised with the -cells. Some DPP-4 expression was localised to the -cells but 
immunostaining for the enzyme was completely absent from the -cells.  
To understand whether PYY mediated its effects on insulin directly, we assessed the 
localisation of Y1R on -cells or with DPP-4 positive cells. We found that Y1R was 
localised with both these proteins. However, since the Y1R antibody was inefficiently 
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weak during immunostaining, we were unable to assess if it co-localised with the other 
antibodies.  
3.6.3. Determining changes in pancreatic expression in the Pyy transgenic mouse 
lines 
Using H&E staining, we were able to detect islet morphological differences in both the 
Pyy transgenic mouse lines. Both Pyy KO and PdxPyy KO mice showed an increase in 
islet cell nuclei when compared to their respective controls. Moreover, changes in 
pancreatic Ins, Gcg and Sst gene expression as well as -, - and -cell area were 
measured in the both groups of the Pyy transgenic mice. Global Pyy KO mice showed 
no difference in pancreatic islet hormone mRNA levels compared to the Pyy WT mice. 
Additionally, -cell area also remained unchanged by the deletion of Pyy in the Pyy 
mice. However, Pyy deletion caused a decrease in -cell and increase in -cell area. 
Subsequently, morphometric analysis of the PdxPyy mice was evaluated. Like the Pyy 
KO mice, the PdxPyy KO mice also showed no difference in -cell area, as well as 
reduced -cell area and an increase in -cell area. 
3.6.4. Conclusion 
In conclusion, the data presented in this chapter is consistent with the intra-islet PYY 
mediating an inhibitory effect on insulin via the Y1R, and DPP-4 appears to regulate 
this action by converting it into an inactive form in the islets (PYY 3-36). Deletion of 
islet PYY appears to contribute to fall in -cell area with an increase in -cell area in 
both the Pyy transgenic mouse models, suggesting a role for PYY in the development of 
at least - and -cells. Collectively, these findings highlight the importance of PYY in 
islet development and function, and concurs with previous published data (Boey et al., 
2006a, Batterham et al., 2006, Chandarana, 2009, Chandarana et al., 2013). However, 
more pharmacological and genetics studies are needed to understand this further. 
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Chapter 4 
 
Investigating the in vivo role of intra-
islet PYY in energy and glucose 
homeostasis
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4. Investigating the in vivo role of intra-islet PYY in energy 
and glucose homeostasis  
4.1. Introduction 
PYY has been the focus of research in the past decade for its role in body weight 
regulation. Post-prandially, gut PYY reduces appetite by activating the anorectic 
hypothalamic homeostatic neurons and inhibiting the feeding-stimulating sites. 
However, prior to these findings, studies demonstrated the presence of PYY in islets and 
a role for PYY in regulating insulin secretion (Bottcher et al., 1989, Bottcher et al., 
1993, Upchurch et al., 1994, Myrsén-Axcrona et al., 1997, Nieuwenhuizen et al., 1994). 
Subsequently, many studies followed which all aimed at understanding the 
physiological role of pancreatic PYY. 
The first of a series of studies aimed at unravelling an in vivo role for PYY in energy 
and glucose homeostasis constructed a transgenic Pyy null mouse (Boey et al., 2006b). 
This mouse was absent of the Pyy gene and thus, of either isoform of PYY. The reported 
KO mouse was obese, hyperphagic but surprisingly HI post- GTT. This was 
accompanied by another Pyy KO mouse which reported a similar findings (Batterham et 
al., 2006). The obese phenotype of this mouse was reversed by administration of 
exogenous PYY 3-36 (Batterham et al., 2006). The following year, Boey and colleagues 
generated  an overexpressing PYY mutant mouse which appeared to be protected from 
DIO but the investigators failed to assess the glucose tolerance in these mice. Moreover, 
when the mice were crossed with leptin deficient ob/ob mice they appeared to have a 
significant reduction in body weight gain and adiposity but this did not ameliorate the 
obese phenotype (Boey et al., 2007). A few years later, a PYY transgenic model was 
developed that deleted PYY in the adult mouse. This mouse was created that allowed 
deletion of PYY cells by diphtheria toxin. The resultant adult PYY KO mouse presented 
with hyperglycaemia attributed to a loss of -cells and a disruption in islet morphology. 
The disturbance in islet phenotype was reduced after a long-acting PYY 1-36 analogue 
was administered (Sam et al., 2012). However, the systemic diphtheria toxin 
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administration deletes PYY in the gut, brainstem and pancreas so this mouse does not 
give insights into the role of pancreatic PYY. In addition, this approach destroys the 
cells and thus hormones that are co-localised with PYY. Subsequently, another report 
using a similar technology as Sam et al.’s produced an adult-onset PYY overexpressing 
mouse using tamoxifen. These mice displayed a reduction in fasting-induced food 
intake, an increase in respiratory exchange ratio, an increase in lipogenic activity and a 
trend towards a reduction in OGSIS (Shi et al., 2012). Furthermore, Pyy null mice fail to 
exhibit the improvement in glucose tolerance, post-bariatric surgery as seen in the 
control mice (Chandarana et al., 2011).   
Data from chapter 3 coupled with previously published findings clearly suggest that 
PYY has a vital role in energy and glucose homeostasis, which is mediated by an 
alteration in insulin release. In particular, the global Pyy KO mouse, which despite 
having an obese phenotype shows a potentiation of GSIS (Batterham et al., 2006, Boey 
et al., 2006b). However, all these studies fail to determine the physiological role of intra-
islet PYY independently of gut PYY action and the significance of this cell population 
still remains unclear.  
Several reports have suggested a role of PYY in body weight and glucose balance (Boey 
et al., 2006b, Batterham et al., 2006, Batterham et al., 2002). The Pyy KO mice to date 
have exhibited global deletion and thus Pyy deletion throughout the GI tract, pancreas 
and brain. However, it is not known how much of a role intra-islet PYY may play in 
mediating these effects. To investigate the in vivo role of intra-islet PYY we generated a 
transgenic mouse with a pancreatic- specific promoter driven excision of the Pyy gene in 
the islets (PdxPyy KO). Thus, this mouse will enable us to potentially distinguish the 
role of the endocrine pancreas from GI and brain PYY and clarify the in vivo role of 
intra-islet PYY in energy and glucose balance. 
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4.2. Hypothesis 
‘Intra-islet PYY deletion mediates an improvement in glucose tolerance caused by 
hyperinsulinaemia’ 
4.3. Aims: 
 To investigate the effects of pancreatic-specific Pyy deletion (PdxPyy KO) on 
food intake, body weight and adiposity, in vivo. 
 To undertake a detailed in vivo glucose phenotyping of the PdxPyy KO mice and 
their wild-type littermate control mice. 
 To assess the effects of Pdx-mediated Pyy deletion on neuro- and 
enteroendocrine mRNA levels that may contribute to the observed phenotypes. 
 
4.4. Study Design:  
PdxCre mice were crossed with Pyy floxed
+/-
 to produce the PdxPyy KO mice (Gannon 
et al., 2000, Herrera, 2000). Since Cre recombinase alone has been shown to alter 
glucose tolerance we used PdxCre+ Pyy WT (PdxPyy WT) mice as controls (Fex et al., 
2007). Using genotyping PCR, the targeted Pdx-mediated Pyy gene deletion was 
confirmed. Confirmation of islet PYY protein deletion was carried out by IHC. A 
detailed in vivo phenotype of these mice was investigated in both sexes. Changes in 
acute and chronic feeding and body weight of the PdxPyy mice were assessed from 
weaning. Additionally, an IPGTT, OGTT in both sexes, and OGSIS were carried out on 
16-18 week old PdxPyy male mice. Body length and gonadal fat mass were determined. 
Furthermore, brainstem, ileal and colonic expression of Pyy were measured. Finally, 
duodenal Cck & Pyy, stomach ghrelin, ileal and colonic proglucagon mRNA expression 
was quantified by qRTPCR.  
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4.5. Results 
4.5.1. Constructing the Pdx-specific Pyy null mouse 
4.5.1.1. Confirmation of Pdx-specific Pyy gene deletion in the PdxPyy KO mouse 
using genotyping PCR. 
The Pdx-1 promoter is highly expressed during pancreatic, stomach antrum and 
duodenal murine ontogeny. Mouse PdxPyy WT and KO were produced by the Cre/loxP 
system (Gannon et al., 2000, Herrera, 2000) (Figure 4.1). Central and peripheral tissues 
were taken from PdxPyy KO mice and their littermate controls to assess genotype 
(Figure 4.2). As described previously, DNA was extracted from the sample and deletion 
was confirmed to the pancreas and duodenum only. The interleukin-2 (IL2) gene was 
used an internal control for the confirmation of DNA extraction.  
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Figure 4.1: PdxPyy mouse targeting strategy. Construction of the PdxPyy mice after recombination and deletion of the flanked LoxP 
Pyy gene. Cre-mediated deletion of the Pyy-coding region was confirmed using primers D1 and D2. The 326 bp product represents the 
presence of the WT allele, with the 350 bp demonstrating the floxed Pyy gene both obtained using the D1 and D2 primers. The 750 bp 
product indicates the Pdx cre gene with the presence of the IL2 allele (324 bp) acting as an internal positive control for the presence of 
genomic DNA. Representative genotyping of LoxP and PdxCre PCR used to detect alleles of interest. N = 5 mice per group. 
Heterozygote (Het), homozygous (Homo), wild type (WT), flanked LoxP sites (flox). 
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Figure 4.2: Evidence for the deletion of Pyy in the PdxPyy KO mouse. Representative genotyping PCR indicating the deletion of 
the Pyy gene in the duodenum and pancreas of the PdxPyy KO versus PdxPyy WT mice. C = cortex, Hy = Hypothalamus, BS = 
Brainstem, H = Heart, Lu = Lungs, L = Liver, K = Kidneys, M = Skeletal Muscle, F = Gonadal fat, Sp = Spleen, P = Pancreas, S = 
Stomach, D = Duodenum, J = Jejenum, I = Ileum, Co = Colon, + and - = controls. N = 10 mice per group. 
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4.5.1.2. Evaluating the protein expression of PYY in pancreatic islets of the 
PdxPyy mice. 
We evaluated whether we could detect PYY protein in the PdxPyy mice. Using insulin 
as a marker for islet localisation, we found PYY immunopositive cells in the PdxPyy 
WT mouse and confirmed PYY protein deletion in the PdxPyy KO mouse (Figures 
4.3A-B). 
 
 
 
 
 
 
 
Figure 4.3: Assessment of Pdx-regulated PYY protein expression in the pancreas of 
the PdxPyy mice. Islet immunostaining for PYY (red), insulin (green) and nuclear 
staining in DAPI (blue) in A) PdxPyy WT and B) PdxPyy KO mice. N = 2 mice per 
group, 2 sections per pancreas, x 20 magnification, line represents: 20 µm. 
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4.5.2. In vivo evaluation of the physiological characteristics of intra-islet Pyy 
deletion on energy and glucose homeostasis 
To assess the physiological role of islet PYY action in the appropriate regulation of 
appetite and body weight, we analysed cumulative food intake and weight gain in both 
male and female PdxPyy KO mice and their littermate controls.  
 
4.5.2.1. Evaluating the effects of Pdx-mediated deletion of Pyy on food intake  
Singly-housed mice were fed ad libitum chow and food weight per cage was recorded 
weekly and thus, food intake was calculated per week. Cumulative weekly food intake 
from weaning until the end of the study remained unchanged in both male and females 
(Figures 4.4A & C). However, when the PdxPyy KO mice were fasted for 16 hours and 
refed ad libitum, the male PdxPyy KO mice showed a significant decrease in cumulative 
acute food intake at 2h (1.0 ± 0.1 g, p= 0.02), 4h (1.2 ± 0.1 g, p= 0.01), 6h (1.6 ± 0.1 g, 
p= 0.02), and 8h hours (2.0 ± 0.2 g, p= 0.05) post-refeed when compared to WT controls 
(2h= 1.4 ± 0.1 g, 4h= 1.7 ± 0.1 g, 6h= 2.2 ± 0.1 g & 8h= 2.5 ± 0.2 g). However, 
eventually both groups were eating the same amount of food by 24 hours (WT= 5.8 ± 
0.3 g & KO= 5.4 ± 0.4 g) (Figure 4.4B). The female mice showed no difference in acute 
feeding behaviour (Figure 4.4D).   
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Figure 4.4: Assessment of food intake in the PdxPyy mice. Cumulative food intake in 
the: A) Male PdxPyy mice: blue. B) Female PdxPyy mice: red. N = 10 mice per group. 
Data represented as mean ± SEM. * p < 0.05, ** p < 0.01. 
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4.5.2.2. Evaluating the effects of Pdx-mediated deletion of Pyy on body weight 
Deletion of Pyy in the PdxPyy mice of both sexes resulted in a significant reduction in 
weight gain during the study period when compared to the PdxPyy WT controls in both 
male and female mice. Male PdxPyy KO mice were significantly lighter from 8 weeks 
of age (p <0.05: Figure 4.5A), whereas, female PdxPyy KO mice were lighter from 
weaning (p <0.01: Figure 4.5C). This difference at weaning implies that pancreatic Pyy 
deletion affects growth, this will assessed further in section 4.5.2.3.     
 
After a 16-hour fast, male PdxPyy WT mice weighed significantly less when fasted than 
when fed ad libitum (p <0.001), as did the PdxPyy KO mice (p <0.01). The male fasted 
or fed WT mice weighed more than the null mice (p <0.0.5: Figure 4.5B). On the other 
hand, female PdxPyy KO mice only significantly weighed more fed than fasted (p 
<0.05: Figure 4.5D).  
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Figure 4.5: Body weight phenotype of the PdxPyy mice. Cumulative body weight gain 
in the: A) Male PdxPyy mice: blue. B) Female PdxPyy mice: red. Fasted or fed body 
weight in: C) Male PdxPyy mice: blue/green. D) Female PdxPyy mice: red/black. N = 
15-25 mice per group. Data represented as mean ± SEM. *p<0.05, **p<0.01, ***p 
<0.001 between genotypes. p < 0.05, p < 0.01, between the fasted or fed groups. 
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4.5.2.3. Evaluating the effects of Pdx-mediated deletion of Pyy on factors that 
may contribute to the observed body weight phenotype. 
To ensure that the body weight difference was not due to somatic growth, in mice aged 
16-18 weeks, we measured the length of the mouse (from nose to anus). The WT mice 
body lengths were not significantly different from the KO mice of both sexes (Male 
WT= 10.74 ± 0.08 cms versus KO= 10.48 ± 0.13 cms and female WT= 10.08 ± 0.17 
cms versus KO= 9.9 ± 0.09 cms) (Figures 4.6A & B).  Fat mass from the gonads was 
removed and weighed in 16-18 week old mice. Male PdxPyy WT mice fat mass was 
0.48  0.03 g and the null mice showed a reduction in gonadal fat (0.36  0.04 g, p 
<0.001: Figure 4.6C-D). In female mice this difference was not apparent (Figure 4.6E).  
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Figure 4.6: PdxPyy KO mice show decreased adiposity. A&B) Body length in the male (blue) and female (red) PdxPyy mice. C) 
Representative image of the PdxPyy mouse body size. D-E) Gonadal fat mass in the male (blue) and female (red) PdxPyy mice. F) 
Ventral representative image of fat pads of the PdxPyy mice. N = 8-10 mice per group aged 16-18 weeks. Data represented as mean + 
SEM. ***p < 0.001.  
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4.5.2.4. Evaluating the effects of Pdx-mediated deletion of Pyy on glucose 
homeostasis. 
Glucose homeostasis was assessed in 18-20 week old PdxPyy mice (body weights: 
males: WT: 28.4 ± 0.7 g, KO: 25.1 ± 0.9 g, p <0.01. Females: WT: 18.5 ± 0.5 g, KO: 
20.4 ± 1.3 g).  The glucose tolerance in these mice was done by performing an IPGTT, 
OGTT and an OGSIS. For the GTTs, a bolus i.p. injection or oral gavage with glucose 
(1g/kg body weight) was administered in age- and sex-matched PdxPyy KO mice and 
their controls. Blood was taken to measure glucose levels from the tail vein before and 
after the injection. For the GSIS, additional blood was taken for measurement of 
circulating insulin levels. 
Fasted blood glucose of the PdxPyy WT mice was not significantly different from the 
KO mice in both male (WT: 3.0  0.2 mM vs. KO: 3.0  0.3 mM: Figure 4.7A) and 
female mice (WT: 3.5  0.4 mM vs KO: 2.9  0.2 mM: Figure 4.7B). 
 
I. IPGTT 
From the IPGTT, the PdxPyy KO mice showed a significant reduction in blood glucose 
levels at t90 and t120 post-injection in the males and t120 in females (Male t90: WT: 
16.7  2.1 mM, KO: 8.6  1.5 mM,  p =0.009, male t120: WT: 12.7  2.0 mM, KO: 5.2 
 0.5 mM p <0.005: Figure 4.7C, female t90: WT: 5.0  0.3 mM, KO: 3.1  0.3 mM p 
<0.002: Figure 4.7D). In addition, the AUC60-120 IPGTT was significantly lower in the 
male PdxPyy KO mice (551.6  87.4 mM/min) compared to the controls (968.8  119.5 
mM/min p <0.05) (Figure 4.7E). The female PdxPyy KO mice showed insignificantly 
reduced AUC90-120 IPGTT (119.1  11.6 mM/min) compared to the controls (162.4  
17.2 mM/min, p =0.059) (Figure 4.7F). 
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Figure 4.7: Assessment of IPGTT in the PdxPyy mice. Glucose homeostasis was assessed in age- and sex-matched PdxPyy mice. 
Glucose (1g/kg body weight) was injected i.p. and blood samples collected for measurement of blood glucose at time points indicated. 
Fasted blood glucose in A) males and B) females. Time course of IPGTT in C) males and D) females. AUC IPGTT in E) males and F) 
females. Data is shown as mean ± SEM of duplicates. N = 6-12 per group, * p < 0.05, ** p < 0.01. 
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II. OGTT and OGSIS 
From the OGTT, the PdxPyy KO mice showed a significant reduction in blood glucose 
levels at t30 in male mice (15.8  1.5 mM vs. WT: 20.9  1.8 mM, p =0.04: Figure 
4.8A). In female mice however, there was no difference in the OGTT response between 
the groups (Figure 4.8B). In addition, the AUC30-120 OGTT was significantly lower in 
the male PdxPyy KO mice compared to the controls (WT: 1487.2  159.9 mM/min vs. 
KO: 972.2  83.3 mM/min: Figure 4.8C). Again, there was no difference in the AUC 
OGTT of the female different PdxPyy mouse groups (Figure 4.8D). Blood was also 
taken at the times indicated in the OGSIS for assessment of insulin release and measured 
by ELISA. At t15, PdxPyy KO mice significantly secreted more insulin (WT: 0.20  
0.04 ng/ml vs. KO: 0.31  0.02 ng/ml, p =0.04), with the AUC0-30 OGSIS showing a 
significant increase in the PdxPyy KO mouse (p =0.027) (Figures 4.8E-F). 
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Figure 4.8: Assessment of OGTT and OGSIS in the PdxPyy mice. Glucose 
homeostasis administered orally and blood samples collected for measurement of blood 
glucose and GSIS at time points indicated. Time course of OGTT in A) males and B) 
females. AUC OGTT in C) males and D) females. E) Time course of OGSIS in males. 
F) AUC0-30 OGSIS. Data is shown as mean ± SEM of duplicates. N = 5-9 per group, * p 
< 0.05, ** p < 0.01. 
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4.5.3. Investigating the possible compensatory factors that may contribute to the 
observed energy and glucose homeostatic phenotypes of the PdxPyy KO mouse 
4.5.3.1. Assessing the hormonal changes that may contribute to the PdxPyy KO 
phenotype: PYY expressing sites.  
Apart from the pancreas, PYY is found expressed in the gut which has known post-
prandial anorectic action (Batterham et al., 2002, Batterham and Bloom, 2003, 
Batterham et al., 2003). However, PYY is also located in the brainstem but the 
physiological role of this set of cells remains unknown (Glavas et al., 2008, Gelegen et 
al., 2012). To determine if changes in gut and brainstem Pyy may be involved in the 
observed phenotypes, we measured Pyy gene expression from these tissues of the 
PdxPyy mice. Whole tissue qRTPCR were performed on the brainstem, ileum, and 
colon. Brainstem, ileal and colonic Pyy expression was not different between the groups 
(Figure 4.9).  
 
 
 
 
Figure 4.9: Assessment of Pyy mRNA in the PdxPyy mice. Whole tissue Pyy 
expression was measured by qRTPCR in A) Brainstem, B) Ileum and C) Colonic tissue. 
Results were normalized to Ubc. Filled bars: PdxPyy WT and patterned bars: PdxPyy 
KO. Data is shown as mean + SEM of duplicates. N= 4-7 per group.   
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4.5.3.2. Assessing the duodenal hormonal changes that may contribute to the 
PdxPyy KO phenotype.  
To assess if the Pdx-directed deletion of Pyy affected duodenal expression of Pyy, 
we measured for changes in mRNA levels. There was no significant difference in 
duodenal Pyy expression between the PdxPyy WT (0.071 ± 0.005 AU) and PdxPyy 
KO mice (0.074 ± 0.02 AU) (Figure 4.10A). Cholesystokinin (CCK), a duodenal 
anorectic peptide was also assessed to determine whether the Pdx-targeting strategy 
was possibly causing compensation for the loss of the Pyy gene. Cck mRNA was 
measured by real-time qRTPCR and remained unchanged between 16-18 week old 
ad libitum fed PdxPyy KO mice and their control littermates (Figure 4.10B).  
 
 
 
 
 
 
Figure 4.10: Assessment of duodenal gut hormone gene expression. Whole tissue 
gene expression was measured from the duodenum for A) Pyy expression and B) 
Cck in the PdxPyy mice. Results were normalized to Ubc. Filled bars: PdxPyy WT 
and patterned bars: PdxPyy KO. Data is shown as mean + SEM of duplicates. N=4-7 
per group.  
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4.5.3.3. Assessing the gut hormone changes that may contribute to the PdxPyy 
KO phenotype.  
In addition to the duodenum, other gut hormones were assessed; stomach ghrelin, 
ileal and colonic proglucagon gene expression were measured. There was no 
difference between the 16-18 week old ad libitum fed PdxPyy KO and the control 
mice (Figure 4.11). 
 
 
 
 
 
 
Figure 4.11: Assessment of gut hormone gene expression in the male PdxPyy 
mice. Whole tissue gut hormone expression was measured by qRTPCR: A) Stomach 
ghrelin, B) Ileum and C) Colonic proglucagon mRNA in the PdxPyy mice. Results 
were normalized to Ubc. Filled bars: PdxPyy WT and open bars: PdxPyy KO. Data is 
shown as mean + SEM of duplicates. N= 4-7 per group.   
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4.6. Summary 
4.6.1. Analysis of Pdx-specific deletion of Pyy 
To understand the specific in vivo role of islet PYY, a transgenic mouse was created; 
PdxPyy KO. PdxCre meditated recombination of the floxed Pyy gene was successful 
causing the deletion of the gene and protein. Duodenal Pyy mRNA levels remain 
unchanged in the PdxPyy KO mice in comparison to the control ad libitum fed mice. 
This work suggests a role for pancreatic PYY in the regulation of body weight and 
glucose metabolism.  
4.6.2. PdxPyy deletion effects on body weight and appetite regulation 
Deletion of pancreatic PYY resulted in no change to weekly cumulative food intake, 
but a significant reduction in food intake at a few time points post a fast-re-feed 
challenge in male mice. Additionally, there was also a reduction in cumulative body 
weight gain in both male and female PdxPyy KO mice compared to the PdxPyy WT 
from weaning to the end of the study.  
To ensure the body weight phenotype was not a result of a difference in somatic 
growth, as was seen in the global Pyy
-/-
 mouse (Boey et al., 2006b), we measured the 
length of the mice and found that PdxPyy KO and WT mice were of a similar body 
length in both male and females. Gonadal fat mass was also measured to see if this 
was contributing to the observed phenotype. Only male PdxPyy KO mice showed 
significantly less fat than the WT mice, this phenotype was not apparent in the 
female groups.  
4.6.3. PdxPyy deletion and glucose homeostasis 
The oral GTT challenge resulted in HI and a reduction in blood glucose in the 
PdxPyy null mouse. We also carried out an IPGTT to see whether the response was 
lost in absence of enteral stimulation and found a significant reduction in blood 
glucose levels but this was observed at a later time. Moreover, in vivo GSIS was 
markedly increased, with a reduction in blood glucose.  
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4.6.4. PdxPyy deletion and the gut 
To assess whether there are compensatory changes to gut hormones as a result of the 
PdxPyy deletion, we initially measured Pyy mRNA in the brainstem (Glavas et al., 
2008, Gelegen et al., 2012) and lower gut (Batterham et al., 2002, Batterham and 
Bloom, 2003). Subsequently, using qRTPCR Pyy expression from peripheral and 
central sites was quantified. This was followed by gut ghrelin, Cck and 
enteroglucagon measurements. This was undertaken to assess whether other gut 
hormones were contributing to the in vivo effects observed in these mice. However, 
no changes were observed in the gut hormone gene expression of the PdxPyy KO 
mice. 
4.6.5. Conclusion 
In summary, this chapter demonstrates that PYY-mediated systems are important for 
the regulation of body weight and glucose homeostasis. In particular, Pdx-specific 
deletion of Pyy led to the successful deletion of islet PYY protein and results in an 
exaggerated GSIS causally linked to a lean phenotype and decreases in adiposity. 
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Chapter 5 
 
Characterising the role of gut 
hormones in hyperinsulinaemic 
hypoglycaemia
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5. Characterising the role of gut hormones in 
hyperinsulinaemic hypoglycaemia 
5.1. Introduction 
Nesidioblastosis in adults or congenital forms of HH is characterised by persistent 
hypoglycaemia due to unregulated secretion of insulin from the pancreatic β-cells. 
Historically adult-onset nesidioblastosis has been rare and was mainly found due to the 
occurrence of non-insulinoma pancreatogenous hypoglycaemia syndrome (NIPHS) 
(Jabri and Bayard, 2004). Though the cause appears to be unknown, as of late there 
appears to be a surge in the frequency of cases. Increasing evidence has suggested this to 
be a result of the GBP weight-loss surgery (Service et al., 2005). At present, two 
theories exist for the reasoning behind nesidioblastoma formation as a complication of 
GBP surgery. The first suggests that obesity induces HI and islet hyperfunction. The 
second hypothesis is that HI is a consequence of GBP (Service et al., 2005, Cummings, 
2005). However, support against the first hypothesis is that individuals with insulinomas 
are not morbidly obese and obese persons have normal islet cell morphology (Service et 
al., 2005). Due to such theories, a deeper understanding for the functional mechanisms 
purporting that bariatric surgery causes nesidioblastosis is becoming of great interest to 
diabetes research.  
Many individuals who have undergone GBP have presented with the dumping 
syndrome. Reports have proposed this to be because of an increase in peripheral GLP-1 
due to the rapid transit of nutrients to the distal gut (Miholic et al., 1991). GLP-1 is 
known to promote β-cell proliferation, neogenesis and inhibit apoptosis. Furthermore, a 
case study highlighted the persistence of post-prandial HH episodes in a person who 
previously had undergone a GBP. The individual required a subtotal pancreatectomy. 
However, 6 months post-surgery and apparent remission, HH returned and the person 
was managed on drugs (Qintar et al., 2012). Hence this case supports the theory that 
GBP has possibly either bypassed the proximal gut hormone(s) (such as GIP: foregut 
theory) and/or overstimulated the distal GI peptide(s) (such as GLP-1 and PYY: hindgut 
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theory) to induce exaggerated HI. This in turn would potentially mediate hypoglycaemia 
and nesidioblastosis. Moreover, DPP-4 regulates these gut hormones and thus, GBP 
may also be altering the biological activity of DPP-4 on these substrates. Furthermore 
DPP-4 inhibition is currently employed to promote the incretin effect in T2DM. 
Ultimately, if GLP-1 and other DPP-4 gut hormone substrates are factors involved in 
this condition, then it brings into question (1) the current practice of GBP as well as (2) 
the use of GLP-1R agonists and DPP-4 inhibitors as therapeutic treatments of obesity 
and T2DM.  
Nesidioblastosis has also been reported in neonates (Rahier et al., 2000). It is more 
commonly referred to and accepted as CHI. CHI incidence is around 1 in 50,000 births 
of the general population and can be transient or persistent. In most cases, defects in the 
KATP channels (channelopathies) cause the congenital form of HH; KATPHI (Senniappan 
et al., 2013). Treatments of such cases usually require constant feeding and 
pharmacotherapy. In medically-unresponsive HH situations, surgical removal of the 
pancreas is required. The overall effect is to reduce insulin secretion and function as 
well as prevent brain damage that occurs as a result of recurring hypoglycaemia. 
However, the surgery has complications and often leads to pancreatic exocrine 
insufficiency and DM (Arya et al., 2013).  
Gene deletion of Sur-1 results in fasted hypoglycaemia and is similar to the human 
KATPHI condition (De Leon et al., 2008). WT mice treated with the GLP-1R antagonist 
exendin (9-39) have shown an increase in fasting blood glucose (De León et al., 2003). 
Therefore Sur-1 null animals were treated with the exendin (9-39) or vehicle and blood 
glucose measured. The KO mice treated with exendin (9-39) had an increase in fasting 
blood glucose when compared to vehicle-treated KO mice. These changes were in the 
absence of body weight, glucose tolerance and insulin sensitivity adjustments (De Leon 
et al., 2008). This was followed by a pilot clinical study by the group. They infused the 
GLP-1R antagonist in patients with KATPHI and aimed to reduce HH (Calabria et al., 
2012). They found a glucose increasing effect and insulin decreased without altering 
circulating glucagon or GLP-1 levels. Overall these studies implicate and support the 
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hypothesis that GLP-1 activity plays an important role in HH and thus, may have the 
potential as a therapeutic target for the treatment of this disease. However, these studies 
have also failed to assess if other gut hormone are involved in the pathophysiology of 
HH.           
Collectively the data supports the theories that gut hormone changes promote HH as a 
result of KATPHI or due to GBP-induced nesidioblastosis. However, the mechanism of 
this effect remains unknown. Taken together, the interaction between the incretins, PYY 
and DPP-4 needs to be examined more closely if (1) we are to gain full therapeutic 
benefit and (2) avoid possible adverse effects of current drug treatments for HH.   
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5.2. Hypothesis 
‘Hyperinsulinaemic hypoglycaemia promotes changes in DPP-4 and its gut hormone 
substrates’ 
5.3. Aims: 
 To determine changes in expression of pancreatic genes involved in energy and 
glucose balance. 
 To characterise the distribution and localisation of islet PYY and DPP-4 in 
healthy pancreatic samples. 
 To determine the proliferating islet-cell subtypes in the KATPHI pancreas. 
 To assess circulating gut hormone changes in patients with KATPHI at HH. 
 To evaluate correlations between metabolites analysed in patient with KATPHI. 
 
5.4. Study Design: 
Using gene expression analysis, we determined changes in mRNA of pancreatic genes 
that may contribute to the KATPHI phenotype of six KATPHI patients against two non- 
KATPHI controls. The localisation of PYY and DPP-4 expression in different islet cell 
subtypes were evaluated in eight healthy pancreata using IHC. Thereafter, we aimed to 
identify the proliferating islet-cell subtype in three KATPHI pancreatic tissues. In 
addition, five KATPHI patients were recruited and studied consecutively. All patients 
underwent a controlled hypoglycaemia screen (reducing i.v. glucose with no feeds) and 
blood was collected at normoglycaemia and at hypoglycaemia. Plasma glucose was 
measured by YSI and plasma insulin using RIAs. Active GLP-1 and total GIP were 
measured using ELISAs and active PYY was measured by RIAs. Finally correlation 
analysis was carried out in five KATPHI patients. 
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5.5. Results 
5.5.1. Assessing the changes in expression of pancreatic genes involved in energy 
and glucose balance.  
To begin we wanted to find possible gene contributors to the HH seen in KATPHI. 
Hence, we analysed the pancreatic gene expression of six KATPHI patients and compared 
them with two non- KATPHI controls. mRNA analysis of KATPHI patients showed an 
increase in DPP-4 expression (control: 5.04 ± 0.39 AU versus KATPHI: 6.13 ± 0.11 AU) 
and a trend towards a down-regulation of PYY expression (control: 5.32 ± 0.01 AU 
versus KATPHI: 4.85 ± 0.08 AU, p = 0.09) when compared to control tissue. Y1R gene 
expression was also down-regulated but this was insignificant (control: 5.69 ± 0.35 AU 
versus KATPHI: 4.80 ± 0.34 AU, p = 0.31). Additionally, SST expression appeared to be 
significantly upregulated in KATPHI (control: 9.18 ± 0.94 AU versus KATPHI: 10.13 ± 
0.04 AU). No changes were observed in the GLP-1R, GIP, GCG and in any pancreatic 
PYY YR subtypes (p >0.05) (Figure 5.1).      
 
 
Figure 5.1: Gene expression results from pancreatic tissue samples of control and 
KATPHI patients. Gene expression of RNA isolated from KATPHI pancreata and control 
donors. N = 6 KATPHI and 2 control. Data shown as + SEM as % of control gene 
expression *p <0.05. Data reproduced from work carried out by Dr S. Senniappan, with 
permission. 
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5.5.2. Characterising the distribution and localisation of islet PYY and DPP-4 in 
normal healthy pancreas from children. 
Primary and secondary antibodies (Chapter 2: Table 2.3) were used as previously 
described. Eight pancreata samples were obtained from healthy normal pancreatic tissue. 
This was following analysis and confirmation by the Histopathology Team at GOSH. 
Using immunofluorescent IHC, protein localisation of PYY and DPP-4 was determined. 
 
5.5.2.1. PYY localisation in α-, β-, and δ-cells. 
To determine if PYY was localised and was similar anatomically to the murine model; 5 
µm pancreata sections from normal healthy and KATPHI patients were immunostained 
for individual cell-markers and PYY. As expected, we found that PYY was not co-
localised with insulin (Figure 5.2A). PYY was found to be co-localised with glucagon in 
α-cells (Figure 5.2B). However, PYY was also absent from somatostatin δ-cells (Figure 
5.2C).  
 
5.5.2.2. DPP-4 localisation in α-, β-, and δ-cells. 
DPP-4 expression appeared to be distributed in and on insulin positive β-cells (Figure 
5.3), as well as with glucagon in α-cells (Figure 5.4). A small population of δ-cells were 
also positive for the expression of DPP-4 (Figure 5.5). However, DPP-4 was absent 
from PYY positive cell populations in normal healthy pancreatic islets (Figure 5.6). 
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Figure 5.2: PYY is only localised to the human α-cells. Representative islet immunostaining in healthy children: (A) PYY (red) and 
insulin (blue) (B) Glucagon (green) and PYY (red). (C) Somatostatin (purple) and PYY (red). Yellow arrow indicates co-localisation 
of proteins. N = 8 with 2 sections per subject. Magnification x 20. Reference line: 50 µm. 
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Figure 5.3: DPP-4 is localised in and on β-cells with insulin in healthy children pancreatic tissue. Representative islet 
immunostaining in healthy children: for insulin (red), DPP-4 (green) Red arrow indicates insulin only positive staining; green arrow 
indicates DPP-4 only positive staining with yellow arrow indicating co-localisation of the two proteins. N = 8 subjects, 2 sections per 
subject. Magnification x 63. Reference line: 10 µm. 
 
DPP-4 Ins Merge 
  145 
 
 
 
 
 
Figure 5.4: DPP-4 is localised in and on α-cells with glucagon in healthy children pancreatic tissue. Representative islet 
immunostaining in healthy children: for glucagon (red), DPP-4 (green). Green arrow indicates DPP-4 only positive staining with 
yellow arrow indicating co-localisation of the two proteins. N = 8 subjects, 2 sections per subject. Magnification x 20. Reference line: 
20 µm. 
Merge GCG DPP-4 
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Figure 5.5: DPP-4 is localised in and on a few δ-cells with somatostatin in healthy children pancreatic tissue. Representative 
islet immunostaining in healthy children: for somatostatin (red), DPP-4 (green). Image inset indicating co-localisation of the two 
proteins. N = 8 subjects, 2 sections per subject. Magnification x 20. Reference line: 20 µm. 
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Figure 5.6: DPP-4 is not co-localised with PYY cells in healthy children pancreatic tissue. Representative islet immunostaining in 
healthy children: for PYY (red), DPP-4 (blue). N = 8 subjects, 2 sections per subject. Magnification x 20. Reference line: 25 µm. 
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5.5.3. Evaluating pancreatic changes in patients with KATPHI. 
5.5.3.1. Morphological changes in patients with KATPHI. 
Normal healthy pancreas was used as control and compared to KATPHI pancreas, which 
were obtained with consent from patients who have a near total pancreatectomy. 
Sections were cut and mounted on superfrost slides and H&E stained for visualisation of 
pancreata architecture. KATPHI pancreas generally had normal morphology and 
distribution of exocrine and endocrine cells however; they appeared to show 
characteristically large islet nuclei when compared to healthy pancreatic tissue (Figure 
5.7).  
 
 
 
 
 
 
 
 
Figure 5.7: Normal and KATPHI pancreatic architecture. Representative images of 
haematoxylin & eosin (H&E) stained sections of pancreas in (A & C) normal and (B & 
D) KATPHI. Blue arrows indicate islet cell nuclear staining and black arrows indicate 
acinar cells (exocrine). (A & B) Magnification x 20, (C & D) magnification x 40. N = 8 
subjects per group, 6 sections per patient. Reference line: 100 µm. 
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5.5.3.2. Proliferative changes in patients with KATPHI.  
KATPHI and control pancreata were sectioned at 5 µm depth and stained for Ki67; a 
marker used to show proliferation. KATPHI pancreas showed an increased number of 
Ki67 nuclear immunostaining when compared to healthy pancreatic tissue (Figure 5.8). 
Performed with the assistance of GOSH histopathology lab. 
 
 
 
  
 
 
Figure 5.8: KATPHI promotes islet-cell proliferation. Representative immunostained 
sections of pancreas in normal and KATPHI using automated Leica stainer for Ki67 
proliferation marker. Black arrow indicates the islet cell nuclear staining absent of Ki67 
staining (brown). Blue arrows indicate Ki67+ acinar nuclear cell staining. Red arrow 
represents Ki67+ islet cell nuclear staining. Magnification x 40. N = 8 subjects per 
group, 2 sections per subject. Reference line: 50 µm. 
 
Normal KATPHI 
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5.5.3.3. Assessment to detect islet expression changes in patients with KATPHI. 
Using IHC, we tried to determine the islet cell subtypes that may be proliferating and 
hence, contribute to the observed phenotype of these patients using Ki67 as a marker for 
proliferation. 
 
KATPHI tissue appeared to show islet -cell proliferation (Figure 5.9), which was absent for 
-cells (Figure 5.10). Islet -cell showed positive immunostaining for the proliferative 
marker, Ki67 (Figure 5.11). In addition, PYY and DPP-4 expression were assessed against 
the proliferative marker. PYY positive cells showed no proliferation (Figure 5.12). 
Whereas, DPP-4 positive cells were clearly also expressing Ki67 (Figure 5.13). 
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Figure 5.9: KATPHI promotes -cell proliferation. Representative immunostained sections of pancreas in (A) normal and (B) KATPHI 
using automated Leica stainer for Ki67 proliferation marker. Immunofluorescent staining for insulin in red. Yellow arrows represent the 
islet cell nuclear staining positive for Ki67 staining (brown). DAPI stains nuclei blue. Magnification x 20 & x 40. N = 3 subjects per group, 
2 sections per subject. Reference line: 50 µm.           
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Figure 5.10: KATPHI is absent in -cell proliferation. Representative 
immunostained sections of pancreas in (A) normal and (B) KATPHI using automated 
Leica stainer for Ki67 proliferation marker. Immunofluorescent staining for 
glucagon in green. Yellow arrows indicate the islet cell nuclear staining positive for 
Ki67 staining (brown). DAPI stains nuclei blue. Magnification x 20 & x 40. N = 3 
subjects per group, 2 sections per subject. Reference line: 50 µm. 
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Figure 5.11: KATPHI promotes -cell proliferation. Representative immunostained sections of pancreas in (A) normal and (B) KATPHI using 
automated Leica stainer for Ki67 proliferation marker. Immunofluorescent staining for somatostatin in green. Yellow arrows indicate the islet 
cell nuclear staining positive for Ki67 staining (brown). Magnification x 20 and x 40. N = 3 subjects per group, 2 sections per subject. Reference 
line: 50 µm. 
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Figure 5.12: KATPHI does not promote PYY-positive cell proliferation. Representative immunostained sections of pancreas in (A) normal 
and (B) KATPHI using automated Leica stainer for Ki67 proliferation marker. Immunofluorescent staining for PYY in red. Yellow arrows 
represent the islet cell nuclear staining positive for Ki67 staining (brown). Red arrow represents Ki67+ islet cell nuclear staining. Magnification 
x 20 and x 40. N = 3 subjects per group, 2 sections per subject. Reference line: 50 µm. 
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Figure 5.13: KATPHI causes DPP-4-cells to proliferate. Representative immunostained sections of pancreas in (A) normal and (B) KATPHI 
using automated Leica stainer for Ki67 proliferation marker. Immunofluorescent staining for DPP-4 in green. Yellow arrows represent the islet 
cell nuclear staining positive for Ki67 staining (brown). DAPI stains nuclei blue. Magnification x 20 & x 40. N = 3 subjects per group, 2 sections 
per subject. Reference line: 50 µm. 
A: Normal 
B: K
ATP
HI 
DPP-4 
DAPI Ki67 
DPP-4 Ki67 
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5.5.4. Changes in plasma gut hormone levels in patients with KATPHI. 
Five patients were recruited for this study with consent obtained from 
parents/guardians. Since pancreatic DPP-4 was significantly increased in KATPHI 
patients, we analysed the gut hormone substrates that may be affected.  
 
5.5.4.1. Recruitment and biochemical characteristics of KATPHI patients 
The age of the patients was 4.8 ± 1.6 weeks (mean ± SD) weeks and body weight 4.5 
± 0.6 kgs. The mean plasma insulin levels were 18.6 ± 8.6 mU/L at normoglycaemia 
and decreased to 10.9 ± 2.9 mU/L (p =0.289) at hypoglycaemia. Plasma glucose 
levels significantly decreased from 6.1 ± 1.0 to 2.4 ± 0.2 mmol/L (p =0.02) (Table 
5.1). 
 
5.5.4.2. Assessing circulating gut hormone levels in patients with KATPHI 
Circulating gut hormone peptides were measured using commercially available 
assays and corrected for body weight. Circulating active PYY levels decreased from 
223.7 ± 63.6 to 215.3 ± 52.1 pg/ml/kg (p =0.772) at hypoglycaemia from 
euglycaemia. Plasma levels of active GLP-1 insignificantly increased at 
hypoglycaemia (1.5 ± 0.5 to 0.8 ± 0.5 pM/kg (p =0.514). Total GIP levels fell from 
28.1 ± 9.8 to 19.5 ± 7.4 pg/ml/kg (p =0.083) at hypoglycaemia (Figure 5.14).  
 
5.5.4.3. Assessing correlations between circulating metabolites in patients 
with KATPHI at normoglycaemia and at hypoglycaemia 
The difference between hypoglycaemia and baseline (normoglycaemia) were 
determined for each metabolite and then corrected for body weight. Correlation 
analysis was carried out using these values and relationship between plasma 
metabolites evaluated. No correlation existed amongst any of the metabolites except 
GLP-1 and PYY (Figure 5.15). 
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  Patient Information 
   AI DT RD JE LA 
 
Gestational weight at 
delivery 
 3.0kgs 
 
4.5kgs 
 
3.2kgs 
 
4.3kgs 
 
2.1kgs 
 
 Age of presentation Birth Birth Birth Birth Birth 
 Current age (weeks) 2 2 2 8 5 
 Histology Diffuse Diffuse Transient HI Diffuse Unknown 
 
Genetics 
 
 Homozygous ABCC8 
mutation 
Maternal heterozygous 
ABCC8 mutation 
ABCC8/KCJN11 
mutation negative 
Unknown-Awaiting 
results 
 ABCC8/KCJN11 
mutation negative 
 Sex Male Male Male Female Female 
 Weight 3.1kgs 4.5kgs 3.18kgs 5.6kgs 2.86kgs 
 Treatment 
 
  
  
Sirolimus,  Octreotide  
 Omeprazole, 
Domperidone 
Rantidine 
Diazoxide 
Chlorothiazide 
120ml/kg/day 25% 
dextrose 
Continue to monitor 
annually  
  
  
16mls/hr 40% dextrose 
 
 
 
10ml/hr 30% dextrose 
 
  
  
 
 
 Pre-screen preparation Fasted 4 hours Fasted 6 hours Fasted 5.5hrs Fasted 4 hours Fasted 3.5 hours 
N
o
rm
a
l 
 
BM (mM) 7.5 4.9 4.7 9.7 3.8 
Glucose (mM) 6.7 6.7 4.2 9.2 3.9 
Insulin (mU/L) 7.9 7.9 10.7 52.7 14 
H
y
p
o
 BM (mM) 3.1 2.6 2.7 2.4 2.7 
Glucose (mM) 2.0 2.0 2.8 2.8 2.5 
Insulin (mU/L) 9.3 9.3 2.7 20.4 12.6 
 
NOTES 
 
 
 
  
 Consanguineous 
parents  
 Diazoxide-unresponsive 
 Gastro-oesophageal 
reflux 
 Right Hydrocele 
 
  
 Shoulder dystocia  
 Lethargic at birth 
 IV dextrose given at 
birth  
 Cardiac murmur: further 
investigation proved 
negative 
 
 Polycythaemia at birth  
 Eventually diagnosed 
as transient HI 
 Diazoxide-unresponsive 
 
 
 
 
 
 
 
 Diazoxide-unresponsive 
 Gastro-oesophageal 
reflux: resolved 
 Cardiac murmur 
 
 
 
 
 
 
 
 
 
Table 5.1: KATPHI patient details. Five patients presenting with KATPHI were recruited to the study and underwent a hypoglycaemia screen. Data 
presented from patient notes. Hypo- hypoglycaemia.   
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Figure 5.14: Assessment of circulating DPP-4-regulated gut hormones in 
patients with KATPHI. Box represents the interquartile range. Horizontal lines 
within boxes represent medians. Whiskers extend the range of gut hormone values 
and shown as ± SEM. N= 4-5 paired values. 
p = 0.792 
p = 0.083 
p = 0.514 
  159 
Figure 5.15: Correlation analysis 
between circulating metabolite 
levels in patients with KATPHI. 
Values taken from the difference 
between normoglycaemia and 
hypoglycaemic state. Correlating 
relationship between: PYY and (A) 
GLP-1 or (B) GIP or (C) insulin or (D) 
serum glucose. Correlating 
relationship between: GLP-1 and (E) 
GIP or (F) insulin or (G) serum 
glucose. Correlating relationship 
between: GIP and (H) insulin or (I) 
serum glucose. N= 3-5 paired values. 
R
2 
= +1 represents positive correlation, 
r
2 
= 0 represents no correlation, r
2 
= -1 
represents negative correlation. P < 
0.05 is deemed significant.  
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5.6. Summary  
Chapter 5 reveals the significance of DPP-4 in mediating gut peptides in HH and 
potentially highlights an undervalued regulator of HI. Understanding the role of 
DPP-4 and its gut hormone substrate may aid in manipulating regulatory pathways in 
nesidioblastosis-induced HH. Overall, this data provides a mechanistic 
understanding of current drug treatments and the potential of therapeutic strategies in 
combating metabolic disorders. 
5.6.1. mRNA analysis of pancreatic genes involved in energy and glucose 
homeostasis 
Genes involved in appetite and glucose metabolism were analysed in pancreatic 
tissue of KATPHI and control subjects. Pancreatic DPP-4 and SST gene expression 
were significantly up-regulated in KATPHI tissue with a trend for a reduction in PYY 
mRNA levels. These findings provide evidence of candidate genes involved in the 
pathology of KATPHI, which have not previously been shown. 
5.6.2. PYY and DPP-4 localisation and expression in the healthy pancreas 
Using IHC, PYY localisation was determined. Unlike the mouse, the healthy human 
pancreas largely expressed PYY to an unknown islet cell, with small amounts being 
expressed with glucagon in -cells. PYY was absent from both - and -cells as well 
as DPP-4 positive cells. On the other hand, in all tissue samples assessed, DPP-4 was 
expressed in the three islet cell-subtypes: -, - and -cells. 
5.6.3. Changes in islet hormone expression of KATPHI patients 
Islets from KATPHI tissue were assessed for morphological changes that may 
contribute to the islet phenotype. KATPHI resulted in more proliferative cellular 
nuclei of both endocrine and exocrine portions of the pancreas. Since Ki67 was 
markedly increased in KATPHI pancreatic tissue, we attempted to determine the 
identification of the islet-cell subtype that appeared to be proliferating in the 
endocrine areas. In KATPHI samples, -, - and DPP-4 positive cells all 
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immunostained for Ki67. In contrast, - and PYY positive cells were absent for the 
proliferating marker.   
5.6.4. Role of gut hormones in KATPHI 
Since DPP-4 mediates gut hormone action and the gene expression suggested the 
DPP-4 is up-regulated, we assumed there was a possibility that circulating gut 
hormones may have changed as a result. Plasma PYY and GLP-1 both remained 
unchanged at hypoglycaemia, however, there was trend for a reduction in GIP levels. 
Correlation analysis unsurprisingly revealed a positive relationship between PYY 
and GLP-1. No other correlations existed between circulating metabolites analysed 
except between the co-localised active GLP-1 and active PYY.  
5.6.5. Conclusion 
Pancreatic DPP-4, SST and PYY genes as well as plasma GIP all appear to play a 
potential role in KATPHI. Moreover, DPP-4 regulates a number of gut hormones; 
PYY, GLP-1 and GIP and all of these hormones have been implicated to have role in 
glucose homeostasis, but limited data is available to suggest a role in KATPHI. The 
IHC reveals that DPP-4 positive cells are proliferating; hence all findings imply a 
role of DPP-4 activity in HH pathogenesis. This chapter provides the basis for 
further investigations into assessing the role of gut hormones in HH. 
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Chapter 6 
 
Discussion and conclusions 
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6. Discussion 
6.1. Chapter 3: Characterisation of the intra-islet PYY system 
The hormones released from the enteroinsular axis play a key role in appetite 
control, glucose regulation and interact to regulate homeostasis of food intake and 
energy expenditure. These effects are known to be mediated through the action of 
gut hormones (Murphy and Bloom, 2006). One such gut hormone is PYY. PYY is 
secreted post-prandially from L-cells in the distal GI tract (Ballantyne, 2006). 
Enzymatic activity by DPP-4 changes the isoform from the full length protein; PYY 
1-36 to PYY 3-36, and this truncated isoform has well known and established 
anorectic effects acting on the Y2R (Batterham et al., 2002, Batterham and Bloom, 
2003, Batterham et al., 2006). However, PYY is also found to be expressed in the 
pancreatic islets of Langerhans with evidence suggesting a role of islet PYY in 
glucose homeostasis (Boey et al., 2006b, Boey et al., 2007, Sam et al., 2012, Shi et 
al., 2012, Zhang et al., 2012). But the physiological role and regulation of this 
population of islet PYY cells still remain largely unknown. 
PYY exerts its action via the YRs; a group of GPCRs. PYY has been previously 
shown to inhibit insulin secretion in vitro (Bertrand et al., 1992). However, it is not 
known which receptor mediates this process. Hence, a murine islet isolation protocol 
was established (Liao, 2012). After the islet isolation protocol was optimized, Yr 
expression was confirmed by qRTPCR analysis. On investigation Y4r was confined 
to the exocrine pancreas since the expression of the receptor was present abundantly 
in pancreatic tissue but absent from islet RNA. The ratio of Y4r:Y1r expression was 
high in the whole pancreas possibly, due to the fact that endocrine islets account for 
only 1-2% of total pancreatic volume. The PP-preferential Y4R is known to have a 
role in exocrine secretion (Park et al., 1993), so it comes as no surprise that this 
receptor subtype is located in the pancreatic exocrine portion. However, currently no 
commercially available Y4R compounds exist so little is known of this receptor.  
Unlike Chandarana et al., who found both Y1r and Y4r mRNA in the pancreatic 
endocrine tissues, we found Y1r as the only PYY receptor-subtype expressed in islets 
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in our studies (Chandarana et al., 2013). There is a possible difference in methods 
used. Whilst handpicking islets and dissociation of isolated islets from the exocrine 
tissue is difficult, we ensured we handpicked the islets three times, each time placing 
these into new dishes and washing to remove any unwanted exocrine debris that we 
found can pass through the cell strainers. This enabled us to pick islets clear of 
unwanted tissue. This could explain the difference between the two findings. 
Therefore it is possible that exocrine tissue attached to the islets was amplified and 
hence, the detections of the Y4r transcript by Chandarana and co-workers. 
PYY 1-36-mediated reduction in insulin release is assumed to have been via the Y1R 
insolated murine islets, but this has not been confirmed to date (Sam et al., 2012, 
Chandarana et al., 2013). These findings are supported by the in vivo phenotype of 
the global Y1r KO mouse which displays a potentiation of GSIS with post-prandial 
HI (Burcelin et al., 2001). Similarly, NPY, an endogenous Y1R ligand has also been 
shown to inhibit GSIS, in vitro. In vivo, Npy
-/- 
mice display enhanced nutrient-
stimulated HI (Imai et al., 2007). Moreover, Morgan et al. reportedly removed 
NPY’s GSIS inhibition by co-incubation with a Y1R antagonist, in vitro (Morgan et 
al., 1998). On the other hand, the PYY 3-36 isoform does not appear to produce a 
change to insulin secretion, in vitro or ß-cell content in vivo (Chandarana, 2009, Sam 
et al., 2012, Chandarana et al., 2013). This is further supported by the absence of Y2r 
gene expression (Chandarana et al., 2009, Chandarana et al., 2013) and suggests that 
islet PYY 1-36, Y1R and DPP-4 are important physiological regulators of glucose 
homeostasis. However, further work is required to establish if the deletion of islet 
Pyy will alter the expression of islet Y1r and Dpp-4 mRNA. In addition, 
investigations into the use of Y1R compounds on insulin and other islet hormones, 
such as glucagon and somatostatin release need further exploration to understand if 
this effect is mediated directly or on a secondary basis. 
To physiologically understand the islet PYY system, it was important to assess the 
anatomical distribution of PYY expressing cells within islets. Using IHC, we 
confirmed the absence of PYY from -cells and found co-expression of PYY within 
a small population of glucagon in -cells in WT mice (Upchurch et al., 1994, 
Myrsén-Axcrona et al., 1997). - and -cells both expressed DPP-4 on their cell-
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surfaces this has previously not be shown (Poulsen et al., 1993, Grondin et al., 
1999). Understandably, the enzyme that regulates PYYs activity on -cells secretion 
will be located on PYY responsive cells. So far we have reported some novel 
observations; PYY was predominantly expressed with somatostatin in -cells. This 
cell population also appeared to be absent of DPP-4 expression. A second cell 
population stained abundantly for PYY and expresses DPP-4 in and on the cell-
surface. However, the identification of this cell subtype requires further analysis. 
Perhaps the two PYY cell populations, i.e. the -cell PYY and the unidentified PYY 
positive cell which shows co-expression of DPP-4, suggests PYY may be an 
intracellular signalling molecule or that PYY may be regulated differently in the two 
islet-cells and potentially have different roles within the islet system.   
PYY exerts its insulinotropic effects through its YRs and as previously demonstrated 
Y1r was the only receptor to be expressed in the isolated islets. If the effect of PYY 
on insulin secretion is direct than we would expect Y1R to be present on responsive 
cells. Consequently, we used IHC to localise Y1R expression on -cells. The Y1R 
was expressed on insulin positive cells, however, due to antibody inefficiency, we 
were unable to assess if Y1R was expressed on any other islet-cell subtype. 
However, we were able to assess and find DPP-4 co-expression with Y1R. 
Physiologically, prolonging PYYs action on the -cell via Y1R could be seen as 
detrimental; hence it is understandable that DPP-4 would ensure a rapid removal of 
PYY 1-36 effects on inhibiting insulin secretion. Y1R-immunostaining has been 
found on PYY-positive cells (Jackerott et al., 1996). Hence, it is possible that PYY is 
an autocrine regulator via the Y1R and thus, would explain the close proximity of 
DPP-4 to remove this effect. 
The islet phenotype of the PYY transgenic mouse models; global Pyy KO and the 
PdxPyy null mouse were evaluated to shed light on the published in vivo and in vitro 
glucose phenotypes (Boey et al., 2006b, Chandarana, 2009). Initially, histological 
examination on both the transgenic mouse groups revealed hyperplasia in the islets 
of the Pyy- and PdxPyy null mice with respect to their controls. However, further 
work with the use of proliferating markers such as bromodeoxyuridine (BrdU) or 
Ki67 could confirm this and further characterise this phenotype. 
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Evaluation of the gene expression in the global Pyy mice was performed to shed light 
on the in vivo glucose phenotype reported (Boey et al., 2006b). No changes in 
pancreatic Ins, Gcg or Sst were found in the Pyy null mice in comparison to their 
littermate controls. Subsequently work analysing the pancreatic morphometry was 
carried out in both the Pyy and PdxPyy mice. Global and pancreatic-specific Pyy 
deletion led to a significant reduction in pancreatic α-cell area, an increase in δ-cell 
volume. However no changes were found in β-cell area in the pancreas of the KO 
mice of both groups compared to their respective controls. Work previously carried 
out by Upchurch and co-workers suggested a role for PYY in development and 
differentiation of specialised colonic enteroendocrine cells (Upchurch et. al, 1996). 
PYY has been identified as one of the earliest peptides to be detected during 
development. Additionally, they showed PYY co-expression in all the colonic cells 
prior to differentiation. Common precursor cells of the lower intestine were 
confirmed to all arise from a PYY-producing endocrine progenitor. However, once 
these cells differentiate they were rarely expressing PYY or dividing (Jackerott et al., 
1996).  
This PYY lineage relationship was also explored in the pancreatic endocrine cells 
(Upchurch et al., 1994, Myrsén-Axcrona et al., 1997, Liu et al., 2006). Here they 
examined the co-expression of PYY with different islet cell subtypes. It was revealed 
that embryonically, PYY co-expresses with all islet hormones including insulin as 
cell clusters. Eventually, the insulin positive cells differentiate from the PYY cells 
and remained like this post-natally and through adulthood. Both these findings led to 
the theory that PYY is a possible developmental differentiation endocrine regulator 
and are made up of one lineage branch. On the contrary, a study ablating Pyy found 
normal development of endocrine cells, yet this mouse model appeared to have also 
deleted the closely located Pp gene (Schonhoff et al., 2005). Sam et al. also deleted 
PYY cells in the adult mouse and this resulted in β-cell loss (Sam et al., 2012). This 
phenotype is rescued by a PYY1-36 analogue. Hence, it is suggests Y1R activation 
causes anti-apoptotic effects in ß-cells, which could be compensated for by islet 
NPY (Y1R ligand) in our mice. In addition, itt remains to be seen whether the 
targeting strategy used in Sam et al.’s mice may have destroyed gap junctions, which 
are known to be important in islet cell-cell communication (Rocheleau et al., 2006). 
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Additionally, both these reports fail to assess the impact of Pyy deletion on other 
islet hormones. 
Limited data exist regarding the role of PYY on glucagon and somatostatin 
secretion. Bertrand et al. have produced data in which they showed no effect of PYY 
on glucagon secretion, in vitro (Bertrand et al., 1992). Though the data from this 
thesis could not confirm or disprove this, we did find PYY to regulate the α- and δ-
cells, ex vivo. One possible explanation is that over time the islet isolation protocol 
has evolved and been manipulated to provide better islet yields and quality as shown 
in this chapter (Li et al., 2009, Liao, 2012). However it is essential to get high-
quality islets and ensure reproducibility of isolation from mice. During evaluation of 
the islet isolation protocol, quality and yield of islets were found to be impacted by 
various conditions including the method of collagenase administration, the 
concentration of collagenase used, the temperature and the duration of digestion. 
Since both islet-cell subtypes are located on the mantle of the islet complexes it is 
possible that damage due to digestion by Bertrand and co-workers have led to the 
absence of the glucagon effect. Additionally, it is also plausible that PYY’s effect in 
our mice is due to PYY’s role in the development of other islet hormones as 
previously explained. 
Since both Pyy- and PdxPyy KO mice have shown enhanced GSIS in vivo, it comes 
as a surprise that pancreatic Ins and β-cell area remain unaltered with respect to 
control mice. Moreover, the loss of α-cell mass in both Pyy transgenic KO mice may 
be the possible explanantion to the exaggerated GSIS phenotype, in vivo. In the 
glucose intolerant- HI state GLP-1R activity is retained but GIPR action is lost 
which jointly leads to a reduction in glucagon levels (Nauck et al., 1993). 
Conversely, T1DM; where the β-cells are destroyed by autoimmunity, lose their 
capability to synthesize endogenous insulin are also known to have post-prandial 
hyperglucagonaemia (Brown et al., 2008). These studies highlight a clear link 
between the deregulation of glucagon function and insulin signaling. Furthermore 
the increase in δ-cell area of both the Pyy and PdxPyy null mice implies that this 
could also be a reason for the difference in pancreatic glucagon expression. In 
support of this finding is the phenotype of the Sst KO mice which lose their glucose-
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dependent suppression of glucagon release (Hauge-Evans et al., 2009). Hence, there 
is a possibility of an augmented somatostatin inhibition on glucagon seen in the 
global- and Pdx- Pyy KO mice and thus promotes a reduction in glucagon cell 
content. However, as yet, no studies have undertaken investigations into assessing 
the effects of various conditions on the secretion of islet PYY. Therefore, a novel 
PYY detection system requires setting up and optimisation to see whether PYY 
release could be measured, in vitro. In doing so, a study to understand and provide an 
insight into the intra-islet PYY system regulation can be devised and can eventually 
identify a novel pathway(s) that islet PYY regulates in a functional approach and to 
complement the data we have produced.  
In light of all this evidence, it is possible that loss of PYY, and thus, its loss of 
function in developmental regulation may result in the changes of some 
insulinotropic inhibitory hormones (such as glucagon and somatostatin that it co-
expresses with during postnatal differentiation). In addition, these hormones may 
contribute to the nutrient-stimulated HI, in vivo seen in the global Pyy KO mouse 
and the PdxPyy KO mouse (Boey et al., 2006b, Chandarana, 2009). Investigations 
using isolated islets from Pyy KO mice incubated with exogenous PYY would 
contribute to confirm if PYY affects somatostatin and/or glucagon release or 
synthesis to be measured by static incubation studies and qRTPCR. In doing this, 
novel mechanisms could be uncovered in the regulation of the intra-islet PYY 
system. 
In conclusion, chapter 3 has provided the basis on which the intra-islet PYY system 
can be investigated further for a role in islet function. Islet DPP-4 also appears to be 
a major regulator in this system, possibly initiating the removal of insulin inhibition 
produced by PYY 1-36s action and converting it to the islet inactive form; PYY 3-
36. The GSIS inhibition appears to be mediated at the Y1R located directly on the -
cells with DPP-4. Moreover, the in vivo data has revealed that deletion of the Pyy 
gene in the islets leads to an augmented GSIS by an indirect change in the insulin-
inhibitory hormones; glucagon and somatostatin. More functional work is needed to 
understand how intra-islet PYY regulates pancreatic endocrine function. Finally, this 
chapter evidently supports the historical data of a possibility of PYY in regulating 
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the development and differentiation of other specialised islet cells and their hormone 
gene expression.  
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6.2. Chapter 4: Investigating the in vivo role of the intra-islet PYY 
in energy and glucose homeostasis. 
Literature to date and the data produced in chapter 3 together demonstrate that PYY 
may have a role in islet function and thus glucose and energy control. Many studies 
have used transgenic models to understand the in vivo role of pancreatic PYY. 
However, they have failed to differentiate between the effects of gut and pancreatic 
PYY. In this thesis we generated data from the first pancreatic-specific Pyy KO 
mouse. Using this mouse model we were able to physiologically understand the 
specific role of islet PYY, in vivo.  
To begin, we evaluated the feeding phenotype of the PdxPyy mice and found no 
difference in weekly cumulative food intake between the groups. The potential 
reason for this could be that our study was underpowered as the effect may be far too 
small to determine by the means we used. It has been suggested that the use of more 
mice is necessary to accurately measure food intake (Speakman, 2010). Further work 
using weight-matched controls or pair-feeding could provide a better way to 
understand if pancreatic PYY mediates feeding behaviour. Since this was not 
possible, we continued to investigate if changes in acute feeding patterns were 
present. We identified that the PdxPyy KO mice were eating less at a number of time 
points. Furthermore, PdxPyy
-/-
 animals weighed less than their littermate controls, in 
vivo, in both the male and female groups. As a result, we hypothesised that a post-
prandial factor was acutely being released that inhibited  an orexigenic factor and 
given that Pdx deletes in the antrum of the stomach this may have reduced ghrelin. 
However, as ghrelin levels remained unchanged in the PdxPyy null animals it 
appears not to be the case. On the other hand, the factor could have promoted more 
satiation in the PdxPyy null group. It was therefore postulated that the factor(s) may 
be a pancreatic endocrine influence on the nutrient-stimulated insulin release, since 
gut hormone mRNA levels were unchanged in the KO group. 
Apart from hypoglycaemia, sympathetic and parasympathetic nervous stimulation 
activates the α-cell granules to be released (Ahren et al., 1999) but there are 
limitations to the understanding of factors that influence α-cell secretion. PYY has 
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been found to be co-stored with glucagon in α-cell granules (Bottcher et al., 1989). 
Thus far it has been thought that these two peptides’ activity on β-cell is in a 
paracrine manner (Nieuwenhuizen et al., 1994). PYY is reported to do this through 
the secondary GPCR messenger: cAMP. Therefore, PYYs inhibitory effect is reliant 
on the inhibition of both the production and effect of cAMP, independent of 
cytosolic Ca
2+
 (Nieuwenhuizen et al., 1994). Surprisingly, glucagon acts on β-cell 
GCGRs to stimulate tonic insulin release (Ahren et al., 1999). This dual inhibitory 
and stimulatory action by the α-cells to regulate insulin function is yet to be 
determined. On the other hand, in parallel to β-cells, δ-cell somatostatin release is 
also activated by glucose and parasympathetic nerve activation. Conversely, 
sympathetic stimulation leads to inhibition of somatostatin secretion (Ahren et al., 
1999). Whilst somatostatin is known to inhibit insulin, islet somatostatin has been 
shown to inhibit intra-islet glucagon secretion via SSTR2, independently of its 
effects on insulin (Cejvan et al., 2003). Overall, the intra-islet system appears to 
work in a local (paracrine) fashion.   
Alternatively, other changes may also arise from the gut. To assess if the PdxPyy 
deletion resulted in compensatory changes of duodenal CCK, mRNA levels were 
measured. Cck gene expression was unaltered in the fed state of the mouse lacking 
the PdxPyy gene. However, the expression may need confirming in the fasted state to 
confirm no compensatory changes by the Pdx-targeted strategy. Additionally, Pyy 
expression in the brainstem and GI tract was assessed to ensure that other areas were 
not counterbalancing the effects of the transgenesis. These PYY synthesis sites 
showed no alteration in gene expression but this requires further clarification in the 
fasted state and different time points since gut hormones are dynamic depending on 
feeding status. Finally, mRNA levels of other gut hormones known to have an effect 
in energy and glucose metabolism are known were assessed. Gut ghrelin and 
enteroglucagon expression were unchanged in the KO mice. In light of all this data it 
appears that the effect of the intra-islet Pyy deletion did not affect peripheral sites of 
PYY. Hence the observed changes were possibly due to alterations in local islet 
function. More research into examining the effects of pancreatic Pyy deletion on 
other islet hormones expression and plasma concentrations (such as PP involved in 
body weight regulation and glucose metabolism) are required.  
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Overall, our in vivo investigations found male mice to have a more pronounced 
difference in their phenotypes which was mostly absent in the female animals. Our 
studies concur with Boey et al.’s findings that reported gender differences in their 
studies (Boey et al., 2006b). Their male Pyy KO mice also exhibited a more 
pronounced phenotype. They attributed this result to an increased level of circulating 
testosterone. Moreover, other researchers have also found gender differences in 
studies when assessing PYY (Kim et al., 2005, Jackson et al., 2010, Wong et al., 
2012). In particular, oestrogen is hypothesised to blunt Y1R activation in studies 
assessing hindlimb blood flow (Jackson et al., 2010). Since we were unable to 
determine if this was the case in our mice, we are unable to comment on whether the 
phenotypic differences were due to sex hormone differences. Further analysis could 
aid in confirming the findings of these reports. 
As previously discussed, the PdxPyy KO mice displayed an exaggerated HI response 
to nutrient-stimulation in vivo and in vitro (Chandarana, 2009). This is similar to the 
reported phenotype of the Pyy KO mouse (Boey et al., 2006b). However, the 
PdxPyy
-/-
 mice also show an increase in glucose disposal. These findings could be 
attributed to the elevated post-prandial plasma insulin concentrations found in the 
PdxPyy null mice. Insulin is known to act as an anorectic hormone, travelling to the 
hypothalamus and stimulating the inhibitory feeding centres (Gerozissis, 2004). In 
addition, high circulating insulin levels have been suggested to contribute to the 
promotion of leptin secretion from the adipose tissue. This would result in a 
reduction in body weight and adiposity which is the phenotype we observed in our 
mice (Barr et al., 1997).  However, we were unable to measure leptin levels in either 
the plasma or white adipose tissue (WAT). Assessment into leptin concentrations of 
the PdxPyy mice would require investigation to confirm if leptin is involved in the 
body weight difference of the PdxPyy animals. In addition, differences in body 
weight composition could be assessed by echoMRI analysis of the animals. This 
would allow the identification of lean to fat mass ratio and provide the factor that is 
contributing to the differences in body weight. PYY overexpressing transgenic 
animals have been reported to show changes in hypothalamo-pituitary-somatotrophin 
(HPS) hormones and accordingly a theory was proposed that PYY may play a role in 
somatic growth (Boey et al., 2008). We therefore crudely assessed if changes in 
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somatic growth were contributing to differences in body weight. However, no 
change was found between groups in both male and female animals. To gain a better 
understanding for the role of PYY in growth, further work looking into circulating 
levels of IGF could be assessed. Another hypothesis is that the obese phenotype of 
the Pyy KO mouse was due to the deletion of the circulating anorectic isoform of 
PYY (PYY 3-36) (Batterham et al., 2006). This isoform is also known to activate the 
improvement in glucose tolerance by Y2R in the hepatoportal system (Chandarana et 
al., 2013a). Consequently, the loss of this bioactive circulating isoform causes 
obesity and glucose intolerance which is observed in the Pyy KO mice (Boey et al., 
2006b, Batterham et al., 2006). To investigate this hypothesis, further work is 
required to assess the concentrations of peripheral PYY in the PdxPyy mice in the 
hepatoportal system.  
In conclusion of chapter 4, differences in body weight phenotypes of the Pyy- and 
PdxPyy KO mice indicate towards a differential role of intra-islet PYY and gut-
derived PYY in energy and glucose homeostasis. It appears like enteroendocrine 
PYY; islet PYY may mediate body weight and appetite effects. PYY deletion 
consequently promotes exaggerated post-prandial insulin release by the regulation of 
other pancreatic hormones in a paracrine manner. In light of these findings, islet 
PYY may be a marker which may act as an important surrogate to assess an 
individual’s susceptibility to HI (Figure 6.1). 
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Figure 6.1: Potential regulatory pathways of the 
intra-islet PYY system. Intra-islet PYY 1-36 inhibits 
GSIS via the Y1R. DPP-4 changes the biological 
activity of PYY by converting it to an islet inactive 
isoform. Overall, this promotes a reduction in the 
inhibition of nutrient-stimulated insulin release.  
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6.3. Chapter 5: Characterising the role of gut hormones in 
hyperinsulinaemic hypoglycaemia 
Whilst DPP-4 and its gut hormone substrates have been extensively researched in the 
past decade, the physiological roles of these regulators in glucose homeostatic 
processes are not fully understood. Traditionally it was viewed that congenital 
mutations in the genes that encoded for the KATP channel subunits caused most cases 
of HH. However, recently nesidioblastosis-induced HH has been reported in many 
cases as a complication of weight-loss GBP surgery. But it still remains elusive as to 
how the bypass procedure may cause physiological dysregulation of the pancreata 
and thus promotes hypoglycaemia (Service et al., 2005, Vella and Service, 2007, 
Singh and Vella, 2012). To our knowledge, apart from GLP-1s effects in HH, other 
DPP-4 gut hormones substrates have not yet been investigated or examined  (De 
León et al., 2003, De Leon et al., 2008, Calabria et al., 2012). Hence studies in this 
thesis aimed to characterise a role for DPP-4 and its gut hormone substrates in HH to 
elucidate a role for these regulators in this condition. 
The gene expression data from chapter 5 has shown there to be a potential role for 
pancreatic PYY in HI, since there was the trend for a reduction in pancreatic PYY 
from KATPHI tissue. Low levels of serum PYY have been previously found to be 
indicative of the predisposition to insulin resistance in first-degree relatives of 
T2DM persons (Boey et al., 2006a). However, this action appears to be mediated by 
gut PYY and not pancreatic PYY (Chandarana et al., 2013a). Hence, we measured 
plasma PYY levels to see if changes could be observed at hypoglycaemia, but no 
difference was found. This suggests two things; (1) pancreatic PYY has a role in HI 
independently of enteroendocrine PYY and (2) the reducing trend of pancreatic PYY 
mRNA seen in HH persons could be due to the increase in pancreatic DPP-4 gene 
expression. This would in turn lead to a reduction in islet PYY and thus cause an 
overall decrease in Y1R-activated inhibition on GSIS. The lack of significance in the 
expression data may be potentially due to the study lacking statistical power. 
Nonetheless crucial roles for pancreatic PYY and DPP-4 have been identified in HH. 
To date a lack of research in identifying the localisation of pancreatic PYY or its 
regulatory enzyme in the human pancreas limits what is known about their role in 
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glucose metabolism since most work carried out to date has been focussed on animal 
models (Upchurch et al., 1994, Myrsén-Axcrona et al., 1997, Hinke et al., 2000, 
Schonhoff et al., 2005). Therefore, the distribution of PYY and DPP-4 expression in 
the pancreatic endocrine system was assessed in humans. PYY was found localised 
to the -cells only (Boey et al., 2007). This finding could in part explain why there 
was probably an absence of a correlation/association between PYY and the 
metabolites analysed. On the other hand, GLP-1 is co-expressed with PYY in ileal L-
cells; and thus explains the significant positive correlation when analysed in the 
study.  
Subsequently, DPP-4 expression was evaluated in the control human tissue. DPP-4 
immunoreactivity has been previously localised to porcine -cells granules but as yet 
no other species have been assessed (Poulsen et al., 1993, Grondin et al., 1999). We 
therefore investigated and confirmed DPP-4 expression to the -, β- and δ-cells in 
normal human pancreatic samples. Thereafter islet phenotyping of KATPHI samples 
were evaluated for an insight into the histological characteristics of the disease. As 
already known, KATPHI tissue samples have more proliferating pancreatic cells than 
the control tissue (Alexandrescu et al., 2010). Therefore, we identified the 
proliferating pancreatic endocrine cells as β-, δ- and DPP-4 positive cells. Given this 
result, it comes as no surprise that DPP-4 mRNA was significantly increased in 
KATPHI patients.  
Moreover, SST gene expression was also significantly increased in KATPHI persons 
which complements the IHC data. Currently, no reports have clearly substantiated a 
role for somatostatin dysfunction in the pathogenesis of HH. Treatment for the HH 
condition include the use of somatostatin mimetics (Yorifuji et al., 2013). However, 
the mechanism of somatostatin analogue action for the success in suppressing HI 
remains unknown. Interestingly, this result is similar to the global and Pdx- Pyy KO 
mouse islet phenotype discussed earlier in the thesis. Hypothetically, there is a 
possible link between pancreatic PYY and somatostatin in promoting HI. The 
proliferating δ-cells are in-line with the mRNA data that implicates KATPHI to induce 
an up-regulation of the SST gene and also confirms it as a likely regulator of HH. 
Nonetheless more detailed studies of somatostatin physiology are needed to unravel 
  
177 
its function in glucose metabolism. Overall, it appears that pancreatic somatostatin, 
PYY and DPP-4 all have a role in HH. However, to gain a better understanding 
further work is required.  
DPP-4 rapidly inactivates the incretin gut hormones and terminates their biological 
function. Post-prandially, the incretins stimulate GSIS and PROINS gene 
transcription via their respective receptors located on β-cells (Baggio et al., 2000) 
and promote a change in plasma glucagon levels (Drucker, 2002). Principally GIP 
acts to induce glucose-dependent insulin release post-meal (Drucker, 2007). To 
unravel a glucoregulatory function of the incretins, investigations into GLP-1/R and 
GIP/R signalling in WT and transgenic mice have been carried out (Baggio et al., 
2000). Gipr KO mice exhibit defective glucose clearance despite having normal 
fasting blood glucose and tolerance in response to an IPGTT, in vivo (Miyawaki et 
al., 1999). Additionally, GIPR blockade by antisera promotes hyperglycaemia also in 
the presence of normal fasting glucose (Baggio et al., 2000). Together all this data 
supports GIPs role as a glucose-dependent, classical ‘incretin’, which requires 
enteral stimulation to promote its glucoregulatory effects (Irwin et al., 2010). While 
GIP has been well-studied in its effects in T2DM, there is no data on its role in HH. 
Hence, we aimed at determining if a link existed. At hypoglycaemia (reducing i.v. 
dextrose) KATPHI subjects showed a trend for a reduction in plasma GIP levels. A 
possible explanation for this finding could be a result of reducing plasma glucose in 
absence of enteral stimulation. These two main factors are required for GIPs incretin 
response. Another explanation is HI may be caused by a reduction in the levels of 
plasma GIP which is seen in persons who have undergone weight-loss surgery 
(Guidone et al., 2006).  
Medically-unresponsive HH persons require a pancreatectomy to prevent recurrent 
hypoglycaemia. However, complications of such invasive treatment include; (1) 
insulin-dependence and (2) reoccurrence of HH as a result of re-routing GI tract by 
the GBP procedure. Currently, there is no literature except case reports assessing 
how the GBP promotes recurrent HH and nesidioblastosis even after pancreatectomy 
(Qintar et al., 2012). Hence an understanding in how gut hormones regulate this 
glucose dysfunction needs further evaluation. On the other hand, a mouse model 
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displaying the features in the pathophysiology of KATPHI was constructed in 1996 
(Scrocchi et al., 1996). In this mouse, the gene that encodes for the KATP subunit Sur-
1 was deleted and this resulted in mild fasting HH and post-prandial hyperglycaemia. 
From the data in chapter 5, we found that the topography of the human pancreas is 
dissimilar to the mouse (chapter 3). Hence, it is possible the pancreatic anatomical 
variation is the explanation for the differences in the hypoglycaemia phenotype of 
the Sur-1 KO mice versus those seen in KATPHI subjects. Despite these differences, 
it is widely accepted that this model allows the development of an understanding of 
KATPHI pathophysiology. Using acetylcholine and GLP-1, Doliba and co-workers 
restored glucose-sensing in Sur-1 KO islets, in vitro (Doliba et al., 2004). GLP-1 
action in the hepatoportal system causes an increase glucose clearance by peripheral 
tissue independently of insulin action. This function appeared to require GLP-1R 
activation which is lost in Glp-1r KO mice and on the administration of exendin (9-
39) (Chandarana et al., 2013a). Thus, GLP-1R signalling may therefore have a role 
in HH (Service et al., 2005).  
For many years, rodent models have been employed to evaluate the capability of 
pancreatic regeneration (Bonner-Weir, 2000). In particular the partial 
pancreatectomy model (Ppx) has shown at 8 weeks post-surgery there is an induction 
to restore both endocrine and exocrine portions (42% of β-cell volume and 27% of 
total weight of sham-control mice) (Brockenbrough et al., 1988, Bonner-Weir et al., 
1983). GLP-1 is known for its role in islet β-cell neogenesis, and regeneration 
(Drucker, 2007). But due to its rapid inactivation by DPP-4, GLP-1R has limited 
capacity. Hence, exendin-4 (a DPP-4 resistant, long acting GLP-1R agonist) was was 
used. Administration of exendin-4 for 10 days post-operatively in the Ppx mice 
resulted in an attenuation of Ppx-induced hyperglycaemia and promoted β-cell 
neogenesis and proliferation (Bonner-Weir et al., 1983, Brockenbrough et al., 1988, 
Xu et al., 1999, Bonner-Weir, 2000). On the other hand DPP-4 inhibitors do not 
appear to be involved in islet cell neogenesis. This has been shown in STZ-induced 
DM rats treated with DPP-4 inhibitors appear to show no reversal or improvement in 
pancreatic morphology (Pospisilik et al., 2003). Additionally, Exendin-4 
overexpressing mice have normal glucose tolerance thought to be a result of the 
down-regulation of endogenous GLP-1R (Baggio et al., 2000). To test this 
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hypothesis, Glp-1r KO were given a Ppx and at 5 weeks post-pancreatectomy, WT 
mice recovered from the Ppx-induced changes in glucose excursions (De León et al., 
2003). However, this effect was absent in the transgenic Ppx group. Clearly this data 
demonstrates that under GLP-1/R action, pancreatic endocrine cells have the 
capacity to redevelop. Conversely, a truncated form of exendin-4; exendin (9-39) is a 
potent GLP-1R antagonist. A single injection of exendin (9-39) given to mice 
promoted a reduction in plasma insulin and an increase in fasting glucose levels 
(Baggio et al., 2000). With chronic administration, the effect continued without 
altering pancreatic insulin expression levels. This was one of the first studies 
identifying a role for GLP-1/R antagonism in the inhibition of HH.  
Individually, GLP-1R and GIPR antagonism induce hyperglycaemia and potently 
reduce GSIS in the +/+ mouse (Baggio et al., 2000). Subsequent research has shown 
that GLP-1R agonists such as exendin-4 have fewer incidences of hypoglycaemic 
events since the drug works in line with the incretin effect and is currently prescribed 
for T2DM. On the other hand, GLP-1R antagonism has shown promise to increase 
blood glucose and lower GSIS (Baggio et al., 2000, De Leon et al., 2008, Calabria et 
al., 2012). It is therefore being researched for its capabilities in improving the effects 
of HH seen in patients with KATPHI and potentially other conditions that induced HH 
such as nesidioblastosis. STZ-induced islet destruction has also shown an increase in 
both islet and circulating GLP-1 levels; hypothetically this is as a response to 
counteract the islet damage (Nie et al., 2000). Treatment in these rodents with GLP-1 
analogues has been shown to improve islet architecture and function (Drucker and 
Nauck, 2006). However, all these studies have failed to assess whether GIP (another 
hormone involved in β-cell function) may be involved in the observed effects. 
During HI, the KATPHI subjects appeared to show no change to circulating GLP-1 
levels which confirms previous reports (De León et al., 2003). It could be plausible 
that GLP-1 concentrations in KATPHI patients at hypoglycaemia or on treatment with 
GLP-1R antagonist were potentially missed since measurements were made from 
systemic blood. As it appears that the hepatoportal system may have been the site to 
take for accurate GLP-1 measurements (Chandarana et al., 2013a). 
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In conclusion of chapter 5, we found proliferation of β- and δ-cells as well as the co-
localised DPP-4 protein in KATPHI pancreatic tissues. These subjects also have an 
increase in pancreatic DPP-4 potentially promoting a reducing trend for pancreatic 
PYY gene expression. Pancreatic reduction in PYY appears to mediate an increase in 
pancreatic SST mRNA as seen in the PdxPyy KO mice. Furthermore, it appears that a 
reduction in plasma GIP concentration (possibly due to a lack of glucose-mediated 
enteral stimulation) causes or exaggerates hypoglycaemia in KATPHI individuals. 
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6.4. Overall conclusion 
It appears that the impact of PYY in the pancreas has been under-recognised. The 
full contribution of intra-islet PYY to the problem of obesity and/or diabetes is 
unknown but it may be substantial. Thus it is important to study and establish a role 
of pancreatic PYY in energy and glucose balance, independently of gut or brain PYY 
effects.  
Hence, we constructed a Pdx-specific Pyy null mouse and studied it against its 
littermate controls and the global Pyy KO mice. Pancreatic deletion of Pyy led to 
abnormal islet-cell development and thus caused an indirect dysregulation of post-
prandial insulin secretion. The loss of pancreatic Pyy results in alterations in the 
expression of other pancreatic hormones analysed. Both the transgenic Pyy mouse 
models analysed have post-prandial HI potentially due to changes in other islet 
hormones. The difference in body weight phenotypes and glucose disposal suggest a 
role of gut PYY in mediating a difference in appetite and energy expenditure. It is 
well-established that circulating PYYs anorectic action and glycaemia control is 
produced by the activity of truncated PYY 3-36 (Batterham et al., 2002, Batterham 
and Bloom, 2003, Batterham et al., 2003, Chandarana et al., 2013a). Hence, it is 
thought that the enzyme DPP-4 has the potential of improving the satiety and 
glucose tolerance effects. However, DPP-4 also appears to be a major regulator in 
this system, possibly initiating the removal of insulin inhibition produced by islet 
PYY 1-36 action. In conclusion to chapters 3 and 4, more work is needed to 
understand if DPP-4 inhibitor use may limit pharmacological therapeutic 
effectiveness and/or produce undesired side effects which are indicated by the 
current findings. 
In summary of chapters 3 & 4, intra-islet PYY 1-36 appears to activate Y1R and 
mediate the inhibition of insulin secretion. Additionally pancreatic PYY 
demonstrates a role in the development of α- and δ-cells which also has the potential 
to indirectly regulate insulin release. Thus, Pdx- expressing PYY inhibition may be a 
target for weight-loss and improved glycaemic control.  
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Overall, chapter 5 suggests that hypoglycaemia may potentially be a result of 
changes in pancreatic insulinotropic genes which includes DPP-4, PYY and SST. 
Plasma GIP concentrations are lower in these persons. Thus there may be potential 
for GIPR-based compounds to be developed for the therapy of conditions that have 
hypoglycaemia. But further research is needed to develop a deeper understanding.  
Overall, data collated from this thesis concludes that gut hormones play an important 
role in energy and glucose homeostasis. 
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Appendix I: Solutions 
Tail lysis buffer (per 100ml): 67 mM Tris-HCl pH 8.8, 16.6 mM (NH4)2SO4, 
6.7 mM MgCl2, 0.5 % v/v Triton X-100, 1 % v/v beta mercaptoethanol 
 
2X KRB stock solution: 136 mM NaCl, 4.7 mM KCl, 1.2 mM KH2PO4, 5 mM 
NaHCO3, 1.2 mM MgSO4 (7H2O) 
 
Quenching buffer (1x KRB): 2x KRB stock solution, 10 mM Hepes, 1 mM 
CaCl2, 2 mM D-glucose, pH to 7.4 and filter the solution 
 
Pancreatic digestion solution: filtered 1x KRB solution (pH 7.4) with 100 
units/ml penicillin + 100 µg/ml streptomycin and 0.225 mg/ml Liberase RI (Roche, 
West Sussex, UK) (2.5 mg/ml stock solution) 
 
Antigen-retrieval solution: 10% Dako antigen retrieval solution concentrate 
(Dako, Cambridgeshire, UK) in 1x PBS (v/v) 
 
Blocking solution: (1) for unconjugated primary antibodies: 10% normal goat 
serum in 1x PBS (v/v) and (2) for the biotin-conjugated antibodies: incubation with 
2 drops of avidin for 10 minutes, followed by 2 drops of biotin for 10 minutes and 
finally 0.1% Dako serum-free protein block in 1x PBS (v/v). 
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Appendix II: Supplementary IHC images for Chapter 3 
Representative z-stacked IHC images of C57BL/6 male mice aged 10-12 weeks:  
Islet immunostaining of:  
(A1) DPP-4 (green) and DAPI (blue) x 100.  
(A2) DPP-4 (green) and DAPI (blue) x 63.  
(A3) DPP-4 (green), Ins (red) and DAPI (blue) x 20.  
(A4) DPP-4 (green), Ins (red) and DAPI (blue) x 100.  
(A5) DPP-4 (green), GCG (red) and DAPI (blue) x 40.  
(A6) DPP-4 (green), GCG (red) and DAPI (blue) x 100.  
(A7) DPP-4 (green), SST (red) and DAPI (blue) x 40.  
(A8) DPP-4 (green), PYY (red) and DAPI (blue) x 40.  
(A9) Y1R (green), Ins (red) and DAPI (blue) x 40.  
(A10) DPP-4 (green), Y1R (red) and DAPI (blue) x 40.  
 
(Image quality best with RealPlayer Software) 
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